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Protein kinases represent one of the largest families of enzymes. Due to their crucial
roles in many cellular processes, protein kinases have become one of the major drug
targets for pharmaceutical companies. In order to be able to determine selective
substrates, elucidate pathway functionality and design potential kinase inhibitors, it is
important to determine kinase substrate specificity. A 10,000-member split and mix
peptide nucleic acid (PNA)-encoded peptide library was used to establish the
substrate specificity of three different protein tyrosine kinases, using a DNA
microarray and a Cy3-fluorescently labelled secondary anti-phosphotyrosine
antibody. This approach was proven to be a powerful tool as several peptides (“hits”)
were rapidly identified as good substrates for the three kinases.
Split and mix combinatorial libraries can generate large peptide libraries consisting
of potentially millions of compounds, but the main disadvantage is the deconvolution
process required to identify active individual peptides from mixtures. The aim of the
second part of the project was to build a PNA-encoded positional scanning library of
FRET-based tetrapeptides to carry out microarray-based proteolytic profiling. As
proof-of-principle, a 625-member library was first synthesised on solid phase using a
split and mix methodology, and successfully used to profile three different proteases.
The concept was then extended to the synthesis of a larger positional scanning library
containing 50,625 different tetrapeptides encoded for by just 60 PNA tags.
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1.1 Peptide nucleic acids
1.1.1 Introduction
A number of issues related to conventional deoxyribonucleic acids (DNAs) or
ribonucleic acids (RNAs) such as enzymatic degradation and mismatch
discrimination have led to the development of numerous DNA (or RNA) analogues.
Peptide nucleic acids (PNAs) have appeared as one very attractive synthetic DNA
mimic, with the first synthesis reported by Nielsen in 1991.1 Instead of the phosphate
deoxyribose backbone of DNAs 1.1, PNAs 1.2 possess an uncharged, achiral and
acyclic polyamide backbone composed of N-(2-aminoethyl)glycine units. Purine
(adenine 1.3 and guanine 1.4) and pyrimidine (cytosine 1.5 and thymine 1.6) bases
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Figure 1.1: Chemical structures of a DNA and a PNA, where NB is one of the four natural
nucleobases
1.1.2 Properties
PNAs can bind specifically to complementary single-stranded DNA, RNA or PNA to
form very stable duplexes based on Watson-Crick base pairing.3 By convention, like
peptides, PNA sequences are written from the N- to the C-terminus. Duplexes can be
formed both in the anti-parallel and parallel orientations but the anti-parallel
orientation (N-terminus of PNA facing the 3’-end of DNA) is strongly preferred
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(Figure 1.2).2 Due to the neutral amide backbone of PNAs, hybridisation can occur
under low salt conditions, and the absence of electrostatic repulsions confers a higher
thermal stability of PNA/DNA duplexes (Figure 1.2) than DNA/DNA duplexes.
Thus, the melting temperature (Tm, temperature at which 50% of a duplex is
dissociated into single strands) of a 15-mer PNA/DNA duplex is about 70 °C
whereas a corresponding 15-mer DNA/DNA duplex has a Tm of about 55 °C. A
much better mismatch discrimination is observed, with a single-base mismatch in a
15-mer PNA/DNA duplex reducing its Tm by 15 °C on average, in comparison to a


















































































Figure 1.2: General structure of a PNA/DNA duplex, in the anti-parallel mode4
PNAs can bind to a double-stranded DNA to form stable triplexes, and different
types of structures have been reported.5 For example, PNA-(DNA)2 triplexes, where
a PNA binds to a double-stranded DNA through Hoogsteen base-pairing, are
observed in the case of cytosine-rich PNAs and guanine/cytosine-rich DNA duplexes
(Figure 1.3B).6 However, under low salt concentrations and with a purine-rich DNA
duplex, PNAs composed of only thymine and cytosine bases (so-called
homopyrimidine PNAs) or containing a high pyrimidine/purine ratio prefer binding
to a double-stranded DNA by strand displacement to form a highly stable triplex




In that case, one PNA binds to the homopurine DNA strand following Watson-Crick
base-pairing rules (by preference in the anti-parallel mode), while the other PNA
binds to the PNA/DNA duplex through Hoogsteen hydrogen bonds (by preference in
the parallel mode), thus forming an internal (PNA)2-DNA triplex. The non-
complementary single-stranded DNA is displaced and forms a so-called “P-loop
structure” (Figure 1.3C).7
Figure 1.3: Schematic representations of (A) a PNA/DNA duplex, (B) a PNA-(DNA)2 triplex
and (C) a triplex invasion complex
However, the formation of triplex invasion complexes containing cytosine in their
sequences is pH-dependent since protonated cytosines are required for Hoogsteen
binding. This limitation can be avoided by connecting the two homopyrimidine PNA
strands by a linker (e.g. an 8-amino-3,6-dioxaoctanoic acid linker8 or a positively
charged lysine-aminohexyl linker9) to form a so-called bis-PNA, and by replacing all
the cytosine residues in the Hoogsteen strand with pseudoisocytosines (Figure 1.4).8
Bis-PNAs are even more stable than triplex invasion complexes, and a Tm of 100 °C
is observed for a 10-mer bis-PNA. The ability of PNAs to bind to a double-stranded
DNA by strand displacement has been successfully used as a powerful tool in
molecular biology and functional genomics.10, 11 Nucleases and proteases do not
recognise the chemical structure of PNAs. This resistance to enzymatic degradation
extends the lifetime of PNAs both in vivo and in vitro,12 and PNAs are stable over a
Chapter 1
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Figure 1.4: Triplex formation using (A) a protonated cytosine and (B) a pseudoisocytosine in the
Hoogsteen strand; (C) schematic representation of a triplex invasion complex with a bis-PNA
1.1.3 Synthesis
Similarly to peptides, PNAs can be synthesised using standard solid phase synthesis
procedures. PNAs are stable to strong acids and weak bases so that diverse protecting
groups have been used for the synthesis of PNAs.2 In two elemental strategies, the
primary amino group of the backbone is protected with Fmoc13 or Boc14 groups, and
the exocyclic nitrogens of the nucleobases with Bhoc or Cbz groups respectively.
Fmoc/Bhoc- and Boc/Cbz-protected PNA monomers are commercially available,
although very expensive. Other protections for the exocyclic amino groups of the
nucleobases (e.g. Mmt, N3, Aloc) have been reported, and the main protecting groups
for the nucleobases are Cbz, Bhoc and Mmt groups.15 Recently, the syntheses of
Fmoc/bis-Boc-protected PNA monomers have also been published.16, 17 However,
the use of Boc/Cbz-protected PNA monomers implies several TFA deprotections
during the PNA synthesis, and harsh acidic conditions (HF or TFMSA) are necessary
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to remove the Cbz protecting groups (this is also the main issue in the case of
Fmoc/Cbz-protected PNA monomers18). To protect the exocyclic amino groups of
the nucleobases, the mild acid-labile Mmt group is preferred, and the synthesis of
Fmoc/Mmt-protected PNA monomers has been reported.19 Although Fmoc/Bhoc-,
Fmoc/bis-Boc- and Fmoc/Mmt-protected PNA monomers require milder
deprotection conditions than HF or TFMSA, it does not allow orthogonal synthesis
with the commercially available Fmoc-protected amino acids. To carry out
orthogonal synthesis of peptide-PNA conjugates, a number of strategies have
emerged.4, 15 For example, the synthesis of Dde/Mmt-protected PNA monomers 1.7
has been described (Figure 1.5).4, 20 The Dde group was described by Chhabra in
1993 and is selective for primary amine groups.21 Dde deprotection is typically
carried out under nucleophilic conditions (transenamination) with 2% (v/v) hydrazine
in DMF, which also deprotects the Fmoc group.21 To have the Dde group fully
orthogonal to the Fmoc group, Bradley developed specific Dde deprotection
conditions using a mixture of hydroxylamine hydrochloride and imidazole.20 These
conditions are milder than hydrazine, compatible with many functional groups and
resins. Moreover, the Dde group is stable to Fmoc deprotection conditions (solution
of 20% piperidine in DMF) and TFA treatments. Other protecting groups (Aloc,
Azoc, 4-N3Cbz) that are orthogonal to Fmoc chemistry have also been used to
protect the primary amino group of the backbone.15 However, Aloc deprotection is
often problematic as it needs to be carried out under neutral conditions using
palladium catalysts, and it was shown that Aloc/Mmt-protected PNA monomers
afforded PNA-peptide conjugates in low yields and purities.4 Similarly neutral
conditions are necessary to remove the Azoc (using phosphines) and 4-N3Cbz (using















Figure 1.5: Structure of Dde/Mmt-protected PNA monomers (Thymine PNA monomers do not
require nucleobase protection)
1.1.4 Applications
Thanks to the enhanced features of PNAs described in section 1.1.2, PNAs have been
applied in numerous biological applications. PNAs can be used in a molecular-
biology and functional genomics role as well as a diagnosis or detection tool.2, 22
1.1.4.1 PNAs in a molecular-biology and functional genomics role
Strand invasion of double-stranded DNA by PNAs have favoured the use of PNAs as
antigene and antisense agents.23 The therapeutic potential of PNAs has been
demonstrated by the use of PNAs for example against viral24 and bacterial25
infections, and cancers.26
In an antigene strategy, transcription of DNA can be inhibited by PNAs, through
formation of a strand-invaded triple-helix that induces a sterical hindrance and blocks
activity of RNA polymerase.27 Antigene PNAs, designed to target the transcription-
initiation sites for the human progesterone receptors A and B, have been shown to
inhibit transcription inside cells by binding to complementary DNA sequences
present in the complex normally formed between DNA, RNA polymerase and
transcription factors.28 In vitro replication of DNA can also be inhibited by PNAs via
triple helix formation,29 and plasmid DNA replication has been blocked in vivo.30
In an antisense way, PNAs are designed to hybridise to complementary sequences of
messenger RNA (mRNA) targets, inhibiting translation of the target genes (e.g.
through the formation of a triple helix structure that induces a steric blockage).31
Antisense PNAs have also been reported to inhibit microRNAs.32 However, an
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important issue in the development of antisense experiments is the poor cellular
penetration of PNAs.33 In fact, due to their non-ionic natures, PNAs are often unable
to enter into target cells via the use of classical transfection agents (e.g. cationic
lipids and polymers). A number of methods such as electroporation,34 co-transfection
with DNA,35 and more recently conjugation of PNAs to cell-penetrating peptides36, 37
(e.g. arginine-rich peptides, penetratin) or steroids38 have been described to enhance
cellular uptake of PNAs. For example, fluorescein-labelled PNAs conjugated to a
hepta-arginine peptide or the Tat48-57 decapeptide were synthesised using Dde/Mmt-
protected PNA monomers 1.7 (Figure 1.5) and efficiently delivered into cells.36 An
alternative is the incorporation of positively charged residues (e.g. lysines, arginines)
into the PNA backbone: recently, it was shown that a guanidine-based PNA (GPNA)
(Figure 1.6), a cell-permeable PNA analogue where D-arginines are incorporated










Figure 1.6: Chemical structure of a GPNA, where NB is one of the four natural nucleobases
Another efficient cellular delivery system relies on the introduction of a
triphenylphosphonium-PNA-carbamate conjugate 1.8 that is degraded in the cytosol
by glutathione into an unstable intermediate 1.9, leading to the release of an








































Scheme 1.1: Mechanism of PNA intracellular release from a triphenylphosphonium-PNA-carbamate
conjugate
PNAs, used in combination with methylases and restriction enzymes, have been
described as a new class of rare genome cutters.10 A short bis-PNA (Figure 1.4C) is
first bound to DNA at a specific site, being consequently protected from enzymatic
methylation, while all the other unprotected sites are methylated. Following removal
of the bis-PNA, cleavage by the methylase-sensitive restriction enzyme occurs at the
designated site, allowing large genomic DNA to be cut into a number of pieces. A
PNA-based system has also been developed to design artificial DNA nickases that
enable the cleavage of selected sequences in one strand of double-stranded DNA.11
This system takes advantage of the ability of bis-PNAs to open-up DNA duplexes by
invasion (Figure 1.4C), thus exposing a single-stranded DNA that hybridises with an
oligonucleotide. The resulting DNA duplex is then cut at a specific site by a
restriction enzyme, followed by enzymatic digestion of the oligonucleotide and




Scheme 1.2: Design of artificial DNA nickases via a PNA-based system
Duplexes formed between a PNA linked to six histidines and a target complementary
DNA have been used in combination with nickel affinity chromatography to purify
nucleic acids.41 The efficiency of the polymerase chain reaction (PCR) of variable
number tandem repeat commonly used in genetic typing can be enhanced by using
PNAs.42 Small allelic products of heterozygous individuals are preferentially
amplified in comparison to large alleles, which can induce false genotyping patterns.
To circumvent this problem and obtain reliable PCR amplification of different size
alleles, PNAs are used to block the DNA template during amplification (the template
is thus unavailable for inter-strand and intra-strand interactions) but not the primer




Scheme 1.3: Schematic representation of a modified PCR reaction using PNA42
As a functional genomics tool, PNAs have been utilised to improve the southern
hybridisation technique that predicts size and sequence information of DNAs.43 To
do so, biotinylated PNAs are first hybridised to denatured DNAs at low salt
concentrations (to disfavour formation of DNA/DNA duplexes) followed by size
separation of single-stranded DNAs by gel electrophoresis. The PNA/DNA duplexes
are then transferred onto a nylon membrane and detected using chemiluminescence-
based methods.
1.1.4.2 PNAs as a diagnosis or detection tool
The unique properties of PNAs have allowed the development of diagnostic assays
and applications in genetics. For example, PNA-fluorescent in situ hybridisation
(FISH) technique uses fluorescently labelled PNA probes to visualise nucleic acid
targets inside cells.44 The PNA-FISH method was first applied to determine the
accurate telomere length of chromosomes using a fluorescein labelled PNA,45 and is
currently used in cancer and aging studies. Another application is the detection of
single base-pair mutations or single-nucleotide polymorphisms (SNPs) in human
genetic diseases using PNA-directed PCR clamping method.46, 47 In the PCR
clamping technique, a PNA sequence is designed to bind to one of the PCR primer
sites, thus blocking formation of a PCR product (PNA does not act as a primer for
DNA polymerase2). However, when a single base-pair mismatch is present in the
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target DNA sequence, the PNA/DNA duplex is strongly destabilised due to a
decrease in its Tm, allowing preferential amplification of the mutated sequence
(Scheme 1.4).
Scheme 1.4: Schematic representation of the PNA-directed PCR clamping method46
PNAs that are labelled with a fluorescent dye and a quencher at each terminus, also
known as molecular beacons, have been used as biosensors for nucleic acid
detection. When not hybridised, the donor and the acceptor labels are in close
proximity so that the fluorescence is quenched. Upon binding to a complementary
DNA or RNA sequence, the fluorophore is distanced from the quencher, leading to
an increase in the dye fluorescence (Scheme 1.5A).48 Recently, this concept has been
adapted to enhance fluorescence and have a better mismatch discrimination, even at
low temperatures. Stemless forced intercalation-PNA molecular beacons have been
designed to have an open conformation containing an intercalator dye (e.g. thiazole
orange) used as a donor and at one end a near infrared dye (e.g. NIR667) used as an
acceptor. Upon hybridisation, the intercalator dye becomes fluorescent if enclosed
within perfectly matched base pairs, and its fluorescence is subsequently quenched
by the near-infrared dye (Scheme 1.5B).49
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Scheme 1.5: Detection of complementary target nucleic acids using A) PNA molecular beacons48 and
B) stemless forced intercalation-PNA molecular beacons (adapted from Socher49)
1.2 Methods of solid phase synthesis
1.2.1 Introduction
Traditional organic reactions are carried out in solution phase to produce one
compound isolated after a work-up and purification. To avoid these time-consuming
steps and solubility issues associated with peptide synthesis, Merrifield introduced in
1963 the concept of solid phase chemistry.50 In solid phase synthesis, molecules are
attached to a functionalised resin containing a linker. Reagents can be added in
excess without complicating the later purification of the product, which is done by
simple washings of the resin with solvents. Solid phase techniques have been
developed to allow parallel and split and mix syntheses of a range of compounds.
1.2.2 Multipin method
The origins of parallel synthesis can be traced to 1984, when Geysen described the
multipin method for antibody epitope mapping. Hundreds of individual peptides
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were synthesised on polyacrylic acid-grafted polyethylene pins arrayed in a
microtitre plate format.51 Reagents were distributed into the wells of a 96-microtitre
plate so that 96 reactions were run in parallel. Common steps of washing,
neutralisation and coupling were simply carried out by simultaneously immersing all
the pins in specific solutions. Other graft polymers such as polyacrylamide and
polystyrene could also be used, and polymers could be functionalised with the
classical linkers used in solid phase chemistry. Although the multipin method is an
effective and inexpensive technique where pins can be easily manipulated, low
loadings are obtained in comparison with standard solid supports.
1.2.3 Tea-bags
Like many other combinatorial methodologies, the tea-tag method was first designed
for peptide synthesis, although it can be generalised to other organic reactions. In
1985, Houghten developed the tea-bag method,52 and reported the synthesis of 248
different peptides obtained in 10-20 mg quantities. Small batches of functionalised
resin beads were sealed in polypropylene mesh packets that looked like tea-bags. The
advantage of the method was the possibility to combine all the common washing,
deprotection and coupling steps, while different amino acid couplings could be
performed by immersing each individual packet in a separate solution containing a
specific amino acid. At the end of the synthesis, final compounds were cleaved from
the solid support, identified via the label placed on each tea-bag, and obtained in
yields and purities comparable to traditional techniques. This evolved into other
techniques such as Irori resin carriers (Figure 1.7). Libraries of compounds are
synthesised inside these polypropylene microreactors using a radiofrequency53 (e.g.
MacroKans, MicroKans) or optical54 (e.g. NanoKans) tagging system.
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Figure 1.7: Different types of Irori resin carriers (reproduced with permission)54
1.2.4 SPOT synthesis
SPOT synthesis, developed by Frank in 1992, allowed the rapid and cost-effective
simultaneous parallel synthesis of large numbers of peptides arrayed on a cellulose
membrane.55 To carry out peptide synthesis, membranes were first derivatised with
an amino functional group by esterification of the hydroxyl groups on cellulose with
Fmoc-β-Ala-OH. In the second step, an amino acid was coupled at a specific location
by manual or automatic dispensing of a solution containing the activated Fmoc-
protected amino acid in a non-volatile solvent, followed by acetylation of the
remaining reactive amino groups. If required, peptides can be released from the
support by introducing a cleavable linker on the derivatised membrane. SPOT
synthesis, which uses simple protocols and small amounts of reagents, has been
applied in many biological applications such as screening for antibody binding or
determination of enzyme substrate specificities.
1.2.5 Split and mix method
The split and mix method was reported by Furka in 1988 for the synthesis of libraries
of equimolar peptide mixtures.56, 57 In this technique, the beads are divided into
separate groups equal to the number of different introduced building blocks.
Following couplings of the reagents to each batch of beads, the entire set of beads is
mixed in one pool and split again for the next coupling. So the synthesis of a library
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with three building blocks (A, B and C) used in three steps yields 27 (33) products
(Scheme 1.6). The library size increases with the number of steps so that a
tetrapeptide library with 20 natural amino acids leads to the generation of 160,000
(204) different compounds, while requiring only 80 coupling reactions! This
powerful methodology avoids reactions of competition between introduced reagents,
and products are present in equimolar quantities in the final mixture. Moreover, one
bead interacts with only one reagent so that each bead displays one type of
compound, hence the concept of “one-bead-one-compound” described by Lam in
1991.58 However, since the library is obtained as a mixture, deconvolution and
encoding strategies are required to identify individual products.
A B
AA AB AC BA BB BC CA CB CC
AAA AAB AAC BAA BAB BAC CAA CAB CAC
ABA ABB ABC BBA BBB BBC CBA CBB CBC









Scheme 1.6: Principle of the split and mix method
1.3 Deconvolution strategies
Different deconvolution approaches have been described for the identification of
biologically active single compounds from mixtures in a combinatorial library. Two




The iterative approach was introduced by Geysen to deconvolute pin-immobilised
peptide mixtures,59 and generalised by Houghten for deconvolution of soluble
mixture-based combinatorial libraries.60 It involves successive steps of synthesis,
screening and selection of the most active mixtures. For example, consider a
combinatorial library synthesised using a split and mix methodology and composed
of 9 compounds obtained in two successive steps (A1, A2, A3 are used as building
blocks for the first step and B1, B2, B3 for the second one). A biological test is first
carried out. If a biological activity is detected (positive test) then three sub-libraries
containing one fixed building block (A1, A2 or A3) are re-synthesised by separate
reactions of A1, A2 and A3 with a mixture of B1, B2 and B3. A biological test is
carried out on each sub-library. Compounds of the sub-library that give a positive
test are individually re-synthesised and screened for identification of the active
product (Scheme 1.7). However, an important drawback of the iterative concept is




















































Scheme 1.7: Principle of iterative deconvolution
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1.3.2 Deconvolution by positional scanning
An alternative to the iterative approach is deconvolution by positional scanning, a
concept developed by Houghten in 1992 that allowed identification of key
compounds at each library position.61 A positional scanning library is divided into a
number of separate sub-libraries equal to the number of introduced reagents. In each
sub-library, one position is fixed with a single residue, while the other positions
contain a mixture of building blocks. All sub-libraries include the same variety of
products with a unique difference the location of the fixed position. Each sub-library
is then screened to instantly determine the best building block at a defined position,
and by combining the positive results, the sequence of the most biologically active
compound is identified (Scheme 1.8). This process can be used to generate consensus
sequences. Unlike the iterative process, no steps of re-synthesis are required and it is
































Scheme 1.8: Principle of deconvolution by positional scanning
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1.4 Encoded combinatorial libraries
1.4.1 Chemical encoding
In 1992, Brenner introduced the theoretical principle of DNA-encoded combinatorial
peptide libraries that could be prepared by alternating synthesis of amino acids and
DNAs on the same solid support using a split and mix strategy (Scheme 1.9).62 Each
peptide would thus be encoded by a unique DNA tag. Following affinity capture on a
target protein, the DNA tags of the selected compounds would be amplified by PCR
and sequenced to reveal the identity of the peptide sequences. In 1993, Affymax63
and Nielsen64 independently demonstrated the validity of this concept. In both
methods, two orthogonal groups (the base-labile Fmoc group and the acid-labile
dimethoxytrityl (DMT) group) were used to allow orthogonal synthesis of peptides
and DNAs. Affymax reported the synthesis of a DNA-encoded library composed of
823,543 heptapeptides.63 The solid support (polystyrene beads) was functionalised
with a mixture of Fmoc-Thr(tBu)-OBt and the succinimidyl activated ester of 4-O-
DMT-oxybutyrate that were used to carry out peptide and DNA synthesis
respectively (Figure 1.8). Using a spectrophotometer, it was found that the construct
1.11 contained a 20:1 ratio of Fmoc-protected amino groups to DMT-protected
hydroxyl groups. Nielsen employed a different construct 1.12 that contained a serine
residue as a core. Controlled-pore glass beads were chosen as the solid support, the
pentapeptide leucine enkephalin was synthesised via the α-amino group of serine and
its DNA tag was built via the hydroxyl group of the serine side chain (Figure 1.8). In
this strategy, upon cleavage of the peptide from the solid support, the peptide


























































































Construct used by Affymax
Construct used by Nielsen
1.11
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Several DNA-encoded libraries were constructed.65 Recently, encoded self-
assembling chemical (ESAC) libraries have been reported as an efficient tool to
identify molecules that bind target proteins.66 In this technique, separate sub-libraries
of oligonucleotide-compound conjugates are synthesised, with each compound
encoded by a specific DNA code. By mixing two sub-libraries, complementary
DNAs can hybridise together to form a DNA duplex. As a result, a very large ESAC
library with diverse chemical groups is generated and incubated with a target protein.
Molecules that bind to the protein with high affinity are eluted, while the unbound
molecules are removed by washing steps. The unique DNA encoding codes of the
binders are amplified by PCR and hybridised to a DNA microarray to “decode” and
identify the structure of the selected pair of ligands (Scheme 1.10). Another example
of DNA-encoded libraries involving enzymatic DNA ligation has been patented by
the companies Nuevolution67 and Praecis.68 A first building block (e.g. amino acid,
small molecule) is chemically linked to an encoding DNA that contains a reactive
functional group, and a second building block is introduced to react with the first
one. A DNA that encodes this second building block is then enzymatically ligated
(e.g. using DNA ligase) to the first DNA. The procedure is repeated using a split and
mix methodology to end up with a DNA-encoded library that can contain more than
109 compounds.
Scheme 1.10: Schematic representation of the selection of a binding molecule from an ESAC library
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Still developed inert haloaromatic tags 1.13 that attached a tag to the resin bead
(Figure 1.9). Following bead screening, bead removal, tag cleavage and















Figure 1.9: General structure of a haloaromatic tag
Another example of a chemical encoding method is the use of sensitised photolabile
tags.70 A 2-alkyl substituted dithiane-based photocleavable molecule is attached to a
ligand while an electron-transfer sensitiser is linked to a receptor. Upon binding of
the ligand to the receptor, the sensitiser is brought into close proximity with the
photolabile tag, and following irradiation, the tag is released in solution, allowing
identification of the active ligand (Scheme 1.11). Peptides, secondary amines and




Scheme 1.11: Use of sensitised photolabile tags to encode solution phase combinatorial libraries
(adapted from Kottani)70
1.4.2 Non-chemical encoding
As chemical tags can interfere with the versatility of chemical synthesis, a number of
non-chemical encoding methods (e.g. spectrometric, electronic, graphical and
physical encoding) have been described.74 To encode combinatorial libraries (using a
tea-bag approach), Nicolaou developed a radiofrequency tagging system, where
semiconductor memory microchips were enclosed within a porous and inert
microreactor along with resin beads.53 At each reaction step, the microreactor was
scanned and a unique radiofrequency signal was recorded on every microchip so that
the synthetic path of each bead was known and the identity of the product could be
deduced. Large peptide combinatorial libraries (at the single bead level) have been
encoded with different fluorescent colloids (containing one, two or three fluorescent
dyes) that are attached non-covalently to the surface of resin beads during each
amino acid coupling reaction. Each resin bead is thus composed of specific




Figure 1.10: Scanning electron microscope images of fluorescent colloidal particles (B) non-
covalently attached to the surface of a polystyrene resin bead (A) (reproduced with permission)75
1.4.3 PNA-encoded libraries
Unlike DNA that is sensitive to harsh conditions of organic synthesis, PNA is
extremely resistant, opening the door to new chemical encoding applications.76 PNA
has been used as a tagging molecule,77 with PNA-encoded libraries being
successfully used to study enzyme substrate specificity.78-82 Winssinger synthesised
PNA-encoded small molecule libraries, in which each PNA tag was used to encode a
small molecule and allow identification of its structure by hybridisation to a
predefined location on a DNA microarray (via formation of a highly stable
PNA/DNA duplex) (Scheme 1.12).78, 79
Scheme 1.12: Hybridisation of a PNA-encoded small molecule library on a DNA microarray
In proof-of-concept experiments, it was shown that the PNA tags did not alter the
activity of the small molecules against a protease.78 PNA-encoded libraries have
been used to identify protease inhibitors.79, 80 Six fluorescein-labelled PNA-encoded
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cysteine protease inhibitors (Figure 1.11) were synthesised on Rink amide resin.
Lysine was first attached to the resin and protected with the Fmoc and Aloc
orthogonal protecting groups to allow synthesis of the peptide acrylate-based
inhibitor and PNA tag respectively. The library was incubated in solution with a
target protease (cathepsin) and the PNA-encoded inhibitors that bound to the
protease were separated from the unbound ones by size exclusion filtration (or using
a gel-based method80) and hybridised to a DNA microarray to decode their structures
via the PNA tags. The approach was also used to measure cysteine protease activity





























Figure 1.11: Structure of a PNA-encoded cathepsin L inhibitor
Bradley reported the syntheses of PNA-encoded split-and-mix peptide libraries to
determine the substrate specificity of different proteases and the abelson tyrosine
kinase.81, 82 In this strategy, the libraries were obtained through alternative couplings
of Fmoc-protected amino acids and Dde/Mmt-protected PNA monomers, which was
made possible thanks to the development of orthogonal deprotection conditions
between the Fmoc and Dde protecting groups (see section 1.1.3).20 Fmoc-Lys(Dde)-
OH was chosen as a core to synthesise the peptide-PNA conjugates. Amino acids
were coupled on the N-terminal side of Fmoc-Lys(Dde)-Rink-PEGA resin 1.14 using
an Fmoc strategy, while the PNA tag was built up on the N-terminal side chain of
lysine using Dde chemistry (Figure 1.12). For instance, a 10,000-member PNA-
encoded peptide library was used to profile chymopapain and subtilisin by using
fluorescein and tetramethyl-6-carboxyrhodamine (TAMRA) as a fluorescence
resonance energy transfer (FRET) system (Figure 1.13).82 Each amino acid was
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encoded by a PNA triplet so that the peptide-PNA conjugates could be incubated
with the target protease in solution (it represented an advantage over solid support
screening approaches since the interaction between the peptide and the protease was
more similar to physiological conditions and it avoided unspecific reactions between
the peptides and the solid surface) and then hybridised to a complementary DNA



























TAMRA -Ala Ser AA4 AA3 AA2 AA1 Ala
4
Figure 1.13: General structure of the PNA-encoded FRET-based peptide library
1.5 Microarray technology
1.5.1 Introduction
Several high-throughput methods have been developed to rapidly generate a large
number of compounds. One key feature is to identify active compounds against
hundreds of biological targets using rapid and inexpensive technologies. Recent
improvements such as miniaturisation and automation of biological assays have
favoured the expansion of microarray technology.83 It is a powerful methodology
that allows the simultaneous study of thousands of molecules in a single experiment.
Indeed a microarray consists of large numbers of known biological molecules
arranged in a structured grid like format. In a typical experiment, biomolecules are
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immobilised onto a solid support (e.g. a glass slide or membrane) at defined
positions, followed by a specific reaction with labelled targets. The resulting
fluorescent signal is analysed to indicate the identity and the abundance of each
labelled target in the starting mixture. Significant advantages are the use of tiny
reaction volumes (microliter volumes) and amount of samples (at the nanomole- and
picomolescale) to carry out microarray experiments. Microarray technology has been
applied to the high-throughput analysis of different biomolecules. A variety of
formats have been developed including DNA,84 protein,85 peptide,86 tissue,87
carbohydrate,88 live cell,89 small molecule90 and polymer91 microarrays. It represents
a powerful tool in many research areas such as genetic screening, proteomics, drug
discovery and diagnostics.83
1.5.2 Types of surfaces and immobilisation
The choice of a microarray surface represents an important criterion. High-quality
microarray surfaces are required to ensure efficient immobilisation of biomolecules
and to avoid unspecific binding with labelled targets. The surface can also influence
the reaction efficiency, the quality of the final data, and it needs to be compatible
with the detection method, for example a low background if used in conjunction with
fluorescence. The most commonly used material is glass, whose main component is
silicon dioxide. Glass slides are flat, planar, transparent, resistant to high
temperatures, easy to handle (standard dimensions of a glass microscope slide: 75
mm x 25 mm), and a key point is the possibility of modifying their surfaces.92
Traditional amine, aldehyde and epoxide surfaces have been developed and are
commercially available. An amine-derivatised surface is created by reacting a glass
surface with 3-aminopropyltrimethoxysilane (Scheme 1.13) (aldehyde and epoxide













Scheme 1.13: Covalent attachment of a reactive primary amine to a glass surface92
Biomolecules can be immobilised on microarrays either via adsorption consisting of
non-covalent interactions between the biomolecules and the slide surface (e.g. DNAs
immobilised on an amine surface through electrostatic interactions between the
phosphate groups of DNAs (negatively charged) and the positively charged amino
groups) or via the formation of a covalent bond. For instance, the attachment of an
amino-modified DNA to an aldehyde surface forms a covalent imine bond that is
reduced into a stable secondary amine using sodium borohydride. This treatment also
minimises the fluorescent background by reducing unreacted aldehyde groups into























In 1994 Fodor from Affymax synthesised an array of 256 different tetranucleotides
using photolithography.93 In this technique, a photolithographic mask was applied to
predefined regions of a glass surface containing photolabile-protected hydroxyl
groups. Following exposure to light, the photolabile protecting groups were
selectively removed in the regions not protected by the mask. A 5’-photolabile N-
acyl-deoxynucleoside-3’-O-phosphoramidite 1.15 was then added to the entire
surface to react with the free hydroxyl groups. Following capping, oxidation and
washing steps, a second photolithography mask was applied to other regions, and
after exposure to light, a second oligonucleotide with a photolabile 5’-protecting
group was coupled. The process was repeated until the expected oligonucleotide
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M1, M2: Photolithographic masksWhere
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Scheme 1.15: Preparation of a DNA microarray using photolithography (adapted from Pease93)
In 1995 Schena used a complementary DNA (cDNA) microarray to quantitatively
measure the expression of 45 Arabidopsis (small mustard plant) genes in parallel.84
DNA microarrays are prepared either by spotting pre-synthesised DNAs onto
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modified glass slides (e.g. aldehyde-derivatised surface, see section 1.5.2), or by
carrying out in-situ DNA synthesis on the solid surface using photolithography93, 94
or inkjet printing.95 The main application of DNA microarrays is gene expression
profiling, where the relative abundance of a gene in two different samples (e.g.
normal and cancer samples) can be identified, with mRNA extracted from each
sample and reverse-transcribed into labelled cDNA with two different fluorescent
dyes (e.g. Cy3 and Cy5). The resulting cDNAs are then mixed in equal amounts and
hybridised to a DNA microarray. Following washing and scanning using two
different channels, the fluorescent signal for each dye is quantified at each spot
location, and the ratio of the fluorescent intensities for the two dyes reveals the level
of expression of each gene in the tested sample (Scheme 1.16).96 Using this
approach, it is possible to rapidly identify which specific genes are expressed at high
levels in diseases such as cancers so that more targeted treatments can be designed.
DNA microarrays can also be used for genome-wide genotyping, resequencing
applications, and detection of mutations or SNPs, identifying if an individual is
susceptible to develop a specific disease.97 Another application referred to as array-
based “comparative genomic hybridisation” has been reported, where two genomes
are compared in a single experiment to determine if particular genes have been
amplified or lost. This type of analysis is particularly useful in cancer research to
follow the progression of the disease.98
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Scheme 1.16: Gene expression profiling using a dual-channel DNA microarray
1.5.4 Peptide microarrays
Following the success of DNA microarrays, new studies have focused on the
development of other types of formats such as peptide microarrays.99, 100 The concept
of peptide microarrays was first introduced by Geysen who described the multipin
method (see section 1.2.2) and later on by Frank using the SPOT synthesis (see
section 1.2.4). In fact, the first microarray was not a DNA but a peptide microarray
composed of 1024 peptides that was synthesised by photolithography and reported
by Fodor in 1991.101 Similarly to DNA microarrays, peptide microarrays can be
synthesised in two main ways, either by in-situ synthesis directly on the solid surface
(using photolithography or SPOT synthesis) or by immobilising pre-synthesised
peptide derivatives (e.g. cysteine-, cyclopentadiene- and alkoxyamine-terminated
peptides, biotinylated peptides),99 using a contact arrayer or an inkjet printing system
(the latter method is preferred for the synthesis of high-density peptide microarrays).
Peptide microarrays have been successfully applied for the high-throughput
screening (HTS) of various enzymes including kinases,85, 86, 102 phosphatases103, 104
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and proteases,82, 105 allowing a unique insight into the substrate specificity of these
enzymes and the identification of biologically active peptides. Peptide microarrays
have also been used in molecular immunology (e.g. antibody epitope
identification,106 antibody diagnostics107) and peptide interactions with other
molecules such as proteins have started to be investigated.100 In comparison with
DNA microarrays, peptide microarrays are less accessible so that a smaller number
of applications have been reported. That’s why many efforts are focusing on the
development of affordable, high quality and high density peptide microarrays that
could be used as a routine tool in drug discovery, diagnostic applications, and the
discovery of new protein binders and inhibitors.
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Chapter 2: A 10,000-member PNA-encoded
peptide library for profiling kinases
2.1 Protein kinases
Protein kinases represent one of the largest families of eukaryotic proteins, with more
than 500 kinases identified within the human genome.108 Their basic function is to
regulate protein phosphorylation by catalysing the transfer of the γ-phosphate of
adenosine triphosphate (ATP) to phenolic groups on tyrosine (so-called tyrosine
kinases) or alcohol groups on serine and threonine (so-called serine/threonine
kinases). Another class of kinases named “dual specificity” kinases are able to
phosphorylate both tyrosine and serine/threonine residues,108 and some kinases that
are mainly found in prokaryotes can phosphorylate histidine residues.109 Protein
phosphorylation is a reversible process, with dephosphorylation controlled by
another family of enzymes called phosphatases.110 Human protein kinases can also
be divided into two main groups, the eukaryotic protein kinases (ePKs) and the
atypical protein kinases (aPKs). The ePKs (478 human protein kinases identified)
contain a similar catalytic domain with conserved sub-domains and common amino
acid sequences.111 The ePKs can be classified into nine groups: (1) the AGC group
(including the cyclic-adenosine monophosphate-dependent protein kinase (PKA),
cyclic-guanosine monophosphate-dependent protein kinase (PKG) and protein kinase
C (PKC) families); (2) the CAMK group (e.g. calcium/calmodulin-dependent
protein kinase); (3) the CK1 group (e.g. casein kinase 1); (4) the CMGC group
(including the cyclin-dependent kinase (CDK), mitogen-activated protein kinase
(MAPK), glycogen synthase kinase 3 (GSK3) and Cdc2-like kinase (CLK) families);
(5) the receptor guanylate cyclase (RGC) group; (6) the STE group (e.g. yeast sterile-
phenotype kinases); (7) the tyrosine kinase (TK) group [e.g. Abelson tyrosine kinase
(Abl)]; (8) the tyrosine kinase-like (TKL) group and (9) the “other” group (including
ePKs that do not belong to any of the above categories).108 The aPKs (40 human
protein kinases identified) are known to have protein kinase activity but have
insignificant sequence similarity to the ePK catalytic domain.108 Most human protein
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kinases phosphorylate at serine or threonine with only about 90 believed to be
protein tyrosine kinases, although to date only a small proportion of these have been
fully characterised.112 Protein kinases control many cellular pathways, in particular
cellular signal transduction processes such as cell division, differentiation, apoptosis
and transcription. Any dysfunction can thus be catastrophic and lead to a variety of
disease states such as cancer, cardiovascular disease, inflammation, diabetes, arthritis
and neurological disorders (e.g. Alzheimer’s disease).113
2.2 Protein kinase inhibitors
In large pharmaceutical companies, about 25% of research projects are related to
protein kinases, focusing on the development of potent protein kinase inhibitors.114
Humanised antibodies as well as many small-molecule kinase inhibitors have
emerged115 and a number have been approved for clinical use such as fasudil 2.1 for
the inhibition of Rho-dependent kinase (treatment of cerebral vasospasm),116
sirolimus 2.2 for the inhibition of the target of rapamycin (immunosuppressive and
antiproliferative properties),117 imatinib 2.3 for the inhibition of the breakpoint
cluster region (Bcr)-Abl (treatment of chronic myelogenous leukemia)118 and
gefitinib 2.4 for the inhibition of the epidermal growth factor receptor (treatment of
metastatic non-small cell lung cancer)119 (Figure 2.1). Recently, a second generation
of kinase inhibitors that are able to overcome resistance of the first approved drugs












































Figure 2.1: Chemical structures of representative small-molecule kinase inhibitors
There is a huge demand for the development of approaches that would help in the
design of new kinase inhibitors. A necessity in the area of kinase analysis is the
ability to determine and understand the exact substrate specificity of any kinase.
2.3 Protein kinase substrate specificity
2.3.1 Protein kinase activity detection techniques
A number of well-established technologies that measure kinase activity have been
reported.122-124 They can be classified into three main categories: radioactive,
antibody, and non-antibody based methods.
Radioactive-based assays are popular due to their high sensitivity and work with any
type of kinase and substrate. In a typical assay, following incubation with a kinase,
radiolabelled phosphate (from 32P or 33P ATP) is incorporated into a peptide or
protein substrate, and radioactivity corresponding to phosphorylation of the substrate
quantified.122 An alternative that can be applied to a high-throughput screening
(HTS) and does not require washing steps is based on a scintillation proximity assay,
where a radiolabelled biotinylated substrate is captured by scintillant streptavidin-
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coated beads, resulting in the emission of light.125 However, environmental, safety
and cost issues have encouraged the development of non-radioactive approaches
such as fluorescence.
Access to a wide range of commercially available phosphospecific antibodies has
favoured the widespread use of antibody/fluorescence-based methods. In a typical
experiment, a fluorescently-labelled phosphospecific antibody is used to specifically
recognise phosphotyrosine or phosphoserine/phosphothreonine residues.126 In an
enzyme-linked immunosorbent assay, following reaction with a kinase, the
phosphorylated peptide is captured on the surface of a 96-well plate, with
phosphorylation detected using a phosphospecific primary antibody, or an enzyme-
conjugated or fluorescently-labelled secondary antibody.122 Recently, new methods
have been developed such as time-resolved (TR) fluorometry127 (e.g. use of long-
lifetime lanthanide labelled antibodies), TR-FRET128 (e.g. use of a terbium-
conjugated phosphospecific antibody as a donor and a fluorescein-labelled substrate
as an acceptor, Scheme 2.1) and fluorescence polarisation129 (e.g. binding of
phosphospecific antibody to a fluorescent phosphorylated peptide, which induces an
increase of the compound molecular weight and consequently a reduction in its
tumbling time).
Scheme 2.1: Principle of TR-FRET
Recently, alternative non-antibody based methods involving the use of
luminescence130 (e.g. quantification of unreacted ATP using a luciferase-based ATP
assay) or fluorescence quenching-based assays131 have started to emerge. In the latter
example, following phosphorylation, the phosphate group of a rhodamine-labelled
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phosphopeptide interacts with Ga3+ metal-ions present on the surface of
microspheres coated with a fluorescent polymer (sensor). Thus, polymer and
quencher are brought in close proximity resulting in quenching of the polymer
fluorescence that was proportional to the level of phosphorylation (Scheme 2.2).
Scheme 2.2: Principle of fluorescence-quenching assays (adapted from Rininsland131)
2.3.2 Protein kinase profiling methodologies
Over the past decade several kinase profiling methods have been developed and a
number of examples are explained in detail below.
In 1995 a solution peptide library (prepared by split and mix methods) was used to
determine the substrate specificity of nine protein tyrosine kinases.132 The general
structure of the library used was Met-Ala-X-X-X-X-Tyr-X-X-X-X-Ala-Lys-Lys-Lys,
where X represents any amino acid excluding tryptophan, cysteine, tyrosine, serine
and threonine. After incubation with a kinase and γ-[32P]-ATP, radiolabelled
phosphorylated peptide mixtures (around 1%) were trapped onto a ferric chelating
column followed by subsequent Edman sequencing.133 The abundance of amino
acids in the phosphorylated fraction at each position around the phosphorylation site
was compared with the abundance of the starting mixture, giving the preferred amino
acids at each position. A consensus peptide sequence of optimal substrates was
predicted for each kinase (e.g. EAIYAAPFAKKK, AEEEIYGEFEAKKK and
AEEEEYFELVAKKKK for the protein tyrosine kinases Abl, Src and epidermal
growth factor receptor (EGFR) respectively), showing that protein tyrosine kinases
have different substrate specificities.
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A positional scanning peptide library tagged with biotin at the C-terminus,
containing nine positions surrounding a central serine/threonine residue was used to
profile eight serine/threonine protein kinases.134 For each sub-library, the fixed
positions corresponded to one of the 20 natural amino acids and the variable
positions to approximately equimolar mixtures of 17 amino acids excluding cysteine,
serine and threonine (Figure 2.2). Additional peptides containing a phosphorylated
serine or threonine were also synthesised. The peptide mixtures were treated in
parallel with γ-[32P]-ATP and a specific kinase before being immobilised onto
avidin-coated membranes allowing quantification by phosphorimaging. The
generality of the method was confirmed by the identification of known amino acid
sequences surrounding the phosphorylation site using three different classes of
serine/threonine kinases (basophilic, acidophilic, and proline-directed kinases).
Using this solution-phase approach, results were found to be more accurate than the
ones obtained when substrates were first bound to the avidin-coated membrane
followed by kinase reaction. Other advantages were the minimal consumption of













Figure 2.2: Schematic representation of the positional scanning peptide library used by Hutti134
Another example was the use of tagged mRNA-peptide and cellular proteomic fusion
libraries, where proteins are covalently linked to their encoding mRNA via a DNA-
puromycin linker (Figure 2.3), to interrogate the non-receptor tyrosine kinase v-
Abl.135 The mRNA peptide fusion library was designed to have a tyrosine residue
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surrounded by five random amino acids, and following modification of the library by
v-Abl, phosphorylated residues were isolated via rounds of immunoprecipitation
with the phosphotyrosine-specific α4G10 antibody, and cDNAs were synthesised and
amplified by PCR.  Sequencing of the cDNAs isolated from the mRNA-peptide
fusion library showed that consensus sequences of the substrates were very similar to
the known v-Abl motif Ile/Val/Leu-Tyr-X-X-Pro/Phe, where X represented any
amino acid.132 PCR products of selected pools of the mRNA-cellular proteomic
fusion library were radiolabelled with [α-33P]-deoxycytidine triphosphate followed
by hybridisation onto a cDNA microarray filter, allowing identification of known in
vivo v-Abl substrates as well as new targets. The tyrosine residues of a few substrates
identified in this study were also mutated to phenylalanine, resulting in inhibition of
v-Abl kinase activity in vivo.
Figure 2.3: Structure of an mRNA-protein fusion
Direct bead-based assays have also allowed the identification of the substrate
specificity of two protein tyrosine kinases, p60c-src and zeta-chain-associated protein
kinase 70 using a “one-bead-one-compound”136 combinatorial peptide library
(104,976 compounds).137 The library was synthesised by ladder synthesis72 using a
split and mix methodology, the general structure of the library contained one fixed
tyrosine residue and four randomised positions of 18 amino acids (excluding cysteine
and tyrosine) as well as two fixed alanines, a β-alanine-ε-aminocaproic acid-β-
alanine-ε-aminocaproic acid (BEBE) spacer and a photolabile linker (PLL).
Following kinase reaction, phosphorylated peptides (on beads) were identified using
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an alkaline phosphatase (AP)-conjugated anti-phosphotyrosine antibody
(phosphorylated beads became dark-red following incubation with the AP substrate
solution and could be isolated). Photocleavage released peptides from the resin, with
peptide sequences identified using ladder based analysis by matrix-assisted laser
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) (Scheme
2.3). The same approach was recently applied to screen the Brk protein tyrosine
kinase.138
Scheme 2.3: HT identification of kinase substrate specificity using a one-bead-one-compound library
(reproduced with permission)137
Two combinatorial pentapeptide and heptapeptide libraries on beads (one peptide per
bead) were used to screen for substrates of the serine/threonine protein kinase PKA.
Following incubation with PKA and γ-[32P]-ATP, radiolabelled beads were isolated
and sequenced to identify the well-known “RRXS” peptide motif for PKA (where X
was any amino acid).139 Another bead-based platform has been used to study
phosphorylation of 26 different kinases.140 Assays were carried out using 900
different peptide substrates that were synthesised in parallel and encoded by a unique
oligonucleotide tag. Following incubation with a kinase or a mixture of kinases,
phosphorylated peptides were detected through chemical phosphate activation and
amine-functionalised dye coupling using 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDC) 2.5. EDC catalyses the coupling of phosphates
but also carboxylic acids to primary amines. To selectively label the phosphorylated
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residue, the authors had to first block the carboxylic groups of the amino acid side
chains using EDC at low pH, which induced formation of unstable O-acylurea
intermediates 2.6 that rearranged to the stable (unreactive) N-acylurea products 2.7
(Scheme 2.4). DNA-encoded phosphorylated peptides could then be selectively
labelled using fluorescein glycine amide 2.8, and hybridised to complementary DNA
sequences attached to individual beads on a BeadArray (Illumina), allowing
identification of the substrates recognised by the kinase. Surprisingly, dyes were then
detected using several antibodies, presumably due to the low level of labelling
(Scheme 2.5). The main advantages of this approach relied on the fact that tyrosine-,
serine- and threonine-phosphorylated peptides could be successfully detected without
the use of radiolabelled-ATP or phosphospecific antibodies.
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Scheme 2.4: Coupling using EDC
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Scheme 2.5: Protein kinase assay developed by Shults140
Several microarray-based methods have also been developed.141 For example, kinase
substrates (cyclopentadiene-capped peptides) were immobilised via a Diels-Alder
reaction on self-assembled monolayers (SAMs) containing benzoquinone groups on
the surface. Inert surfaces of SAMs prevented unspecific binding with proteins or
radioisotopes, thus eliminating the requirement of blocking steps. Immobilised
peptides were uniformly accessible to kinases, with phosphorylation detected using
surface plasmon resonance, fluorescence and phosphorimaging. This approach was
used to determine the non-receptor tyrosine kinase c-Src activity and evaluate three

























































Scheme 2.6: Immobilisation of the optimal c-Src kinase substrate on a SAM followed by on-chip
phosphorylation
Similarly peptides containing a C-terminal cysteine were immobilised on SAMs
displaying maleimide groups on gold surfaces to study kinases and quantitatively
evaluate inhibition of these kinases by known inhibitors. Kinase assays simply
required addition of a specific kinase on SAMs followed by treatment with the 2,4,6-
trihydroxyacetophenone matrix, and analysis by MALDI-TOF MS, although only
seven peptides were studied.142 The same group also adapted this approach to assay
multiple enzyme (seven kinases and four phosphatases) activities by combining
microfluidic networks and peptide arrays. In that case, a poly(dimethylsiloxane)
(PDMS) stamp with six microchannels was sealed on top of the SAM, solutions of
peptide substrates were filled into each channel and added on the SAM. Following
washings, the PDMS stamp was reapplied to the SAM in a perpendicular way so that
each channel crossed the six parallel lines of immobilised peptides. Finally, solutions
containing different enzymes were injected into each separate channel and incubated
on the SAM, before subsequent MALDI-TOF MS analysis (Scheme 2.7).143
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Scheme 2.7: Use of microfluidic networks and peptide arrays to assay multiple kinases (reproduced
with permission)143
Recently, another label-free method that uses cysteine-terminated peptide-conjugated
gold nanoparticles attached to an amine-functionalised glass surface and matrix-free
secondary-ion mass spectrometry analysis has been reported to determine Abl and
PKA specificity.144 Microarrays of 710 or 1394 peptides (13-mers), generated by
SPOT synthesis,55 with subsequent oxime attachment to a glass slide and
phosphorylation by a kinase in the presence of radioactive ATP allowed
“phosphorimaging” and analysis of PKA (Figure 2.4) and 3-phosphoinositide-
dependent kinase specificity respectively.102 The same strategy was applied to
determine the preferred substrates of casein kinase 2, and for Abl protein tyrosine
kinase, preferred substrates were identified using a fluorescein-labelled anti-
phosphotyrosine antibody, giving results comparable to those obtained using
radioactivity.145 It was also shown that Abl phosphorylation sites could be predicted
using a peptide microarray containing 1433 peptides.146
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Figure 2.4: A peptide microarray image obtained after incubation with PKA and 32P-ATP
(reproduced with permission)102
A 125-member PNA-encoded library (Figure 2.5) has been incubated with the
protein tyrosine kinase Abl, before being immobilised on a DNA microarray and
treated with a fluorescein isothiocyanate-labelled anti-phosphotyrosine antibody.
Encoding of each randomised amino acid by a specific PNA triplet enabled rapid and
easy identification of peptide sequences phosphorylated by the kinase Abl.81 Later,
Harris reported the use of PNA-encoded peptides to study kinase activity in a similar






R = H or R = Fluorescein :










(PNA triplet)4 (PNA triplet)3 (PNA triplet)2 (PNA triplet)1
Figure 2.5: General structure of the 125-member pool of a PNA peptide library
2.3.3 Aim of the project
The huge potential of using PNA-encoded libraries to profile a specific protein
kinase has been proven.77, 81 However, several factors such as different PNA melting
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temperatures, variations in concentration and hybridisation efficiency of the different
library members had to be taken into consideration. To have robust and reliable data,
it became essential to design PNA-encoded libraries that contained internal controls.
This was successfully achieved by Bradley who introduced the dual colour concept.82
This relied on a FRET system, composed of the donor fluorescein and the quencher
TAMRA, integrated within the PNA-encoded library. This technique was efficiently
applied to interrogate 10,000 protease substrates. The aim of the project was to
transpose this dual colour approach to determine protein kinase substrate specificity
via the use of a specifically designed 10,000-member split-and-mix PNA-encoded
FRET based peptide library, allowing quantification of phosphorylation.
2.4 Optimisation of the detection methodology
2.4.1 Introduction
Despite the large number of available methods capable of detecting phosphorylated
peptides, it remains an important and difficult task to select the correct one. To
develop a general and valuable approach, the use of a non-radioactive antibody-
based methodology that could be applied to HTS appeared an attractive strategy. Yao
used fluorescently-labelled antibodies for the detection of phosphorylated tyrosine
and serine.126 Moreover, the detection of phosphorylated peptides within a PNA-
encoded library using a fluorescein isothiocyanate-labelled anti-phosphotyrosine
antibody has proven efficient.81 However, one remaining issue implied by the use of
fluorescently labelled antibodies is the possible lack of specificity that can produce
false positives and interfere in the interpretation of the results. Therefore, it was
necessary to prove that the selected fluorescently labelled antibodies specifically
recognised tyrosine- or serine-phosphorylated peptides and not any particular amino
acid or peptide motif. Although the final objective was to apply this detection
method to peptide-PNA conjugates, control experiments were first carried out using
peptide microarrays, containing some tyrosine/serine (non)phosphorylated peptides.
This allowed antibody binding selectivity as well as optimisation of antibody titres.
Regarding possible interactions of antibodies with PNA tags, an additional
experiment was carried out with an unmodified PNA-encoded library (no incubation
with a kinase and ATP) and is reported in section 2.5.2.
Chapter 2
-46-
2.4.2 Syntheses of control and phosphorylated peptides
To prove that fluorescently labelled antibodies were specific to tyrosine or serine
residues, known kinase substrates of the protein tyrosine kinase Abl (EAIYAAPF)132
and protein serine kinase PKA (ALRRASLG known as Kemptide)147 as well as their
corresponding phosphorylated peptides were synthesised. Four acetyl-capped
peptides [Ac-ALRRASLG-PEG-NH2 2.9, Ac-ALRRApSLG-PEG-NH2 2.10, Ac-
EAIYAAPF-PEG-NH2 2.11 and Ac-EAIpYAAPF-PEG-NH2 2.12, where PEG =
(CH2)2-O-(CH2)2-O-(CH2)2] were thus assembled via solid phase synthesis using a 2-
chlorotrityl chloride resin and Fmoc-protected amino acids. An additional peptide
labelled with 5(6)-carboxyfluorescein (Fluorescein-EAIYAAPF-PEG-NH2 2.13) was


































































R = Ac, R' = H: 2.11 or R' = PO3H2: 2.12
R = Fluorescein, R' = H: 2.13
R' = H: 2.9 or R' = PO3H2: 2.10
R'
O
Figure 2.6: Chemical structures of the control and phosphorylated peptides
To synthesise phosphorylated peptides, preformed protected phosphoamino acids
(Fmoc-Tyr(PO(OBzl)OH)-OH and Fmoc-Ser(PO(OBzl)OH)-OH) were used. During
Fmoc deprotection, the addition of piperidine onto a peptide containing a
phosphoserine with a bis-protected phosphate 2.14 can lead to rapid β-elimination of
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the phosphate group and formation of the corresponding dehydroalaninyl peptide
2.15.148 Wakamiya showed that this side reaction can be almost totally eliminated
using a mono-protected phosphoserine derivative (e.g. Fmoc-Ser(PO(OBzl)(OH)-
OH) due to ionisation of the phosphate group that inhibits the β-elimination (Scheme
2.8).149 Perich tested different uronium, BOP or DIC-based coupling methods and
reported HBTU/HOBt/DIPEA, HATU/HOAt/DIPEA as the most efficient coupling
procedures to incorporate these building blocks. A classical coupling reagent such as
DIC resulted in a higher proportion of deleted peptides due to a possible participation
of the phosphate hydroxyl group during the activation step.150 Thus, phosphorylated



































































Peptide with a mono-protected
phosphoserine derivative
Scheme 2.8: Stability of phosphoserine derivatives to piperidine
Since the peptides needed to be immobilised onto glass slides, a spacer (2-[2-(2-
aminoethoxy)ethoxy]ethanamine) was first attached onto the resin to give 2.16.
Syntheses of the known Abl substrate 2.11 and the fluorescein-labelled peptide 2.13
were carried out using a CEM Liberty microwave peptide synthesiser that allowed
increased coupling efficiency, reduced reaction times and automation of the washing
steps. Fmoc deprotections were carried out at 25 °C and peptide couplings were
performed under microwave irradiation at 60 °C for 20 min (double coupling).
Peptides were capped with either an acetyl group to give only one free amine for
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immobilisation or 5(6)-carboxyfluorescein (fluorescein) for labelling. The formation
of various side products during the in-situ activation of fluorescein has been reported
by Fischer,151 but these impurities could be easily eliminated by treating the resins
with 20% piperidine in DMF prior to cleavage. Finally, peptides were released from
the resin using a solution of TFA/TIS/DCM (50/45/5) for 2 h and purified by






































































2.11,R=Ac : 2.13R=Fluorescein :
tBuO
2.16
Scheme 2.9: Microwave-assisted preparations of Ac-EAIYAAPF-NH-PEG-NH2 2.11 and
Fluorescein-EAIYAAPF-NH-PEG-NH2 2.13. Reagents and conditions: (a) 2-[2-(2-
aminoethoxy)ethoxy]ethanamine (10 eq), dry THF, 16 h; (b) 20% piperidine in DMF, 2 cycles of 7
min, 25 °C; (c) Fmoc-AA-OH (5 eq), HBTU/HOBt (5 eq), DMF (0.2 M), 20% DIPEA in NMP (10
eq), 20 min, 60 °C; (d) Repeat (c); (e) Repeat (b)-(d); (f) Ac2O/pyridine (50/50), 1.5 h when R=Ac or
5(6)-carboxyfluorescein (5 eq), HBTU/HOBt (5 eq), DMF (0.1 M), DIPEA (10 eq) followed by




However, since the minimum working scale for the microwave peptide synthesiser
was 100 mg of resin, the phosphorylated peptides were synthesised manually at 25
°C using 25 mg of resin. Regarding Kemptide 2.9 synthesis, some deleted peptides
(one missing arginine) could be observed using the microwave peptide synthesiser;
the advantage of manual synthesis was that coupling of arginine could be repeated
several times until completion by running a ninhydrin test (see section 4.1.2). The
use of Wang linker instead of 2-chlorotrityl chloride resin didn’t improve the purity
of the crude compound. The main problems for this peptide were the partial
deprotection of the 2,2,4,6,7-pentamethyldihydro-benzofuran-5-sulfonyl (Pbf) group
on arginine. Due to the presence of two consecutive arginines, the reagent K cocktail
(TFA/H2O/phenol/thioanisole/EDT: 82.5/5/5/5/2.5) had to be used to fully remove
the two Pbf groups.
2.4.3 Printing onto CodeLink slides
CodeLink slides (Amersham Biosciences) are coated with a hydrophilic polymer
containing N-hydroxysuccinimidyl (NHS) esters that can covalently immobilise









CodeLink slides Formation of a stable amide bond
Scheme 2.10: Immobilisation of amine-modified compounds onto CodeLink slides
Solutions containing the peptides Ac-EAIYAAPF-PEG-NH2 2.11, Ac-ALRRASLG-
PEG-NH2 2.9, Ac-EAIpYAAPF-PEG-NH2 2.12, Ac-ALRRApSLG-PEG-NH2 2.10
and Fluorescein-EAIYAAPF-PEG-NH2 2.13 at 8 different final concentrations (A=5
mM, B=1 mM, C=0.5 mM, D=0.1 mM, E=50 µM, F=10 µM, G=1 µM and H=100
nM) in printing buffer were printed onto CodeLink slides in region 1, 2, 3, 4 and 5
respectively (16 replicates, 4x4 sub-arrays) (Figure 2.7). Using fluorescein filters,
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peptide and phosphorylated peptide printing was confirmed since fluorescent spots
for the control peptide 2.13 (region 5) could be observed (Figure 2.7).
Figure 2.7: Image of the peptide microarray obtained using a fluorescein filter (no background
reprocessing)
2.4.4 Detection of tyrosine-phosphorylated peptides
Cyanine dyes have a wide range of biological applications including labelling of
nucleic acids or proteins.152 Sulfonated Cy3 is a water soluble highly fluorescent dye
belonging to the cyanine dye family that can be detected using a rhodamine filter.
FluoroLink MAb Cy3 labelling kit (Amersham Biosciences) was used to label a
commercially available monoclonal anti-phosphotyrosine (mouse IgG2b isotype)
clone PY-20 antibody (Sigma). The Cy3 dye was synthesised with an NHS ester that












Figure 2.8: Sulfonated activated Cy3
Cy3 was conjugated to the antibody, and unconjugated dye was separated from the
labelled antibody by gel filtration. The ratio of dye/protein corresponding to the
average number of dye molecules coupled to each protein molecule was calculated
by determining the dye concentration using the extinction coefficient of the Cy3 dye
at 552 nm and the absorbance of labelled protein at 280 nm. The calculated ratio of
dye/protein was really low (values are usually between 4 and 12, but a value of 1.2
was obtained), indicating a low labelling of the antibody. Two factors such as protein
concentration and reaction pH may have influenced the labelling efficiency of the
reaction.
The method described by Diamond was chosen as an alternative strategy.153 In this
approach, protein active slides were first coated with a specific kinase substrate.
Small molecules solubilised in 10% glycerol kinase reaction buffer along with ATP
were printed on substrate-coated slides followed by activation with a kinase that was
aerosol sprayed. Finally, slides were treated with a primary antibody and an Alexa
Fluor 555-labelled secondary antibody, allowing amplification of the signal. This
detection method was applied to the screening of more than 20 serine/threonine and
tyrosine kinases (Scheme 2.11).
Scheme 2.11: Detection method using primary and labelled secondary antibodies
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Thus, for the peptide microarray experiment, a monoclonal anti-phosphotyrosine
(mouse IgG2b isotype) clone PY-20 antibody (Sigma) was used as a primary
antibody and a Cy3-goat anti-mouse IgG (H+L) conjugate (Invitrogen) as a
secondary antibody. Before antibody addition on the peptide microarray, it was
essential to block the chip using 0.05% Tween-20 and phosphate buffered saline
(TPBS)/ 0.1% Bovine Serum Albumin (BSA) to avoid non-specific binding. The
ratios of primary and secondary antibodies were then optimised. After blocking the
chip, addition of an anti-phosphotyrosine antibody (diluted 1/500) and a Cy3-labelled
secondary antibody (diluted 1/1000), the chip was scanned using a Cy3 filter (Figure
2.9).
Figure 2.9: Image of the peptide microarray obtained using a Cy3 filter (no background reprocessing)
Only the tyrosine-phosphorylated peptide 2.12 immobilised on the slide (printed in
region 3) could be detected, confirming the high specificity of the pair of antibodies
against the phosphorylated tyrosine residue. A decrease in fluorescence intensity was
observed as the concentration of the printing solution containing 2.12 reduced from
0.5 mM to 100 nM. However, for higher printing solution concentrations (1 mM and
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5 mM), bigger spots were noticed and the fluorescence intensity appeared to decrease
due to self-quenching of the Cy3 dye. This method was really sensitive since a 1 μM
final concentration of the printing solution containing 2.12 could be readily detected.
2.4.5 Detection of serine-phosphorylated peptides
The same procedure was applied and optimised to detect serine-phosphorylated
peptides but using a monoclonal anti-phosphoserine (mouse IgG1 isotype) clone
PSR-45 antibody (Sigma) as a primary antibody and the same Cy3-labelled
secondary antibody. The pair of antibodies bound to all immobilised peptides so that
it was not possible to specifically detect serine-phosphorylated peptides. False-
negative results and high cross-reactivity were the main drawbacks associated with
the use of the anti-phosphoserine/threonine antibodies.145 Unlike the anti-
phosphotyrosine antibodies that recognised a phosphorylated tyrosine independently
of adjacent amino acids, anti-phosphoserine/threonine antibodies were sequence
dependent. Thus, the development of a custom antibody for a specific protein serine
kinase is often required. An alternative could be to use a small molecule fluorophore
phosphosensor such as the Pro-Q Diamond dye (λex = 555 nm and λem = 580 nm) that
interacts selectively with phosphorylated residues and does not rely upon any
sequence context. Tyrosine-, serine- and threonine-phosphorylated peptides
immobilised on microarrays were efficiently detected following incubation of the
slides in Pro-Q Diamond phosphoprotein stain.154 Other strategies involve β-
elimination under basic conditions of a serine-phosphorylated peptide followed by
addition of a fluorescently labelled thiol155 (Scheme 2.12) or adaptations of the
method described by Shults (see section 2.3.2).140 In the latter case, following
incubation with a protein serine kinase and ATP, the phosphate group of PNA-
encoded serine-phosphorylated peptides would be activated using EDC 2.5 with
subsequent selective labelling using an amine-functionalised dye. Following
hybridisation of these fluorescently-labelled PNA-encoded serine-phosphorylated

























Scheme 2.12: Nucleophilic attack by Cy3-labelled thiol on dehydroserine
Several attempts to carry out on-chip β-eliminations of a serine-phosphorylated
peptide using Ba(OH)2
156 or NaOH155 as bases followed by addition of a fluorescein-
labelled thiol synthesised in the laboratory were unsuccessful (peptide microarrays
printed in section 2.4.3 were used). Due to the silane base coating of the CodeLink
slides, it was not recommended to incubate slides in solutions with a pH greater than
9. NaOH solutions (pH > 9) were used to optimise β-eliminations of serine-
phosphorylated peptides, this might have resulted in base-mediated hydrolysis of the
Si-O-Si bond and damage to the surface of the slide. Moreover a very high
background was obtained after addition of the labelled thiol. The same negative
results were obtained using aldehyde slides.
In conclusion, it was not possible to detect selectively serine-phosphorylated peptides
immobilised on a microarray. However, detection of tyrosine-phosphorylated
peptides using a pair of antibodies (anti-phosphotyrosine and Cy3-labelled secondary
antibodies) was successfully achieved. Future experiments to determine kinase
substrate specificity will thus only focus on the profiling of protein tyrosine kinases.
2.5 Determination of the kinase substrate specificity from a
10,000-member PNA-encoded library
2.5.1 General structure of the library
Herein is described an approach that allows the screening and analysis of 10,000
kinase substrates in a single experiment, with analysis of ALL 10,000 members of
the library on a one by-one basis via the combined application of DNA microarrays,
fluorescently labelled secondary antibodies and PNA-split and mix encoding.78, 81, 82,
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157 This was achieved by the split and mix synthesis of a 10,000-member PNA-
encoded library containing the peptide sequence -Phe-Gln-AA4-AA3-Tyr-AA2-AA1-
Ile-Lys- (Figure 2.10), with the expected phosphorylation site surrounded by four
variable positions (AA1, AA2, AA3 and AA4), each containing 10 different amino
acids. This library was synthesised by Bialy and Díaz-Mochón.158
























Figure 2.10: General structure of the 10,000-member PNA-encoded library
The library contained both natural and unnatural amino acids with differing
properties (hydrophobic, hydrophilic, neutral, basic and acidic); Tyr was not included
in the randomised positions to avoid multiple phosphorylation sites. Each amino acid
was encoded by a specific PNA triplet (Table 2.1) to give an encoding PNA tag
composed of a PNA dodecamer. The orthogonality and robustness of the PNA and
peptide split and mix chemistry have been reported previously.4, 20, 36 The PNA tag
was also supplemented with two common PNA sequences at the C-terminus (CC)
and three at the N-terminus (AAG) to help control the selectivity of hybridisation and
reduce mismatches.159 Two PEG spacers were also added between the peptide arm
and the PNA oligomer to distance the peptide away from the PNA strand and finally,
every peptide was labelled with fluorescein in order to allow internal control of each
and every library member.81, 82
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Table 2.1: The PNA tags used to encode amino acids of the library












Following solid-phase synthesis, the library was incubated with the Abelson non-
receptor tyrosine kinase (Abl)160 and ATP allowing phosphorylation of any peptides
recognised by Abl, with subsequent pull down (hybridisation) of the 10,000-member
PNA-encoded library onto the DNA microarray. In this approach, all 10,000 peptides
are in essence “delivered” to a specific address on the array by virtue of their specific
and unique tag (zip or post-code) via anti-parallel PNA/DNA duplex formation
(Scheme 2.13).81, 82
Scheme 2.13: Hybridisation of the library
The arrays used contained 22,575 features with 10,000 oligonucleotide sequences
complementary to the PNA sequences (each in duplicate) and 2,575 control DNA
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sequences that were designed to be non-complementary to any of the PNA tags in the
library. Analysis of the image obtained after scanning the chip using a fluorescein
filter showed a total absence of fluorescence on the 2,575 control sequences [e.g.
empty white circles (see insert)], confirming the highly selective hybridisation
(Figure 2.11). Every fluorescent spot represents a unique peptide, whose sequence is
known via its PNA tag and location on the array. Note the variation in fluorescence
intensity which highlights differences in hybridisation and synthesis efficiency that
has to be controlled using relative ratios of fluorescence rather than absolute values.
Figure 2.11: Image of the 22,575-member custom DNA microarray using a fluorescein filter
In essence the DNA array has been converted into a peptide array containing some
phosphorylated peptides. These were subsequently detected using a
primary/secondary antibody approach as explained in section 2.4.4. Therefore, an
anti-phosphotyrosine antibody (mouse IgG, diluted 1/500) was added on the array
followed by addition of a Cy3-labelled secondary antibody (anti-mouse IgG, diluted
1/500).153 The dilution factor of the secondary antibody was higher than the one
optimised for peptide microarrays in order to simply obtain a stronger Cy3
fluorescence signal after scanning. Any phosphorylated peptides [“hits”, e.g. red
spots in white circles, Figure 2.12 (see insert)], localised onto its defined-DNA, were
readily identified by scanning the DNA microarray using a Cy3 filter (Figure 2.12).
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Figure 2.12: Image of the 22,575-member custom DNA microarray using a Cy3 filter.
To verify that the pair of antibodies had no affinity with any PNA tag from the
library, an unmodified 10,000-member PNA-encoded library (no incubation with Abl
and ATP) was hybridised on the DNA chip. After incubation (in a blocking buffer),
the chip was treated with the primary antibody followed by addition of the secondary
labelled antibody. No fluorescence was observed, confirming once again the high
specificity of this pair of antibodies (data not reported).
2.5.3 Dual control approach
Since every peptide was labelled with fluorescein, the resulting ratio of
Cy3/fluorescein provided an internal control for each and every member of the
library, which was crucial due to natural variations in melting temperatures,
concentrations, as well as differences in hybridisation efficiency between the 10,000
different library members. The use of just Cy3 fluorescence for example would mean
it would be impossible to distinguish between high efficiency phosphorylation of a
PNA-peptide conjugate that hybridises poorly and low efficiency protein kinase
modification with a higher concentration. Comparing the Cy3/fluorescein ratio of
every feature allows relative quantification of the fluorescence, independent of any
other factors, allowing Abl to be accurately profiled, with the highest ratio of
Cy3/fluorescein corresponding to the peptide best recognised by Abl (Scheme 2.14).
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It should be noted that experiments were carried out twice to avoid any false
positives. To minimise cost issues, it was also possible to strip the probes and re-
hybridise the 22,575 custom DNA microarrays up to three times, using a stripping
buffer (2.5 mM Na2HPO4, 0.1% (v/v) SDS, 95 °C, 10 min).
161




The dual colour system represented a two-channel microarray experiment, with the
presence of two different fluorescent dyes, fluorescein and Cy3. Since fluorescein
was used as a label for each library member, analysis of the array using the
fluorescein channel confirmed that all library members had been synthesised and
hybridised onto the DNA microarray. The second channel Cy3 was used to quantify
the level of phosphorylation. After scanning the chip at two different wavelengths,
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two images were obtained for each dye, and the signal ratio of Cy3/fluorescein was
calculated for each peptide at each spot location.
2.6.2 General interpretation of the results
For the three screened kinases, data were reprocessed and interpreted in the same
manner. The following explanations can thus be read as a general guideline. An
Excel macro (see supplementary data on the attached DVD-ROM) allowed every
DNA sequence to be correlated to its PNA tag and hence its peptide, which in
combination with BlueFuse (BlueGnome, Cambridge, UK) allowed extensive mining
and manipulation. BlueFuse works with a Bayesian framework using statistical
models to produce a single confidence estimate for each ratio, where every duplicate
is compared in terms of spot quality, signal intensity and regularity between the Cy3
and fluorescein channels. Values vary from 0 to 1, with the highest value
corresponding to a high degree of confidence in the calculated ratio of
Cy3/fluorescein. Although similarities with gene expression profiling exist, the
analysis used here differed in many respects due to the fact that the majority of the
features in the Cy3 channel had little if any signal (most peptides were non-
phosphorylated). In order to gain valuable data, only features (specific peptides) with
a Cy3 intensity twice that of the background were considered. Thus, a number of
single initial signals (duplicates of each DNA oligomer existed scattered across the
array) were obtained. This data was then verified by identification of all duplicates
from within these single signals removing those with a standard deviation (StdDev)
higher than 0.25 (comparing normalised ratios of Cy3/fluorescein intensities for each
feature with values ranging from 0 to 1). Finally, the meaningful number of peptides
phosphorylated by a specific tyrosine kinase (“hits”) was given with very high
confidence. Raw and reprocessed data for the three screened kinases are available as
excel files on the attached DVD-ROM. After being reprocessed using BlueFuse, data
were visualised as a 2D scatter plot using Spotfire (Cambridge, USA), with the y axis
corresponding to the ratio of Cy3/fluorescein and the x axis to the amino acids
present at one of the randomised positions (AA1, AA2, AA3 and AA4) of the library.
Thus, profiles (percentages) of the amino acids that were the most accepted for each
position were easily and quickly obtained, before being compared with sequences of
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known kinase substrates. Moreover, since the highest ratios of Cy3/fluorescein
correspond to the best peptides recognised by the tyrosine kinase, the top peptide
sequences were generated. Finally, a protein basic local alignment search tool
(BLAST) search using the Swiss-Prot database was performed with the top 25
peptide sequences.162, 163 Analysis was run against the non-redundant protein
sequence database. To have a biological meaning, only the highest scores of
similarities as well as the lowest expectation values were considered. In fact, a low
expectation value is generally associated with a significant match among the
database sequences.164 Thus known and putative interacting partners were identified
for each profiled protein tyrosine kinase.
2.7 Enzymatic assays with Abelson tyrosine kinase (Abl)
2.7.1 Introduction
The non-receptor tyrosine kinase Abl is involved in the regulation of cell
proliferation, transcription, apoptosis, cell adhesion and stress responses.160, 165 A
fusion protein called the breakpoint cluster region (Bcr)-Abl has been associated with
human chronic myelogenous leukaemia (CML). The Bcr-Abl gene, which is formed
by a translocation between chromosomes 9 (Abl gene) and 22 (Bcr gene), is
overexpressed in cells compared to the normal gene that encodes the Abl kinase and
is responsible for progression of the disease.166 Patients suffering from CML are
treated with the well-known Bcr-Abl kinase inhibitor imatinib 2.3.118 In the case of
poor efficiency of imatinib 2.3, a new class of inhibitors such as dasatinib and
nilotinib that have recently emerged on the market are administrated.167
2.7.2 Specificity of Abl
Kinase assays were carried out using Abl kinase (mouse recombinant protein) and
data were reprocessed as explained in section 2.6. From the 22,575 possible
substrates, 703 single initial signals were firstly identified, resulting in 155 final
peptides (“310 duplicative hits”) that were phosphorylated by Abl (Scheme 2.15).
Sequences of the 155 “hits” recognised by Abl are listed in Appendix I.
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Scheme 2.15: Scatter plots for Abl (reprocessed using BlueFuse); Cy3 intensity was expressed in
relative fluorescence units (RFUs)
Broad specificity for the amino acids in positions AA4 and AA1 was found whereas
high selectivity was clearly observed for the amino acids around the phosphorylation
site (Tyr) in the AA3 and AA2 positions. Glu seems to play a crucial role in Abl
phosphorylation since it was the most frequent amino acid found in each randomised
position, confirming that this protein tyrosine kinase accepts acidic residues around
the phosphorylation site (Asp was not chosen as a building block in the library
synthesis due to its similarity to Glu).132, 137 Glu (85 “hits” out of 155, 55%) was
clearly the most accepted amino acid in the AA3 position. Thus, an acidic, negatively
charged amino acid on the amino side of tyrosine seems to be important for efficient
phosphorylation by Abl. A smaller proportion of Val (18%) and Ser (11%) were also
observed. In the AA2 position, Abl displayed a preference for polar amino acids such
as Ser (35%) and acidic residues such as Glu (32%). In the AA4 and AA1 positions,
Abl was observed to be less specific and accepted a broad range of amino acids such
as Ser (24%), Glu (19%), D-Val (17%) in the AA4 position and Ser (22%), Val
(18%), Glu (13%) in the AA1 position (Figure 2.13).
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Figure 2.13: Bar graphs showing the proportion of amino acids at the four randomised positions in
the 155 “hits”
When these results were compared with the sequences of known Abl kinase
substrates such as tyrosine-protein phosphatase non-receptor type 6 (PTN6), mouse
double minute 2 (Mdm2), docking protein 1 (dok1) and myoblast determination
protein 1 (MYOD1), marked similarities were displayed. The preferred amino acids
Glu (Asp), Ser and Val identified from the library screening were found around the
phosphorylation site tyrosine, confirming the accuracy of the results (Table 2.2).
Table 2.2: Pentapeptide sequences of known Abl substrates (the known Abl substrate phosphorylation
sites are indicated and amino acids in bold letters were identical to the amino acids identified at the
AA1, AA2, AA3 and AA4 positions of the library)


















Dok1 DOK1_MOUSE Y314 SVYSD
Dok1 DOK1_MOUSE Y397 EGYEL
MYOD1 MYOD1_MOUSE Y30 DFYDD
MYOD1 MYOD1_MOUSE Y212 MDYSG
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2.7.3 Specificity of the top peptide sequences for Abl
The data from the 155 “hits” could also be analysed to generate the sequences of the
best 10 substrates accepted by Abl (Table 2.3) using the ratios of Cy3/fluorescein
calculated for each peptide (Figure 2.14). In this study, the optimal peptide (with the
highest ratio of Cy3/fluorescein) recognised by Abl was FQSEYEVIK. This peptide
contained the SEY motif that appeared 5 times in the top 10 peptides, revealing this
to be an important factor in Abl specificity. Moreover, among the 155 “hits”, 21
peptides contained the SEY motif and 14 were found in the top 40 peptide sequences
(see Appendix I). By generating the top peptide sequences, it was also possible to
identify amino acids that were not necessary present in a large number at AA1, AA2,
AA3 and AA4 positions but had a high ratio of Cy3/fluorescein and consequently an
important biological meaning. For example, 8 peptides contained Ile (5%, Figure
2.13) in the AA3 position and these peptides were among those giving the highest
ratios of Cy3/fluorescein (Figure 2.14). In the top 10 peptide sequences, Ile appeared
3 times in the AA3 position (Table 2.3). The Abl optimal substrate predicted by
Songyang132 contains the motif I/VYXXP, where X represents any amino acid.
Although Pro was replaced by Ile in the library (Figure 2.10), Ile was successfully
identified as an important amino acid at the AA3 position. It is known that Abl
accepts a wide range of substrates168 and one of the advantages of the method was
that optimal peptides for Abl, rather than consensus sequences, were identified.
Moreover, unlike other techniques137 that gave large number of “hits” without
relative quantification, the approach described here offered the advantage of not only
detecting phosphorylated peptides but also quantifying the extent of phosphorylation
(the higher the ratio of Cy3/fluorescein, the greater the extent of phosphorylation).







1) FQSEYEVIK 4.50 6) FQSIYEPIK 3.44
2) FQSEYESIK 4.45 7) FQSIYSPIK 3.32
3) FQSEYSFIK 4.16 8) FQPEYSEIK 3.29
4) FQSEYVFIK 4.03 9) FQSEYEEIK 3.27
5) FQVIYESIK 3.62 10) FQVEYESIK 3.26
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Figure 2.14: Representation of the 155 “hits” recognised by Abl
2.7.4 Interacting partners for Abl
Only the most important amino acids around the phosphorylation site (pentapeptide)
were taken into account in the BLAST search,162 and analysis was run against the
mouse organism. Among the top 25 peptides (see Appendix I), proteins that are
involved in known Abl signalling pathways169, 170 and implicated in leukaemia171
were readily identified (Table 2.4).160 In particular, the second most phosphorylated
peptide (SEYES) was the well known Abl substrate, c-Jun amino-terminal kinase
(JNK).169 In response to DNA damage, JNK phosphorylation of 14-3-3 proteins
induces dissociation of the complex formed between the cytoplasmic Abl and the 14-
3-3 proteins, resulting in translocation of Abl to the nucleus and DNA-damage-
induced apoptosis.169 Chemokines and their receptors control leukocyte migration
and maturation, lymphocyte traffic, and C-C chemokine receptors have been found to
be expressed in B cells of different types of leukaemia.171 It has recently been
reported that Abl phosphorylated the epidermal growth factor receptor (EGFR) on a
specific tyrosine phosphorylation site and inhibited endocytosis of the EGFR.  Abl
also increased cell-surface expression of EGFR and Abl/EGFR signalling might be
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involved in human tumours.170 Although the role of Abl with G protein coupled
receptor (GPCR) kinases and diacylglycerol kinase gamma is not fully understood,
our data revealed that Abl might interact with these proteins.172, 173 GPCRs are the
largest family of cell-surface receptors involved in a diverse range of signalling
pathways, implicated in numerous disease states (e.g. cancer, cardiovascular disease,
neurodegenerative disorders),174 and Abl may play an important role in GPCR
signalling.172 So far it has been shown that overexpression of diacylglycerol kinase
gamma inhibited macrophage differentiation of human leukaemia cells.173
Table 2.4: Predicted proteins
Protein name Swiss-Prot Identified “hit”
G-protein coupled receptor kinase GRK6_MOUSE 1) SEYEV
c-Jun amino-terminal kinase JIP2_MOUSE 2) SEYES
Diacylglycerol kinase gamma DGKG_MOUSE 11) SEYSS
G-protein coupled receptor kinase GRK5_MOUSE 14) EVYSS
C-C chemokine receptor CCR6_MOUSE 24) RVYSE
Epidermal growth factor receptor substrate EP15_MOUSE 25) PVYEK
To illustrate the generalisation of this approach, two other tyrosine kinases, human
epidermal growth factor 2 (Her2) and vascular endothelial growth factor receptor 2
(VEGFR2) were profiled.
2.8 Enzymatic assays with human epidermal growth factor
2 (Her2)
2.8.1 Introduction
Her2 (also known as Her2/neu, erbB2 and EGFR2) belongs to the EGFR family of
receptor tyrosine kinases involved in signal transduction pathways (cell growth and
differentiation).175 Overexpression (amplification) of Her2 has been found in breast,
ovarian, gastric, lung and colon cancers,112 with the Her2 gene amplified in more
than 25% of human primary breast cancers.176 The humanised monoclonal antibody
trastuzumab can block proliferation of cells overexpressing Her2, increasing survival
of patients suffering from breast cancer, when used in combination with
chemotherapy.177 A second-generation of inhibitors120 such as lapatinib that is able to
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block activity of both EGFR and Her2 have been used to treat advanced breast
cancer.178
2.8.2 Specificity of Her2
Kinase assays were carried out using Her2 kinase (human, recombinant, N-terminal
GST tag) and data were reprocessed as explained in section 2.6. Some 2879 single
initial signals were found, giving 299 final peptides (598 duplicates) that were
selected as “hits” for Her2. Sequences of the 299 “hits” recognised by Her2 are listed
in Appendix II. Profiles of the amino acids that were the most accepted for each
randomised position are shown in Figure 2.15.
Figure 2.15: Bar graphs showing the proportion of amino acids at the four randomised positions in
the 299 “hits”
Surprisingly, Her2 showed a remarkable preference for the unnatural amino acid D-
Pro at the C-terminus site of the phosphorylation site. Thus, looking at the 299 “hits”,
in the AA1 position, D-Pro was the most accepted amino acid (34%) along with Ser
(28%). This was also observed in the AA2 position, where D-Pro (22%), Ser (20%)
and D-Val (17%) were the most common amino acids. Moreover, in the top 15
peptides (appendix II), 10 peptides in the AA1 position and 7 in the AA2 position
contained D-Pro, with the sequence D-Pro/D-Pro (AA2/AA1) represented five times.
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This preference was also confirmed in Figure 2.16, where the highest ratios of
Cy3/fluorescein in positions AA2 and AA1 were peptides containing D-Pro. These
results were particularly interesting since even though L-Pro was present in positions
AA1 and AA2, Her2 had a clear preference for D-Pro. The marked preference for this
unnatural amino acid was unexpected and was not observed in other library screens.
However, it is already known that protein kinase C can phosphorylate both D and L-
amino acids.179 In this study, several nonapeptides (Lys-Arg-Pro-Ser-Gln-Arg-Ala-
Lys-Tyr) containing one, two or nine D-amino acids at different positions were
tested. It was found that protein kinase C phosphorylated all the peptides, even
peptides containing only D-amino acids or a D-serine, at different kinetic rates. The
Michaelis constant Km values for the peptides containing one D-amino acid were
similar to the one obtained with L-amino acids, but the presence of a higher number
of D-amino acids or the replacement of serine by threonine resulted in a lower
phosphorylation rate and an increased Km value.
Her2 was less specific for the amino acids in positions AA4 and AA3 but a small
preference for Lys (18%), Glu (14%) and Ser (14%) in the AA4 position and Ser
(23%), Lys (17%) and D-Ala (16%) in the AA3 position could be noticed (Figure
2.15). Since the most preferred amino acids at the randomised positions were
unnatural amino acids, it was not possible to compare these results with known Her2
substrates.180 It should be noted that low ratios of Cy3/fluorescein were obtained due
to very bright fluorescent spots observed when the chip was scanned using a
fluorescein filter (Table 2.5) but the experiments were run twice, giving similar
results regarding Her2 specificity (see section 2.8.3).







1) FQpRYPpIK 1.40 9) FQEAYRSIK 1.09
2) FQVRYFpIK 1.34 10) FQIaYppIK 1.08
3) FQFaYppIK 1.32 11) FQPRYSpIK 1.08
4) FQpIYppIK 1.20 12) FQISYppIK 1.07
5) FQpAYpRIK 1.16 13) FQRSYFpIK 1.06
6) FQKIYppIK 1.14 14) FQVRYRSIK 1.06




Figure 2.16: Representation of the 299 “hits” recognised by Her2
2.8.3 Interacting partners for Her2
Among the top 25 peptides (see Appendix II), six peptide sequences contained
natural amino acids so that the BLAST search was run against the human organism
using these six peptides. To have robust data, it was necessary to enter the whole
peptide sequence -Phe-Gln-AA4-AA3-Tyr-AA2-AA1-Ile-Lys- instead of considering
only the 4 amino acids present around the phosphorylation site. By using the
pentapeptide sequences, low similarity scores and high expectation values were
obtained, and consequently the identified proteins did not have a significant
biological meaning. Although only six peptide sequences were used for the BLAST
search, proteins that are present in breast cancer181, 182 or known to interact with
Her2183 were identified (Table 2.6). For instance, the breast tumour-amplified kinase
gene that encodes a putative serine/threonine kinase has been found to be amplified
and overexpressed in human breast cancer cell lines.181 The role of Her2 in mitogen-
activated protein kinase activation is vital and Her2 is used as a coreceptor for GPCR
signalling in the heart.183 The ephrin receptors are the largest group of human
receptor tyrosine kinases and play an important role as regulators in the development
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and the progression of cancer. It has been demonstrated that upregulation of the
ephrin receptor EPHA7 induces tumorigenesis and invasiveness of different types of
breast cancer cells.182
Table 2.6: Predicted proteins (in the identified “hits”, amino acids in bold letters were identical to the
protein sequence amino acids)
Protein name (sequence) Swiss-Prot Identified “hit”
Breast tumour-amplified kinase (YQETYKRI) STK6_HUMAN 16) FQEIYKRIK
G protein coupled receptor 158 (EIYKRKK) GP158_ HUMAN 16) FQEIYKRIK
Ephrin receptor EPHA7 (FQTRYPS) EPHA7_ HUMAN 25) FQSRYPSIK
2.9 Enzymatic assays with vascular endothelial growth
factor receptor 2 (VEGFR2)
2.9.1 Introduction
The receptor tyrosine kinase VEGFR2 (also known as the kinase insert domain-
containing receptor (KDR) and Flk1) is a member of the vascular endothelial growth
factor (VEGF) family that plays crucial roles in angiogenesis and vasculogenesis.184
Among the VEGFR inhibitors that have been developed, one of the most efficient is
bevacizumab, a humanised monoclonal antibody that binds VEGF before its
attachment to its receptors. It improves survival of patients with non-small cell lung,
colon, renal and breast cancers but has to be used in combination with
chemotherapy.185 Alternatively, small-molecule inhibitors that target several receptor
tyrosine kinases including VEGFR2 have appeared. Thus, sunitinib maleate186 has
been approved for treatment of gastrointestinal stromal tumours and advanced renal-
cell carcinoma.187 Another example is sorafenib that is also used for treatment of
kidney cancer as well as advanced primary liver cancer.188
2.9.2 Specificity of VEGFR2
Kinase assays were carried out using VEGFR2 kinase (human, recombinant, N-
terminal GST tag) and data were reprocessed as explained in section 2.6. Some 8156
single initial signals were found. Thus, unlike the two other kinases, VEGFR2 was
much less specific and accepted a broad range of amino acids, giving a much greater
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number of 829 “hits” (1658 duplicate peptides) (sequences of the 829 “hits”
recognised by VEGFR2 are available as excel files on the attached DVD-ROM).
A slight preference for polar amino acids (both acidic and basic) immediately
adjacent to the phosphorylation site (positions AA3 and AA2) could be observed: Glu
(AA3/AA2:20%/16%), Lys (AA3/AA2:17%/16%) and Ser (AA3/AA2:17%/14%) were
the most commonly observed amino acids. In the AA4 and AA1 positions, Lys (15%)
and D-Pro (18%) were respectively the most common amino acids (Figure 2.17).
Figure 2.17: Bar graphs showing the proportion of amino acids at the four randomised positions in
the 829 “hits”
2.9.3 Specificity of the top peptide sequences for VEGFR2
Although Ile (5%) was the least accepted amino acid in the AA4 position (Figure
2.17), peptides containing Ile at this specific position were the ones with the highest
ratios of Cy3/fluorescein (Figure 2.18). This was confirmed with the number of
peptide sequences containing the hydrophobic amino acid Ile in the AA4 position: 5
and 14 for the top 10 (Table 2.7) and 50 peptide sequences (see Appendix III)
respectively. This observation has not been reported in the literature yet. Moreover,
since the motifs IAY and IAYP appeared 3 times and twice in the top 10 and 3 “hits”
respectively, it seems to be important in VEGFR2 specificity (Table 2.7).
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Figure 2.18: Representation of the 829 “hits” recognised by VEGFR2







1) FQIAYPFIK 10.80 6) FQIRYPPIK 6.79
2) FQFRYEIIK 9.15 7) FQEAYPEIK 6.77
3) FQIAYPPIK 8.50 8) FQIAYvpIK 6.71
4) FQFEYISIK 7.95 9) FQFRYKFIK 6.56
5) FQPAYIvIK 7.17 10) FQIVYppIK 6.53
2.9.4 Interacting partners for VEGFR2
Similarly to the two other screened tyrosine kinases, a BLAST search was run
against the human organism. To obtain high scores of similarities and low
expectation values, both pentapeptide sequences and the whole peptide sequence -
Phe-Gln-AA4-AA3-Tyr-AA2-AA1-Ile-Lys- were used for the BLAST search. Results
were also in agreement with known VEGFR2 signalling proteins (Table 2.8).189-191
For example, it has been reported that leptin and its receptors favour the development
of breast cancers, increase the levels of VEGFR and the expression of VEGFR2 in
tumour cells.189 The protein kinase C controls the down-regulation of VEGFR2 via
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potential phosphorylation of serine residues in the VEGFR2 carboxyl-terminal
domain.190 Sphingosine 1-phosphate induces endothelial cell proliferation and
migration via endothelial differentiation GPCRs. A signalling pathway involving
GPCRs, VEGFR2, the tyrosine kinase Src and the CrkII adaptor protein has been
shown to improve the mobility of human umbilical vein endothelial cells.191
Table 2.8: Predicted proteins (in the identified “hits”, amino acids in bold letters were identical to the
protein sequence amino acids)
Protein name (sequence) Swiss-Prot Identified “hit”
Leptin receptor isoform 1 (FQIRY) LEPR_HUMAN 6) FQIRYPPIK
Protein kinase C, theta (IVYRD) KPCT_ HUMAN 12) IVYRE
Endothelial differentiation
G protein coupled receptor 6 (IIYSF)
EDG6_ HUMAN 23) IIYSF
2.10 Conclusion
The high-throughput screening of 10,000 tyrosine kinase Abl substrates in a single
experiment has been demonstrated via the detection of tyrosine-phosphorylated
peptides (“hits”) using a non radioactive, selective and sensitive method based on a
primary anti-phosphotyrosine antibody and a fluorescently labelled secondary
antibody. The use of PNA-encoded libraries simplified the deconvolution process
and the microarray format allowed minimal amounts of kinase (60 pmol), library (5
nmol) and antibodies (0.4 μg per antibody) to be used. ALL 10,000 members of the
library were analysed, allowing a unique insight into the substrate requirements of
Abl; however it is a general method as there is no need to have any previous
knowledge about an optimal kinase substrate. The dual colour approach (ratio of
Cy3/fluorescein) was essential to allow accurate profiling, and gave a set of peptides
that were phosphorylated in agreement with known Abl interacting partners, while
new target proteins were quickly and simply identified by analysis of the top peptide
sequences and BLAST searching. The approach was used to profile and identify
specific proteins for two other tyrosine kinases, Her2 and VEGFR2, showing its
generality, while adaptations140 will allow serine and threonine kinases to be
analysed allowing rapid and efficient substrate deorphaning.
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Chapter 3: PNA-encoded positional scanning
libraries to profile protease substrate specificity
3.1 Proteases
Proteases, also known as proteinases, peptidases or proteolytic enzymes, specifically
catalyse the hydrolysis of amide bonds in peptides and proteins. Proteases constitute
one of the largest eukaryotic protein families, with more than 550 proteases
identified in the human genome (around 2% of the gene content).192, 193 Proteases are
classified into six categories: serine (e.g. chymotrypsin, trypsin, subtilisin), cysteine
(e.g. papain, caspase), threonine (e.g. proteasome), aspartic acid (e.g. renin, pepsin,
human immunodeficiency virus (HIV)-1 protease), metallo- (e.g. thermolysin,
carboxypeptidase A) and glutamic acid proteases. Proteases can cleave either at the
N-terminus (so-called aminopeptidases) or C-terminus (so-called carboxypeptidases),
or within the peptide/protein (so-called endopeptidases). For aspartic acid, metallo-
and glutamic acid proteases, a molecule of water acts as nucleophile to hydrolyse
peptide bonds, with the amide bond polarised by Lewis acid catalysis. In the case of
serine, cysteine and threonine proteases, the mechanism usually involves a catalytic
triad, where a histidine residue is used to activate a serine, cysteine or threonine side
chain and place it in a position that favors deprotonation. This results in the
formation of an “alkoxide” or “thiolate”, which are better nucleophiles than alcohols
and thiols.193
Proteases play a multitude of fundamental roles in many biological pathways such as
cell or viral proliferation, differentiation, apoptosis, DNA replication and
transcription, blood coagulation, tissue remodelling, wound repair, inflammation and
angiogenesis.193 Consequently, aberrant regulation of protease activity results in
important diseases such as viral infections, cancer, Alzheimer’s, inflammatory, renal
and cardiovascular diseases.194 Proteases are thus significant drug targets in the




Several important drugs in the market or in clinical trials are protease inhibitors.194,
195 One of the first major protease inhibitors are those of the metalloprotease
angiotensin-converting enzyme that are used to regulate blood pressure and for the
treatment of post myocardial infarction and congestive heart failure. An example is
the pro-drug enalapril 3.1 (Figure 3.1), which is metabolised in vivo to the active
form enalaprilat by hydrolysis of the ethyl ester following oral administration.
Several antiretroviral drugs have also been developed, for instance ritonavir 3.2 and
indinavir 3.3 are inhibitors of the HIV protease and are used in the treatment of
acquired immunodeficiency syndrome (Figure 3.1). Proteases and their inhibitors can
also be used as diagnostic and prognostic biomarkers. The serine protease
plasminogen activator and the plasminogen activator inhibitor-1 as well as the serine
protease kallikrein 3 have been successfully used as diagnostic biomarkers in breast
and prostate cancers respectively.195 So far effective protease inhibitors have been
mainly applied to treat cardiovascular, inflammatory, kidney and infectious diseases
but many other therapeutic areas still need to be explored. To design efficient drugs
against proteases and identify new substrates, it is necessary to understand the

































Figure 3.1: Chemical structures of representative protease inhibitors
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3.3 Protease substrate specificity
3.3.1 Introduction
Proteases are able to selectively recognise potential targets among a large number of
substrates. This key feature called substrate specificity allows for maintenance of the
correct functioning of most biological pathways. The knowledge of the substrate
specificity of a protease is vital to understand its function, and to identify its
physiological substrates and elaborate selective inhibitors. The standard
nomenclature for protease substrate cleavage is shown in Figure 3.2. As a general
rule, amino acids on the N-terminal side of the scissile bond (the cleavable bond) are
labelled P1, P2, P3, etc. (“non-prime side”), while amino acids on the C-terminal side
of the scissile bond are labelled P1’, P2’, P3’, etc. (“prime side”). The corresponding
binding sites are referred to as S1, S2, S3, S1’, S2’, S3’, etc. The amino acids in the
peptide immediately adjacent to the cleavage site (P1, P1’) but also the ones in the
other positions (P2, P2’, P3, P3’, etc.) play a significant role in protease specificity. A
number of methods to profile protease substrate specificity have been developed by
identifying the preferred “non-prime” and “prime” amino acids. The most common
strategies that are based on the use of irreversible inhibitors, Edman degradation of
peptide mixtures, positional scanning libraries of fluorogenic substrates, microarrays






































Figure 3.2: Standard nomenclature for protease substrate cleavage
3.3.2 Use of irreversible inhibitors
The “non-prime side” substrate specificity of the proteasome has been studied using
positional scanning libraries of peptide vinyl sulfones (Scheme 3.1).196 Peptide vinyl
sulfones acted both as inhibitors of the proteasome and substrate mimics that were
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covalently bound to the protease active site via Michael addition of the active site
nucleophile onto the vinyl sulfone. To determine inhibitor binding, positional
scanning libraries or individual compounds were incubated with the protease in a
competition assay, followed by subsequent addition of a general radiolabelled
inhibitor to label any remaining active site nucleophiles of the protease. Following
separation of the protease with sodium dodecylsulfate polyacrylamide gel
electrophoresis, the efficiency of the peptide vinyl sulfone as an inhibitor was
assessed by the decrease in radioactivity in comparison with a 100% radiolabelled




















Scheme 3.1: General structure of a positional scanning library of P1-asparagine peptide vinyl sulfones
3.3.3 Edman degradation of peptide mixtures
Another strategy, using mixtures of acetyl-capped peptides, has been used to profile
the “prime side” substrate specificity of a cysteine protease.197 The peptides were
incubated with the protease, resulting in the formation of cleaved peptides containing
a free amino group, whose sequences were determined by Edman degradation,133
with the first round of sequencing giving information about the P1’ position, the
second round on the P2’ position, etc. This approach was successfully applied to
determine the substrate specificity of six enzymes belonging to the matrix
metalloprotease family.198 The “prime side” substrate specificity was obtained using
a combinatorial peptide library that was subjected to partial proteolytic cleavage (up
to 10% cleavage) and subsequent Edman degradation. The results obtained from the
first round of sequencing were then used to design a second library, where preferred
amino acids were fixed on the C-terminal side, providing information about the
“non-prime side” specificity of the six proteases.
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3.3.4 Positional scanning libraries of fluorogenic substrates
Positional scanning libraries of fluorogenic substrates have been used to rapidly
determine the N-terminal (“non-prime side”) substrate specificity of proteases. For
example, Ellman profiled two serine proteases plasmin and thrombin using a
tetrapeptide positional scanning library of fluorogenic 7-amino-4-methylcoumarin
(AMC) peptide substrates.199 In this strategy, a specific amino acid known to have
affinities with the target protease had to be held constant at the P1 position in order to
direct the cleavage site. Since serine proteases require basic amino acids at the P1
position, lysine was chosen as the fixed P1-amino acid. The 6,859-member library
was composed of three sub-libraries, in which one position (P2, P3 or P4) was
respectively fixed, while the other two contained an equimolar mixture of 19 amino
acids. The three sub-libraries were synthesised by solid-phase synthesis using the
N,N-cyanomethylacylsulfonamide “safety-catch” linker. Nucleophilic attack by the
fluorogenic AMC lysine (P1)-amino acid to the support-bound positional scanning
library released compounds in solution. The products were added to 57 individual
microwells, each one corresponding to an addressed position (one of the 19 amino
acids fixed at either P2, P3 or P4 positions) and containing 361 (19
2) AMC-derivatised
tetrapeptides. Upon proteolytic cleavage at the P1 position, the fluorophore AMC 3.4
was liberated in solution and its fluorescence quantified, allowing the rapid
measurement of cleavage rates for a library of compounds (Scheme 3.2). This
approach could be generalised to other classes of proteases since any amino acids
could be fixed at the P1 position. It represented an advantage over previous methods,
where P1-amino acid AMC derivatives had to be linked to the solid support through
the side chain functional group, thus limiting the choice of amino acids to specific
difunctional residues (e.g. aspartic acid).200
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Scheme 3.2: General concept for the synthesis of a fluorogenic AMC positional scanning library
However knowledge about the protease substrate specificity at the P1 position was
required to synthesise the above P1-fixed positional scanning library. To overcome
this limitation, Ellman developed the bifunctional fluorophore 7-amino-4-
carbamoylmethylcoumarin (ACC) 3.5 that allowed for the direct coupling of the
fluorophore to a solid support and Fmoc-based solid phase peptide synthesis (SPPS)
(Scheme 3.3).201 A tetrapeptide positional scanning library of fluorogenic ACC
peptide substrates composed of 137,180 members was used to study the P1 position
and profile the substrate specificity of several serine and cysteine proteases using a
microtitre plate format. In that case, the P1 position was diversified using 20 amino
acids and the P2, P3 and P4 positions contained an equimolar mixture of 19 amino
acids. This P1-positional scanning library was made up of 20 wells (one for every
constant amino acid at the P1 position), each containing 6,859 (19
3) peptide
substrates. Similar kinetic profiles were obtained using a fluorogenic ACC or AMC
P1-fixed (lysine) positional scanning library. Moreover, the ACC fluorescence was
found to be three-fold superior to AMC, thus reducing necessary enzyme and
substrate concentrations.201 Data obtained from the screening of a tetrapeptide
positional scanning library of fluorogenic ACC peptides and a 4,000-member PNA-
encoded small molecule library202 were used to profile proteolytic activities in dust
mite extracts and determine the cysteine protease activity of the house dust mite
Dermatophagoides pteronyssinus allergen Der p 1.203 Recently, a 160,000-member
tetrapeptide positional scanning library of ACC peptide substrates with completely
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randomised P1, P2, P3 and P4 positions was used to determine the N-terminal (“non-
prime side”) substrate specificity of papain-like cysteine and parasite proteases.204
However it should be noted that this method will not detect cleavage between amino
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Scheme 3.3: General concept for the synthesis of a fluorogenic ACC positional scanning library
A positional scanning library of fluorogenic peptides capped with 5-fluorosalicyclic
acid 3.6 at the N-terminus was synthesised to study the “prime side” substrate
specificity of bovine α-chymotrypsin.205 Upon proteolytic cleavage, 5-
fluorosalicyclic acid 3.6 was released in solution as a free carboxylic acid and


























Scheme 3.4: Use of a fluorogenic positional scanning library to study the “prime side” protease
substrate specificity
3.3.5 Microarray-based techniques
To increase the throughput of positional scanning libraries of coumarin-based
substrates, identify subsite interactions between amino acids, and reduce the needed
amounts of enzyme and library, Salisbury reported the use of alkoxylamine-
derivatised fluorogenic ACC peptide microarrays to rapidly determine protease
substrate specificity (Scheme 3.5).105 Peptides with the general structure Ac-peptide-
ACC-linker-ONH2 were covalently linked to an aldehyde-derivatised microarray
surface via oxime formation. The serine protease thrombin was profiled using a 361-
member peptide positional scanning library (Ac-Ala-P3-P2-Lys-ACC-linker) and to
ensure a good access of the immobilised peptides to the protease, the aldehyde slides
were derivatised with BSA. The enzymatic assays were carried out by adding a
protease solution directly on the whole microarray surface, with proteolytic cleavage
identified via the generation of fluorescent spots. The results were in accordance with
previous solution-phase assay data using positional scanning libraries of fluorogenic
substrates.199 Later on, this approach was adapted and nanodroplet microarrays were
developed to profile 4 human blood serine proteases,206 11 papain-like cysteine and
13 serine proteases207 using 722-member positional scanning libraries of ACC
peptides. The substrates were printed as glycerol nanodroplets on a microarray,
followed by aerosol addition of a protease solution to simultaneously initiate all
enzymatic reactions. The advantages of the method were that there was no need for
peptide and slide derivatisation and the substrates were kept in a low-volatile
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solution-phase environment (glycerol), thus reducing non-specific binding, protease
denaturation and accessibility issues observed when the substrates are covalently
attached to the microarray. In a similar approach, Angenendt performed solution-
based inhibition assays of Cathepsin D by printing the fluorogenic substrate, the
enzyme and the inhibitors on a microarray in successive spotting steps using a
contact robotic printer.208
Scheme 3.5: Fluorogenic ACC peptide microarray
Another method based on the use of PNA-encoded fluorogenic substrates that
combines the advantages of solution-phase enzymatic assays and microarray
technology has been reported.157 A split and mix combinatorial library of 192
rhodamine tetrapeptide substrates encoded by 14-mer PNA tags was synthesised by
alternating the use of Fmoc-protected PNA monomers and Aloc-protected amino
acids.202 Rhodamine was used as a latent fluorophore and an increase in fluorescence
was only observed upon cleavage of the amide bond between the substrate and
rhodamine (thus the amino acid adjacent to rhodamine corresponded to the P1
position) (Scheme 3.6). The mixture of compounds was incubated in solution with
the target protease and immobilised onto a DNA microarray for deconvolution and
profiling of the “non-prime side” substrate specificity of thrombin, plasmin, caspase-































































Scheme 3.6: Protease profiling using a PNA-encoded rhodamine-substrate library
3.3.6 FRET-based peptide libraries
FRET-based peptide libraries have successfully been used to study the “prime” and
“non-prime side” protease substrate specificities.209 In this strategy, a peptide is
labelled with a donor fluorophore at one end and an acceptor at the other end so that
the donor fluorescence is quenched by the acceptor. Following proteolytic cleavage,
the donor and the acceptor are spatially separated, thus resulting in a significant
increase in the donor fluorescence, which is proportional to the substrate cleavage
rate. Direct proteolytic assays have been carried out on solid support-bound FRET-
based peptide libraries to profile the serine protease subtilisin Carlsberg,210
Escherichia coli leader peptidase and the aspartyl protease napsin A.211 In this last
example, an amino acid labelled with the donor fluorophore N-(2-aminoethyl)-4-
amino-3,6-disulfo-1,8-naphthalimide (lucifer yellow) was first coupled to the solid
support followed by the split and mix synthesis of a peptide library and final
coupling with the acceptor 4-(4-dimethylaminophenylazo)benzoic acid (dabsyl).
Following treatment of the library with the target protease, the most fluorescent resin
beads (that corresponded to the best peptides recognised by the protease) were
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isolated and analysed by Edman degradation133 (Scheme 3.7).211 Petrassi investigated
the “prime” and “non-prime” substrate specificities of serine, threonine and cysteine
proteases.212 A tetrapeptide ACC-positional scanning library was first used to study
the specificity of the “non-prime side”, which allowed the identification of optimal
residues at the P1, P2, P3 and P4 positions. A FRET-based positional scanning library
was subsequently prepared by coupling the identified optimal “non-prime” sequence
that was labelled with a donor molecule to a previously synthesised positional







































is quenched by dabsyl
Scheme 3.7: Use of a FRET-based peptide library to profile the protease napsin A
Recently, the development of PNA-encoded FRET-based peptide libraries have
allowed for the rapid and efficient profiling of several proteases.81, 82 A 125-member
PNA-encoded peptide library was used to determine the substrate specificity of
pepsin (with AA4 = Leu) using the fluorescein (donor fluorophore) and dabcyl
(internal quencher) FRET system (Scheme 3.8).81 Each amino acid was encoded by a
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PNA triplet, allowing the enzymatic assay to be carried out in solution and all
members of the library (cleaved and non-cleaved peptides) to be analysed following
immobilisation onto a DNA microarray. Fluorescence intensities were measured
before and after proteolytic cleavage, with an increase in fluorescein intensity
corresponding to a peptide cleaved by the protease (Scheme 3.8). The power of this
concept was then increased via the introduction of internal controls (see section
2.3.3) in a 10,000-member PNA-encoded library of FRET-based peptides
(fluorescein was used as the donor fluorophore and TAMRA as the quencher and
internal control) (Figure 1.13).82 Using this method, two proteases (chymopapain and
subtilisin) were profiled using minimal consumption of protease (60 pmole) and
library (3.5 nmole). Cleavage with a protease resulted in an increase of the
fluorescein fluorescence and the highest ratios of fluorescein/TAMRA corresponded
to the best peptides recognised by the enzyme. A recent microarray-based approach
reported that short PNA sequences can form stable PNA/DNA duplexes and a 7-mer
PNA-encoded substrate labelled with the two fluorescent dyes TAMRA and 5(6)-
carboxy-X-rhodamine (ROX) was used to detect the activity of the aspartic protease
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Scheme 3.8: Protease profiling using a PNA-encoded FRET-based peptide library
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3.4 PNA-encoded FRET-based positional scanning libraries
3.4.1 Aim of the project
PNA-encoded FRET-based peptide libraries have been successfully used to
determine the substrate specificity of not only kinases but also proteases.81, 82 The
aim of the project was to build a PNA-encoded positional scanning library of FRET-
based tetrapeptides to carry out microarray-based proteolytic profiling. This new
concept would combine the advantages of different approaches previously reported
by Houghten (positional scanning libraries61), Ellman (positional scanning libraries
of fluorogenic substrates204) and Bradley (PNA-encoded FRET-based peptide
libraries81, 82). Thanks to the use of PNA tags and the microarray format, the
enzymatic assays would be performed in solution using minimal quantities of
enzyme and library before immobilisation of the PNA-encoded substrates to a DNA
microarray for deconvolution and identification of the cleaved peptides. The use of a
FRET-based library would allow the study of the “prime” and “non-prime side”
protease substrate specificity. Similarly to the 10,000-member PNA-encoded FRET-
based peptide library reported by Bradley,82 a dual colour approach would be used to
introduce a FRET system and internal controls within the library. By synthesising a
PNA-encoded positional scanning library, the preferred amino acids for each position
would be identified and only the position of the fixed amino acid would be encoded
with a PNA tag so that the number of synthetic steps and PNA tags required for the
synthesis of very large libraries would be significantly reduced. For example, a
10,000-member PNA-encoded combinatorial tetrapeptide library requires the use of
10,000 PNA tags to encode each peptide, whereas only 40 PNA tags are necessary in
a positional scanning library, thus avoiding the use of expensive customised DNA
microarrays and facilitating microarray data analysis. This chapter reports the
syntheses and the enzymatic assays carried out using a 625-member PNA-encoded




3.4.2 General concept of PNA-encoded positional scanning libraries
The general concept of PNA-encoded positional scanning libraries is illustrated using
the example of a 625-member PNA-encoded tetrapeptide positional scanning library
containing five different amino acids at each of the four positions in the library. The
library is divided into four separate sub-libraries, where in each sub-library one
position within the tetrapeptide is fixed with one of the five amino acids and encoded
by a PNA tag, while the other three positions contain an equimolar mixture of the
same five amino acids. The library is built on solid phase using a split and mix
methodology. For the first sub-library synthesis, after splitting the resin into five,
each batch is coupled with one of the five amino acids used as building blocks and
encoded by five different PNA tags. Each pool is then mixed and split again into
five. Following coupling of three additional amino acids using traditional split and
mix approaches, a pot containing 625 different tetrapeptides is encoded by five PNA
tags. The second, third and fourth sub-libraries are synthesised in a similar manner
except that amino acids in the second, third and fourth positions are encoded by five
different PNA tags. It is noteworthy that all the PNA tags are different from each
other since the final objective is to hybridise the whole library in a straightforward
manner on a single DNA microarray to profile protease substrate specificity and
identify the preferred amino acids at a specific position. Moreover, each sub-library
is composed of the same number of compounds that differ only from the position of
the encoded amino acids. Thus, a PNA-encoded positional scanning library






















































































































(x 5) (x 5) (x 5)
(x 5) (x 5) (x 5)
(x 5) (x 5) (x 5)
(x 5) (x 5) (x 5)
Scheme 3.9: Schematic representation of a 625-member PNA-encoded tetrapeptide positional
scanning library
3.4.3 Synthetic strategy
Polyethylene glycol dimethyl acrylamide (PEGA) resin 3.7, developed in 1992 by
Meldal,214 was used to construct the libraries. PEGA resin is obtained by
copolymerisation of bis-2-acrylamidoprop-1-yl-PEG, 2-acrylamidoprop-1-yl[2-
aminoprop-1-yl]-PEG and dimethyl acrylamide (Figure 3.3). PEGA resin was chosen
due to its excellent swelling properties in both organic (DMF, DCM, TFA, alcohols)
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and aqueous media. It is also a highly flexible (presence of a high content of PEG),
biocompatible and polar resin that favours the solubilisation of peptides and the























Figure 3.3: Chemical structure of PEGA1900 resin (n = 43)
To enable final cleavage of the products, an acid labile linker such as the Fmoc-Rink
amide linker215 3.8 was necessary (Figure 3.4). The next important criterion in the
design of the libraries was to choose specific protecting groups to carry out PNA and
amino acid couplings under orthogonal conditions. Since global acidic cleavage
conditions were selected, and final cleavage conditions should remove the
compounds from the solid support and cleave all the protecting groups, it was
necessary to choose base-labile protecting groups. Amino acids were protected with








Figure 3.4: Chemical structure of the Fmoc-Rink-amide linker
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For PNA synthesis, PNA monomers were used, where the nucleobases (except
thymine) were protected with the acid-labile protecting group Mmt and the amino
group of the backbone with Dde,4 fully orthogonal to the Fmoc group (see section
1.1.3).20 It was shown that the fastest cleavage kinetics in terms of Dde deprotection
was obtained using PEGA resin (complete deprotection in one hour). To introduce a
FRET system in the library in a similar way as the technique described for the
10,000-member PNA-encoded FRET-based peptide library synthesis,82 one more
orthogonal protecting group was required to protect the amino side chain of lysine
during the positional scanning library synthesis and later on deprotect it to couple the
donor fluorophore. It had to be orthogonal to basic and acidic conditions so that the
palladium-labile protecting group Aloc was chosen.
3.5 Synthesis of Dde/Mmt-protected PNA monomers
3.5.1 Retrosynthesis of Dde/Mmt-protected PNA monomers
The four Dde/Mmt-protected PNA monomers 3.9 were synthesised by coupling the
Dde-protected backbone 3.10 to the corresponding Mmt-protected derivatised
nucleobase 3.11, with subsequent saponification of the Dde-protected backbone’s























Scheme 3.10: Retrosynthesis of Dde/Mmt-protected PNA monomers (No Mmt amino protection is
required for thymine)
3.5.2 Synthesis of the Dde-protected backbone
Condensation of 1,2-ethanediamine 3.12 with chloroacetic acid afforded 3.13 in 66%
yield. Compound 3.13 was esterified with thionyl chloride in methanol to give 3.14
in 88% yield. The primary amine of 3.14 was selectively protected with a Dde group,
using Dde-OH 3.15 (previously synthesised from acylation of dimedone with
Chapter 3
-91-
DCC/DMAP activated acetic acid)216 in the presence of DIPEA to afford the Dde-

























Scheme 3.11: Synthesis of the Dde-protected backbone. Reagents and conditions: (a) ClCH2CO2H
(0.1 eq), 0 °C then 25 °C, 16 h; (b) SOCl2 (5 eq), MeOH, 0 °C then reflux, 16 h; (c) Dde-OH 3.15 (1
eq), DIPEA (2 eq), DCM, 16 h
3.5.3 Synthesis of the adenine PNA monomer
The exocyclic amino group of adenine 3.16 had to be protected to avoid any side
reactions occurring at this position. Moreover, to obtain selective N9 over N7
alkylation, adenine 3.16 was first alkylated with methyl 2-bromoacetate, in the
presence of NaH to afford 3.17 in 50% yield.14 Protection of the primary amine with
Mmt was carried out using Mmt chloride in the presence of N-ethylmorpholine
(NEM) in pyridine/DCM followed by purification (removal of the by-product Mmt-
OH) to give 3.18 in 82% yield. Saponification of 3.18 with NaOH afforded in 86%
yield the derivatised adenine 3.19, which was coupled to the Dde-protected backbone
3.10 using HBTU as a coupling reagent to give 3.20 in 85% yield. This coupling step
was also carried out using PyBOP as the coupling agent, but HBTU allowed for
better yields and shorter reaction times. A final saponification afforded the adenine
PNA monomer 3.21 in 72% yield (Scheme 3.12). It was necessary to carry out
several recrystallisations to obtain a 100% pure compound. Highly pure PNA
monomers were required since the PNA-encoded libraries were synthesised on solid
phase using a split and mix methodology, generating mixtures of compounds that




















































R = CH3: 3.20, R = H: 3.21
Scheme 3.12: Synthesis of the adenine PNA monomer. Reagents and conditions: (a) BrCH2CO2CH3
(2 eq), NaH (1.1 eq), DMF, 25 °C, 16 h; (b) Mmt-Cl (1.5 eq), NEM (1 eq), pyridine/DCM (1/1, v/v),
40 °C, 16 h; (c) 1 M aqueous NaOH, reflux 2 h then 25 °C, 2 h; (d) HBTU (1.2 eq), DIPEA (1 eq),
CH3CN, 25 °C, 1 h; (e) MeOH/2 M aqueous Cs2CO3 (2/1, v/v), 25 °C, 1 h
3.5.4 Synthesis of the thymine PNA monomer
Thymine 3.22 was first alkylated with methyl 2-bromoacetate, in the presence of
K2CO3 to afford 3.23 in 58% yield, followed by saponification with NaOH to afford
the derivatised thymine 3.24 in 50% yield.14 Similarly to the adenine PNA monomer
3.21, the derivatised thymine 3.24 was coupled to the Dde-protected backbone 3.10
to give 3.25 in 77% yield, followed by saponification to afford the thymine PNA
monomer 3.26 in 40% yield.4 The low yields are explained by the poor solubility of



















































Scheme 3.13: Synthesis of the thymine PNA monomer. Reagents and conditions: (a) BrCH2CO2CH3
(1.3 eq), K2CO3 (1 eq), DMF, 25 °C, 16 h; (b) 2 M aqueous NaOH, reflux, 3 h; (c) HBTU (1.2 eq),
DIPEA (1 eq), CH3CN, 25 °C, 1 h; (d) MeOH/2 M aqueous Cs2CO3 (1/1, v/v), 25 °C, 1 h
3.5.5 Synthesis of the cytosine PNA monomer
To improve cytosine’s solubility in organic solvents, the exocyclic amino group of
cytosine 3.27 was first protected using Mmt chloride in the presence of NEM in
pyridine/DCM yielding 3.28 in 84% yield,19 followed by alkylation of 3.28 with
methyl 2-bromoacetate and NaH to afford 3.29 in 87% yield. In this case, the by-
product Mmt-OH was easily removed by recrystallisations in diethyl ether.
Saponification of 3.29 gave the derivatised cytosine nucleobase 3.30 in 74% yield. In
this case, PyBOP was used as the coupling reagent to couple 3.30 to the backbone
3.10 giving 3.31 in 57% yield. HBTU was not used as it was more difficult to purify
the product and lower yields were obtained. Compound 3.31 was saponified and
purified in a similar way to the adenine PNA monomer 3.21 to afford the cytosine























































Scheme 3.14: Synthesis of the cytosine PNA monomer. Reagents and conditions: (a) Mmt-Cl (1.5
eq), NEM (1 eq), pyridine/DCM (1/1, v/v), 50 °C, 16 h; (b) BrCH2CO2CH3 (2 eq), NaH (1.1 eq),
DMF, 25 °C, 16 h; (c) 2 M aqueous NaOH, reflux 2 h; (d) PyBOP (1.1 eq), DIPEA (2 eq), DMF, 25
°C, 16 h; (e) MeOH/2 M aqueous Cs2CO3 (2/1, v/v), 25 °C, 1 h
3.6 Synthesis of a 625-member PNA-encoded positional
scanning library
As proof-of-principle, the synthesis of the first sub-library of a 625-member PNA-
encoded tetrapeptide positional scanning library (PNA encoding of five amino acids
located in the first position of the tetrapeptide) was first investigated.
3.6.1 Selection of amino acids
To introduce good “diversity” into the library, five natural amino acids with differing
properties were chosen: alanine 3.33 (hydrophobic), serine 3.34 (hydrophilic), lysine
3.35 (basic and hydrophilic), glutamic acid 3.36 (acidic and hydrophilic) and proline
3.37 (hydrophobic and cyclic) (Figure 3.5). The side chains of serine 3.34 and
glutamic acid 3.36 were protected with tert-butyl groups, while a Boc group was















Glutamic acid 3.36 Proline 3.37
Figure 3.5: Chemical structures of the five selected amino acids
3.6.2 Design of the PNA tags
A 12-mer PNA has been proven to be a suitable length for hybridisation, and the
formation of strong PNA/DNA duplexes with good mismatch discrimination.77, 81
PNA tags were composed of twelve PNA monomers, with the first seven PNA
monomers common to all the amino acids encoded within the library, and a
quintuplet PNA used as the encoding sequence. PNA tags were designed with
specific criteria.217 To avoid aggregation and solubility issues in aqueous solutions,
the purine content was limited to 60% and sequences did not contain more than four
consecutive adenines or three contiguous guanines. Moreover, it was essential not to
design self-complementary PNA sequences with inverse repeats, hairpins or
palindromes since it leads to aggregation with formation of very stable PNA/PNA
duplexes. The presence of a common 7-mer PNA was important to have PNA tags
with similar Tm and obtain homogeneous detection of the library members after
hybridisation. The PNA tags differed by at least three base pair mismatches to ensure
effective and selective hybridisation, where every PNA tag hybridised with its
complementary DNA immobilised on a DNA microarray. Following these basic
rules, a common 7-mer PNA with the sequence GATCATC (from N → C) was
designed as well as the 5-mer PNA tags used to encode the five amino acids in the
first position of the tetrapeptide (Table 3.1). The guanine PNA monomer used to
prepare these PNA tags was synthesised by Diaz-Mochon.4
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Table 3.1: Sequences of the 5-mer PNA tags of the first sub-library






3.6.3 Synthesis of the common part of the library
3.6.3.1 Synthesis of Fmoc-Lys(Dde)-OH
The common part of the library was synthesised using Fmoc-Lys(Dde)-OH 3.38 as a
core. This core allowed for attachment to the solid support through the carboxylic
acid functionality, the construction of the PNA tag using Dde chemistry20 on the side
chain amine and Fmoc-based SPPS through the α-amino group. The condensation of
Fmoc-Lys-OH 3.39 with Dde-OH 3.15 in refluxing ethanol and TFA for 60 h














Scheme 3.15: Synthesis of Fmoc-Lys(Dde)-OH. Reagents and conditions: (a) Dde-OH 3.15 (2 eq),
TFA (0.1 eq), EtOH, reflux, 60 h
3.6.3.2 Synthesis of Fmoc-PEG spacer-OH
A hydrophilic and highly flexible spacer such as PEG was also connected to the resin
as it increased the solubility of every library member. Moreover, if the peptides and
their PNA tags were too close in proximity, undesirable interactions could appear
and the cleavage site might not be fully accessible to the protease. Nucleophilic
attack by one primary amine of the starting compound 3.40 on succinic anhydride
3.41 gave 3.42. Following protection of the remaining free amine with an Fmoc































Scheme 3.16: Synthesis of Fmoc-PEG spacer-OH. Reagents and conditions: (a) CH3CN, 25 °C, 3 h;
(b) Fmoc-OSu (1.3 eq), CH3CN, DIPEA, pH 8-9, 25 °C, 16 h
3.6.3.3 Synthesis of the common part of the library
In the first step, the Fmoc-Rink amide linker 3.8 was loaded onto PEGA resin 3.7,
which was followed by removal of the Fmoc group and coupling with Fmoc-
Lys(Dde)-OH 3.38. In the last two steps, the Fmoc group was first deprotected
followed by stepwise couplings with the Fmoc-PEG spacer-OH 3.43 and the
commercially available Fmoc-Lys(Aloc)-OH to afford compound 3.44. The
construction of the 7-mer PNA with the sequence GATCATC (from N → C) was
carried out on the amino side chain of Fmoc-Lys(Dde)-OH 3.38 using Dde
chemistry.20 The common part of the library 3.45 was thus obtained. All the
couplings were carried out using PyBOP as the coupling reagent and completion of










































Common part of the library
f, g
Scheme 3.17: Synthesis of the common part of the library. Reagents and conditions: (a) Fmoc-Rink-
amide linker 3.8 (5 eq), PyBOP (4.8 eq), DMF (0.1 M), NEM (10 eq), 25 °C, 6 h; (b) 20% piperidine
in DMF, 2 cycles of 10 min, 25 °C; (c) Fmoc-Lys(Dde)-OH 3.38 (5 eq), PyBOP (4.8 eq)/HOBt (5 eq),
DMF (0.1 M), DIPEA (10 eq), 25 °C, 6 h; (d) Fmoc-PEG spacer-OH 3.43 (5 eq), PyBOP (4.8 eq),
DMF (0.1 M), NEM (10 eq), 25 °C, 6 h; (e) Fmoc-Lys(Aloc)-OH (5 eq), PyBOP (4.8 eq)/HOBt (5
eq), DMF (0.1 M), DIPEA (10 eq), 25 °C, 6 h; (f) NH2OH.HCl (1.3 eq)/imidazole (1 eq), NMP/DMF,
25 °C, 1 h; (g) Dde/Mmt protected PNA (5 eq), PyBOP (4.8 eq), DMF (0.1 M), NEM (10 eq), 25 °C,
6 h; Repeat 6 times steps f and g
An analytical amount of the common part of the library 3.45 was cleaved from the
resin using a mixture of TFA/TIS/DCM (90/5/5). The HPLC trace of the crude
compound showed an excellent purity (91%), which implied over 99% purity per
chemical step (22 steps including deprotection steps). MALDI-TOF MS analysis
showed the mass of the expected compound (Figure 3.6). The purity and the small
number of deletion sequences confirmed the efficiency of the PNA coupling steps.4
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Figure 3.6: HPLC spectrum (ELSD, 91% purity) and MALDI-TOF MS spectrum, top left of the
common part of the library 3.45 after acidic cleavage
3.6.4 Synthesis of the first sub-library
The synthesis of the 625-member PNA-encoded positional scanning library (first
sub-library) was carried out. In this section, all the couplings were carried out using
PyBOP as the coupling reagent and completion of each reaction was verified by
running a ninhydrin test.220 The common part of the library 3.45 was split into five
pools. Each batch was subjected to Fmoc deprotection followed by coupling with one
of the five selected Fmoc-protected amino acids (Ala, Ser, Lys, Glu and Pro). After
Dde deprotection20 on each batch, the encoding PNA arm was built to encode the
first position of one amino acid in the tetrapeptide. Each pool contained a different
amino acid and was consequently encoded with a different 5-mer PNA tag (Table
3.1). After mixing all the pools, a mixture of compounds 3.46 was obtained. In the
two following schematic representations 3.18 and 3.19, the seven PNA monomers
are abbreviated to “7-mer PNA”, while the five different PNA monomers used as
encoding tags are noted “5-mer PNA”. Moreover, the general structure of the library
is also simplified by representing only the lateral chain of the core lysine onto which









































































Scheme 3.18: Schematic representation of the PNA encoding of the first position in the tetrapeptide.
Reagents and conditions: (a) 20% piperidine in DMF, 2 cycles of 10 min, 25 °C; (b) Fmoc-AA-OH (5
eq), PyBOP (4.8 eq)/HOBt (5 eq), DMF (0.1 M), DIPEA (10 eq), 25 °C, 6 h (where AA = amino
acid); (c) NH2OH.HCl (1.3 eq)/imidazole (1 eq), NMP/DMF, 25 °C, 1 h; (d) Dde/Mmt protected PNA
(5 eq), PyBOP (4.8 eq), DMF (0.1 M), NEM (10 eq), 25 °C, 6 h; Repeat 4 times steps c and d
The resulting mixture 3.46 was then split into five different pools. Following Fmoc
deprotection, each batch was coupled with one of the five Fmoc-protected amino
acids and mixed again. This procedure was repeated twice to end up with a pot 3.47
containing 625 different tetrapeptides encoded by five PNA tags (Scheme 3.19). The
general structure of the first sub-library 3.47 that is obtained at the end of the split








































5-mer PNA-7-mer PNA NH
5-mer PNA-7-mer PNA NH
5-mer PNA-7-mer PNA NH
5-mer PNA-7-mer PNA NH
Scheme 3.19: Schematic representation of the 625-member PNA-encoded positional scanning library
(first sub-library), where X = equimolar mixture of five amino acids. Reagents and conditions: (a)
20% piperidine in DMF, 2 cycles of 10 min, 25 °C; (b) Fmoc-AA-OH (5 eq), PyBOP (4.8 eq)/HOBt


















Figure 3.7: General structure of the 625-member PNA-encoded positional scanning library (first sub-
library) before the introduction of the FRET system, where O = one of the five encoded amino acids
and X = equimolar mixture of five amino acids
To detect and monitor proteolytic activity, a FRET system was introduced within the
library to produce an internally quenched fluorescent peptide. An important criterion
was to choose the correct donor fluorophore/acceptor fluorophore (quencher) couple
so that the emission spectrum of the donor fluorophore overlaps with the absorption
spectrum of the quencher. The donor/quencher couple 5(6)-carboxyfluorescein
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(fluorescein)/rhodamine was chosen, with fluorescein being effectively quenched by
the nearby rhodamine acceptor in a FRET system. Fluorescein was selected as the
donor (λex = 495 nm and λem = 520 nm) and rhodamine as the acceptor (λex = 545 nm
and λem = 580 nm) since these two dyes were biocompatible, cheap and fluorescence
could be easily detected in most instruments using standard filters.
It has been previously reported that the introduction of a spacer at the end of the
peptide sequence allowed better hydrolysis kinetics.221 However, if the spacer is too
long then the FRET system would not work properly as the two fluorophores would
be too far away from each other. If it is too short then the protease would not have
good access to the cleavage site. Consequently the 4-carbon spacer γ-amino butyric
acid (γ-Abu) was used. Following Fmoc deprotection, the commercially available
Fmoc-γ-Abu was coupled to resin 3.47 to give the expected compound 3.48. Finally,
the FRET system was incorporated in the library. Fluorescein was attached to the
lateral chain of lysine on the C-terminal side of the cleavage site, while rhodamine
was attached to the N-terminal end. Another Fmoc deprotection and coupling with
rhodamine afforded the rhodamine-labelled compound 3.49. The Aloc group was
then removed under neutral conditions using a catalytic amount of Pd(PPh3)4 in the
presence of PhSiH3 as a scavenger in dry DCM. In order to avoid oxidation of the
palladium, the deprotection was carried out under an inert atmosphere (N2).
222
Coupling with fluorescein with subsequent washings with 20% piperidine in DMF to
remove impurities151 afforded the internally quenched fluorescent peptide 3.50. A
final acidic cleavage (TFA/TIS/DCM: 90/5/5, 2 h) released the compounds from the
solid support and simultaneously removed all the acid-labile side chain protecting
groups of amino acids and PNA monomers. The first sub-library 3.51 was obtained
in 67% yield (> 99% yield per chemical step (46 steps including deprotection steps)).
This yield was calculated using the first sub-library 3.51 average mass of 5135.5
g/mol, obtained using both the average masses of the five amino acids and the four
Dde/Mmt-protected PNA monomers (Scheme 3.20). Since a mixture of 625 different
compounds was obtained, it was no longer possible to determine the identity of every









































































Scheme 3.20: General structure of the 625-member PNA-encoded positional scanning library (first
sub-library), where O = one of the five encoded amino acids and X = equimolar mixture of five amino
acids. Reagents and conditions: (a) 20% piperidine in DMF, 2 cycles of 10 min, 25 °C; (b) Fmoc-γ-
Abu-OH (5 eq), PyBOP (4.8 eq)/HOBt (5 eq), DMF (0.1 M), DIPEA (10 eq), 25 °C, 6 h; (c)
Rhodamine (5 eq), PyBOP (4.8 eq), DMF (0.1 M), NEM (10 eq), 25 °C, 6 h; (d) Pd(PPh3)4 (0.1
eq)/PhSiH3 (24 eq), dry DCM, N2, 2 cycles of 15 min; (e) 5(6)-carboxyfluorescein (5 eq), PyBOP (4.8
eq), DMF (0.1 M), NEM (10 eq), 25 °C, 6 h; (f) TFA/TIS/DCM (90/5/5), 2 h
To verify the presence of the FRET system within the first sub-library, two resin
beads were taken up at the end of the first sub-library synthesis (just before acidic
cleavage) and scanned using fluorescein and rhodamine filters. Fluorescent images of
the two resin beads 3.51 are shown in Figure 3.8, confirming the correct labelling of
the first sub-library with the two dyes.
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Figure 3.8: Fluorescent images of two resin beads from the 625-member PNA-encoded positional
scanning library (first sub-library): (A) fluorescein image; (B) rhodamine image; (C) superimposed
image of fluorescein and rhodamine images
3.7 Synthesis of a 50,625-member PNA-encoded positional
scanning library
3.7.1 Introduction
The 625-member PNA-encoded positional scanning library (first sub-library) 3.51
was successfully synthesised and used to profile three different proteases (results of
the enzymatic assays are reported in section 3.8.2). Consequently, the concept was
extended to the synthesis of a larger PNA-encoded positional scanning library
composed of 50,625 different tetrapeptides encoded for by just 60 PNA tags. To
reduce the amount of PNA monomers needed to synthesise the library, fifteen amino
acids were chosen from the 20 natural amino acids excluding Asn and Asp (similar
side-chain structures and polarity to Gln and Glu respectively), Leu (similar side-
chain structure and polarity to Ile), Cys and Met (to avoid formation of disulfide
bonds and oxidation of the sulphur). The library was also divided into four separate
sub-libraries, in which 15 different amino acids were held constant at one position in
the tetrapeptide and encoded by a specific PNA tag, while the other three positions
contained an equimolar mixture of 15 amino acids. Each sub-library contained
50,625 (154) different compounds encoded by 15 PNA tags, and in total only 60
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Scheme 3.21: Schematic representation of a 50,625-member PNA-encoded tetrapeptide positional
scanning library
3.7.2 Design of the PNA tags
To design the 60 PNA tags, the method used for the 625-member PNA-encoded
positional scanning library could have been adapted to the synthesis of a larger
positional scanning library by fixing a common 6-mer PNA (ATCATC, from N →
C) and then encoded every amino acid with a 6-mer PNA tag. However this approach
required the use of the four natural bases, and some PNA monomers such as the PNA
guanine monomer  are difficult to synthesise on large scale (solubility issues, poor
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yields).4 Brenner labelled each nucleic acid of a library with a DNA tag composed of
only three natural bases (A, C and T) by using the following four-base “words”
(TTAC, AATC, TACT, ATCA, ACAT, TCTA, CTTT, and CAAA).223 A total
number of 16,777,216 (88) tags of 32 bases could be used, allowing encoding of very
large combinatorial libraries. It was also demonstrated that the systematic presence
of three A-T and one G-C complementary base pairs between duplexes ensures the
generation of isothermal Tm’s. All these features appeared as an attractive strategy to
design the 60 PNA tags. Each PNA tag was composed of three four-base “words” to
produce a 12-mer PNA tag. To minimise PNA aggregation and avoid the preparation
of PNA tags containing more than four adenines in a row, with an adenine content
superior to 60%, or composed of five consecutive thymines (these PNAs are difficult
to synthesise, resulting in the formation of deleted sequences224), the four-base
“words” TTAC, AATC, CTTT and CAAA were not used. The 60 PNA tags were
designed following the recommendations described in section 3.6.2. Each PNA tag
was fixed with a four-base “word”, different between the four sub-libraries (TCTA,
ACAT, ATCA and TACT were used for the first, second, third and fourth sub-
libraries respectively). Within a sub-library, a specific amino acid was thus encoded
by an 8-mer PNA tag and all the PNA tags differed by at least 3 mismatches to have
a good discrimination between perfect and mismatched duplexes (Table 3.2).
Table 3.2: Sequences of the PNA tags (from N → C) used to encode amino acids in the four sub-
libraries
1st sub-library 2nd sub-library 3rd sub-library 4th sub-library
Ala TCTA TCTA TCTA TCTA TCTA ACAT TCTA TCTA ATCA TCTA TCTA TACT
Arg TCTA ACAT TCTA TCTA ACAT ACAT TCTA ACAT ATCA TCTA ACAT TACT
Gln TCTA ATCA TCTA TCTA ATCA ACAT TCTA ATCA ATCA TCTA ATCA TACT
Glu TCTA TACT TCTA TCTA TACT ACAT TCTA TACT ATCA ACAT TCTA TACT
Gly ACAT TCTA TCTA ACAT TCTA ACAT ACAT TCTA ATCA ACAT ACAT TACT
His ACAT ACAT TCTA ACAT ACAT ACAT ACAT ACAT ATCA ACAT ATCA TACT
Ile ACAT ATCA TCTA ACAT ATCA ACAT ACAT TACT ATCA ACAT TACT TACT
Lys ACAT TACT TCTA ACAT TACT ACAT ATCA TCTA ATCA ATCA TCTA TACT
Phe ATCA TCTA TCTA ATCA TCTA ACAT ATCA ACAT ATCA ATCA ACAT TACT
Pro ATCA ACAT TCTA ATCA ATCA ACAT ATCA ATCA ATCA ATCA ATCA TACT
Ser ATCA ATCA TCTA ATCA TACT ACAT ATCA TACT ATCA ATCA TACT TACT
Thr ATCA TACT TCTA TACT TCTA ACAT TACT TCTA ATCA TACT TCTA TACT
Trp TACT TCTA TCTA TACT ACAT ACAT TACT ACAT ATCA TACT ACAT TACT
Tyr TACT ACAT TCTA TACT ATCA ACAT TACT ATCA ATCA TACT ATCA TACT
Val TACT ATCA TCTA TACT TACT ACAT TACT TACT ATCA TACT TACT TACT
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3.7.3 Synthesis of the four sub-libraries
The common part of the 50,625-member PNA-encoded positional scanning library
3.44 was synthesised following the procedure described in section 3.6.3.3, and then
split into four equal batches of resin, where the different four-base “words” (TCTA,
ACAT, ATCA and TACT for the first, second, third and fourth sub-libraries
respectively) were built on the side chain of lysine using Dde chemistry20 to give the
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Figure 3.9: Synthesis of the common part of the four sub-libraries. Reagents and conditions: (a)
NH2OH.HCl (1.3 eq)/imidazole (1 eq), NMP/DMF, 25 °C, 1 h; (b) Dde/Mmt protected PNA (5 eq),
PyBOP (4.8 eq), DMF (0.1 M), NEM (10 eq), 25 °C, 6 h; Repeat 3 times steps a and b
An analytical amount of resins 3.52, 3.53, 3.54 and 3.55 were cleaved from the resin
using a mixture of TFA/TIS/DCM (90/5/5). The HPLC traces and the MALDI-TOF
MS spectra of the crude compounds are displayed in Figure 3.10. Excellent purities
of 78% (> 98% purity per chemical step), 84% (99% purity per chemical step), 83%
(99% purity per chemical step) and 85% (99% purity per chemical step) were found
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for the first, second, third and fourth sub-libraries respectively. MALDI-TOF MS
analysis showed the expected masses of the compounds. It was extremely important
to carry out these analyses since the next steps of split and mix generated mixtures of
compounds that could not be characterised by HPLC and MALDI-TOF MS.
Figure 3.10: HPLC spectrum and MALDI-TOF MS spectrum, top left of the common part of (A) the
first sub-library; (B) the second sub-library; (C) the third sub-library; (D) the fourth sub-library
The four sub-libraries were synthesised separately using the common part of the sub-
libraries 3.52, 3.53, 3.54 and 3.55, and following the procedure described for the
625-member PNA-encoded positional scanning library (see section 3.6.4), except
that fifteen amino acids were coupled on each batch of resin and each amino acid
was encoded by an 8-mer PNA tag. The final general structures of the four sub-
libraries of the 50,625-member PNA-encoded positional scanning library 3.56, 3.57,
3.58 and 3.59 are displayed in Figure 3.11. Images of one resin bead of the first sub-
library (obtained just before the final acidic cleavage) validated the presence of the



































































Figure 3.11: General structure of the 50,625-member PNA-encoded positional scanning library (four
sub-libraries), where O = one of the fifteen encoded amino acids and X = equimolar mixture of fifteen
amino acids
Figure 3.12: Fluorescent images of one resin bead from the 50,625-member PNA-encoded positional
scanning library (first sub-library): (A) fluorescein image; (B) rhodamine image; (C) superimposed
image of fluorescein and rhodamine images
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3.8 Determination of protease substrate specificity
3.8.1 General concept
Following solid-phase synthesis, each peptide of the PNA-encoded positional
scanning library was labelled with the donor fluorophore fluorescein at the C-
terminus and the acceptor fluorophore rhodamine at the N-terminus so that the
fluorescein fluorescence was quenched by rhodamine. In a typical enzymatic assay,
the library was incubated in solution with the target protease (Figure 3.13) and the
resulting solution was added onto a DNA microarray. Thus, both cleaved and non-
cleaved peptides were hybridised onto the DNA microarray. Following washing, the
microarray was scanned at two different wavelengths to quantify the level of
proteolysis (Figure 3.14). At the rhodamine wavelength, the fluorescent spots
corresponded to the non-cleaved peptides, where the fluorescein fluorescence was
quenched by rhodamine, while at the fluorescein wavelength, the fluorescent spots
corresponded to the cleaved peptides, where a disruption of the FRET system led to
an increase in fluorescein intensity. The protease substrate specificity was accurately
profiled by calculating the ratios of fluorescein/rhodamine for every feature, with the
highest ratios of fluorescein/rhodamine corresponding to the preferred amino acids

































Figure 3.13: Example of a proteolytic cleavage of a PNA-encoded FRET-based peptide positional
scanning library, where O = encoded amino acid and X = equimolar mixture of amino acids
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Figure 3.14: Protease profiling using a PNA-encoded FRET-based peptide positional scanning library
3.8.2 Experiments using the 625-member PNA-encoded positional
scanning library (first sub-library)
3.8.2.1 Proof of solution-phase proteolytic cleavage
Before carrying out microarray-based proteolytic profiling, it was essential to verify
that peptides from the 625-member PNA-encoded positional scanning library (first
sub-library) could act as protease substrates. To do so, the first sub-library (100 µM
final concentration) was assayed in solution with the serine protease subtilisin A (10
µM final concentration), and the fluorescein emission was monitored by
spectrofluorometry, at an excitation wavelength of 480 nm and an emission
wavelength of 520 nm. After 30 min incubation, a significant increase in fluorescein
fluorescence was observed, proving that proteolytic cleavage occurred (Figure 3.15).
Two peaks should have been observed at 520 nm (fluorescein emission) and at 585
nm (rhodamine emission). Although there was no peak at 585 nm, the fluorescent
images displayed in Figure 3.8 confirmed the presence of rhodamine, and the “red”
colour of all resin beads indicated that the beads were properly labelled with
rhodamine. Moreover, in future experiments reported in section 3.8.2.3, the images
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of the microarray obtained after hybridisation with the first sub-library (see Figure























before subtilisin A addition
10 min after subtilisin A
addition
20 min after subtilisin A
addition
30 min after subtilisin A
addition
Figure 3.15: Fluorescence spectra obtained with the 625-member PNA-encoded positional scanning
library (first sub-library) before and after incubation with subtilisin A
3.8.2.2 Preparation of DNA microarrays
Five different 3’-amino modified 12-mer DNAs (Table 3.3), each complementary to
one of the five PNA tags (Table 3.1), with an additional spacer composed of six
thymines (to separate the DNA/PNA from the microarray surface) were printed onto
commercially available aldehyde-derivatised glass slides (see section 1.5.2) using a
robotic microarrayer. To verify successful DNA printing on the surface, a 3’-amino-
5’-fluorescein modified 12-mer DNA, whose sequence was not complementary to
any of the five PNA tags, was also printed as a control. Each DNA oligomer was
printed as five replicates (1 x 5 sub-arrays), and this pattern was duplicated across the
microarray (Figure 3.16). In the following sections, all the positions of the printed
DNAs were named according to the encoded amino acid (e.g. the names Ala, Ser,
Lys, Glu and Pro corresponded to the DNAs complementary to the PNAs that




Table 3.3: Sequences of the modified 12-mer DNAs
Encoded amino acid
Modified 12-mer DNA (from 5’ → 3’)







1 1 1 1 1
2 2 2 2 2
3 3 3 3 3
4 4 4 4 4
5 5 5 5 5
6 6 6 6 6
1 = Ala 3 = Lys 5 = Pro
2 = Ser 4 = Glu 6 = control
1 1 1 1 1
2 2 2 2 2
3 3 3 3 3
4 4 4 4 4
5 5 5 5 5
6 6 6 6 6
1 = Ala 3 = Lys 5 = Pro
2 = Ser 4 = Glu 6 = control
Figure 3.16: Schematic representation of the pattern used for DNA printing on a microarray
After DNA printing, the slides were washed and scanned using a fluorescein filter.
Fluorescent spots where the fluorescein-labelled DNA (control) was printed were
observed, confirming that the printing was successful.
3.8.2.3 Hybridisation onto DNA microarrays
To determine the best library concentration for hybridisation, the first sub-library
was hybridised onto a DNA microarray at four different concentrations (5 μM, 500
nM, 50 nM and 5 nM). Following washing and scanning of each microarray using a
rhodamine and a fluorescein filter, the intensities of the spots were analysed using
the FIPS software (LaVision BioTech). Median values and standard errors were
calculated for the five different features containing the same encoded amino acid,
which was followed by the calculation of the average median values and standard
errors of each encoded amino acid between the duplicated patterns (Figure 3.17). The
greater the PNA hybridisation, the greater the rhodamine fluorescence was. A 5 μM
concentration was found to be optimal, producing the highest (but not saturated)
fluorescent signals. The choice of a lower concentration would have generated





























Figure 3.17: Correlation between rhodamine intensity and the first sub-library concentration (values
correspond to the average of ten replicates)
Images of the microarray obtained after hybridisation with the first sub-library at a 5
µM concentration are displayed in Figure 3.18. At the rhodamine wavelength, it was
confirmed that hybridisation was selective since no fluorescent signal was observed
where the non-complementary fluorescein-labelled DNA (control) was printed and
each PNA hybridised with its complementary DNA. All the replicates gave very
similar fluorescent spots. Small differences in the rhodamine spot intensity between
different encoded amino acids were observed (Figures 3.17 and 3.18), confirming
that all PNAs did not hybridise with the same efficiency and that internal controls
were necessary. At the fluorescein wavelength, the control fluorescence intensity was
very high, and very weak fluorescent spots (close to the background intensity) were




Figure 3.18: Images of the microarray hybridised with the first sub-library using A) a rhodamine filter
and B) a fluorescein filter; C) schematic representation of the microarray pattern, where Ctrl is the
fluorescein-labelled control
3.8.2.4 Enzymatic assays
All the enzymatic assays were performed following the procedure described in
section 3.8.1. The data were reprocessed by calculating the ratio of
fluorescein/rhodamine for each feature, and determining the median values and
standard errors of the ratio of fluorescein/rhodamine for each encoded amino acid,
which was followed by the calculation of the average median values and standard
errors of each encoded amino acid between the duplicated patterns. The 625-member
PNA-encoded positional scanning library (first sub-library) was used to profile the
substrate specificities of three different proteases.
The first enzymatic assay was carried out using the aspartic endopeptidase pepsin.
Pepsin, whose name was given by Schwann in 1836, was the first animal enzyme to
be identified and is one of the main digestive proteases of the stomach (along with
chymotrypsin and trypsin).193, 225 Pepsin cleaves peptide bonds between large
hydrophobic/aromatic amino acids, with the preferential cleavage sites being the P1
and P1’ positions, where the large hydrophobic residues Phe and Leu are preferred. In
general, pepsin has a very broad specificity (this is appropriate due to its role in
digestion) and accepts a large variety of amino acids.193 The images of the
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microarray hybridised with the first sub-library following pepsin incubation in
solution are shown in Figure 3.19. The use of the rhodamine wavelength confirmed
that the hybridisation was selective, while new fluorescent spots corresponding to
peptides cleaved by pepsin could be observed at the fluorescein wavelength. Since
some fluorescent spots were close to the background intensity at the fluorescein
wavelength (e.g. at the positions where the DNA that encoded the amino acid Ala
was printed), the fluorescein-labelled control fluorescence intensity was increased up
to saturation so that it was easier to observe the other fluorescent spots. If the same
approach would have been applied to Figure 3.18, only small differences in the
fluorescein spot intensity would have been observed between the different encoded
amino acids, and the replicate intensity would have been very similar. In Figure 3.19,
the fact that a proteolytic cleavage occurred was confirmed by the presence of
important differences between the different encoded amino acid fluorescent signals
at the fluorescein wavelength. If no peptides were recognised by pepsin, similar
fluorescein spot intensities between the different encoded amino acids would have
been observed. Following data reprocessing (see Appendix IV), a first profile was
obtained, confirming the broad specificity of pepsin since all five residues were
accepted and no particular amino acid was strongly preferred (Figure 3.20). It should
be pointed out that the approach described here detected cleavage anywhere in the
peptide, and the preferred amino acids (but not the consensus sequences) were
identified at each position of the peptide.
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Figure 3.19: Images of the microarray hybridised with the first sub-library following pepsin
incubation in solution using A) a rhodamine filter and B) a fluorescein filter; C) schematic
representation of the microarray pattern, where Ctrl is the fluorescein-labelled control
Figure 3.20: Profile of pepsin obtained using the 625-member PNA-encoded positional scanning
library (first sub-library) (values correspond to the average of ten replicates)
A second enzymatic assay was carried out using the serine endopeptidase subtilisin
A that was discovered in 1947 by Linderström-Lang and Ottensen.226 Subtilisins are
also non-specific proteases, P1 and P4 being the most important positions. In the P1
position, large and non-β-branched hydrophobic amino acids are preferred but basic
amino acids can be tolerated. Hydrophobic amino acids are strongly preferred in the




Following data reprocessing (see Appendix V), the results confirmed that subtilisin
A was not a highly specific protease (Figure 3.21) since polar, basic, acidic and
hydrophobic residues were all tolerated (similar ratios for Ser, Lys, Glu and Pro).
Interestingly the small hydrophobic residue Ala was clearly the most preferred amino
acid, which agreed well with the known specificity of the P2 position.
193
Figure 3.21: Profile of subtilisin A obtained using the 625-member PNA-encoded positional scanning
library (first sub-library) (values correspond to the average of ten replicates)
The last enzymatic assay was performed using the serine endopeptidase trypsin that
was discovered in 1876 by Kühne.193 Trypsin is a digestive protease that strongly
prefers to cleave peptide bonds on the carboxyl side of Lys and Arg. Large
hydrophobic and positively charged amino acids are preferred in the P1’ and P2’
positions respectively.193 Following data reprocessing (see Appendix VI), trypsin
showed the expected preference for the basic amino acid Lys193, 201 (Arg was not
present in the library) but also a marked preference for Ala (Figure 3.22), which
agreed particularly well with the results reported by Jakubke, who described the
peptide sequence Gly-Pro-Ala-Lys-Leu-Ala-Ile-Gly as a good substrate for trypsin
(cleavage after the residue Lys).227 By looking at proteolytic cleavage anywhere in
the peptide, the residue Lys that was known to play a crucial role in trypsin activity
and the cooperative role of Ala were both identified in a single experiment. This




Figure 3.22: Profile of trypsin obtained using the 625-member PNA-encoded positional scanning
library (first sub-library) (values correspond to the average of ten replicates)
3.8.3 Experiments using the 50,625-member PNA-encoded positional
scanning library
3.8.3.1 Proof of solution-phase proteolytic cleavage
Each sub-library (50 µM final concentration) was separately assayed in solution with
trypsin (20 nM final concentration), and the fluorescein emission was monitored by
spectrofluorometry, at an excitation wavelength of 480 nm. Proteolytic cleavage for
each sub-library was confirmed by the significant increase of the fluorescein
intensity (Figure 3.23). Although the four sub-libraries had the same concentration
(based on UV absorbance measurements), different profiles for the emission spectra
were obtained. When the first, second and fourth sub-libraries were excited at 480
nm, two peaks were observed at 520 nm (fluorescein emission) and at 585 nm
(rhodamine emission), with the peak at 520 nm being the most intense; for the third
sub-library, both peaks had similar intensities. Since proteolytic cleavage was clearly




Figure 3.23: Fluorescence spectra obtained with the 50,625-member PNA-encoded positional
scanning library before and after incubation with trypsin
3.8.3.2 Preparation of DNA microarrays
DNA microarrays were prepared following the procedure described in section
3.8.2.2, except that fifteen different 3’-amino modified 12-mer DNAs (Table 3.4),
each complementary to one of the fifteen PNA tags (Table 3.2), were printed onto
aldehyde-derivatised glass slides as five replicates (1 x 5 sub-arrays) following the
pattern shown in Figure 3.24C.
Table 3.4: Sequences of the modified 12-mer DNAs (from 5’ → 3’)
1st sub-library 2nd sub-library 3rd sub-library 4th sub-library
Ala TAGA TAGA TAGA ATGT TAGA TAGA TGAT TAGA TAGA AGTA TAGA TAGA
Arg TAGA ATGT TAGA ATGT ATGT TAGA TGAT ATGT TAGA AGTA ATGT TAGA
Gln TAGA TGAT TAGA ATGT TGAT TAGA TGAT TGAT TAGA AGTA TGAT TAGA
Glu TAGA AGTA TAGA ATGT AGTA TAGA TGAT AGTA TAGA AGTA TAGA ATGT
Gly TAGA TAGA ATGT ATGT TAGA ATGT TGAT TAGA ATGT AGTA ATGT ATGT
His TAGA ATGT ATGT ATGT ATGT ATGT TGAT ATGT ATGT AGTA TGAT ATGT
Ile TAGA TGAT ATGT ATGT TGAT ATGT TGAT AGTA ATGT AGTA AGTA ATGT
Lys TAGA AGTA ATGT ATGT AGTA ATGT TGAT TAGA TGAT AGTA TAGA TGAT
Phe TAGA TAGA TGAT ATGT TAGA TGAT TGAT ATGT TGAT AGTA ATGT TGAT
Pro TAGA ATGT TGAT ATGT TGAT TGAT TGAT TGAT TGAT AGTA TGAT TGAT
Ser TAGA TGAT TGAT ATGT AGTA TGAT TGAT AGTA TGAT AGTA AGTA TGAT
Thr TAGA AGTA TGAT ATGT TAGA AGTA TGAT TAGA AGTA AGTA TAGA AGTA
Trp TAGA TAGA AGTA ATGT ATGT AGTA TGAT ATGT AGTA AGTA ATGT AGTA
Tyr TAGA ATGT AGTA ATGT TGAT AGTA TGAT TGAT AGTA AGTA TGAT AGTA




Compared to the 625-member PNA-encoded library, a higher library concentration
was required to hybridise the 50,625-member PNA-encoded positional scanning
library (all four sub-libraries) onto the DNA microarray. Since a 25 µM final library
concentration produced low fluorescent signals, a 50 µM final library concentration
was used. Images of the microarray obtained after hybridisation are displayed in
Figure 3.24. At the rhodamine wavelength, the selectivity of the hybridisation was
confirmed, while at the fluorescein wavelength, low fluorescent spots were observed
due to the quenching of fluorescein by rhodamine.
Figure 3.24: Images of the microarray hybridised with the 50,625-member PNA-encoded positional
scanning library using A) a rhodamine filter and B) a fluorescein filter; C) schematic representation of
the microarray pattern
The first enzymatic assays were carried out by incubating the 50,625-member PNA-
encoded positional scanning library (all four sub-libraries) with trypsin for 2 h at 37
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°C. Images of the microarray hybridised with the library following trypsin incubation
are shown in Figure 3.25. At the rhodamine wavelength, each PNA tag of the four
sub-libraries hybridised with its complementary DNA, generating fluorescent spots
with similar intensities between the replicates but also between the different encoded
amino acids since the PNA tags were designed to have similar Tm’s. However, at the
fluorescein wavelength, instead of having spots with different intensities according to
the peptide cleavage rate, all fluorescent spots had virtually identical intensities.
Figure 3.25: Images of the microarray hybridised with the 50,625-member PNA-encoded positional
scanning library following trypsin addition using A) a rhodamine filter and B) a fluorescein filter; C)
schematic representation of the microarray pattern
The data were reprocessed by calculating the ratio of fluorescein/rhodamine for each
feature, and determining the median values and standard errors of the ratio of
fluorescein/rhodamine for each encoded amino (see Appendix VII). The profile
obtained showed no detectable variation in substrate specificity (Figure 3.26). A
Chapter 3
-123-
clear preference for positively charged (Lys, Arg) and hydrophobic residues (Ala)
should have been observed (see section 3.8.2.4). Different assay conditions were
tested, varying the concentration of trypsin (from 1 nM to 2 µM) and the time of
incubation (from 30 min to 16 h), or by carrying out on-chip assays (a fresh solution
of trypsin (450 nM) was added every hour onto the PNA/DNA microarray over a
period of 6 h) but no difference was observed.
Figure 3.26: Profiles of trypsin obtained using the 50,625-member PNA-encoded positional scanning
library (values correspond to the average of five replicates)
Enzymatic assays were carried out using two other enzymes, the cysteine protease
chymopapain (Figure 3.27, see Appendix VIII for data reprocessing) and the aspartic
protease pepsin (Figure 3.28, see Appendix IX for data reprocessing) but once again,
very similar ratios of fluorescein/rhodamine for all the different encoded amino acids
were observed. A broad specificity was expected for pepsin but chymopapain prefers
the amino acids Ala, Pro, Val and Lys in positions P4 to P1.
228 The fluorescent spots
observed at both rhodamine and fluorescein wavelengths as well as the results
obtained by spectrofluorometry (see section 3.8.3.1) proved that a FRET system was
present in the library and that proteolytic cleavage occurred in solution. However,
once the peptides were immobilised onto the microarray, it was not possible to detect
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any cleavage. The only differences between the 625- and the 50,625-member PNA-
encoded positional scanning libraries were the number of library members and the
PNA tag sequences. Each microarray spot would contain 125 or 3,375 different
peptides (625- or 50,625-member library respectively). One hypothesis to explain the
results could be that if too many peptides were hybridised at the same location then
there could be some interactions between the two dyes fluorescein (cleaved peptides)
and rhodamine (non-cleaved peptides), thus affecting the fluorescence intensity.
Figure 3.27: Profiles of chymopapain obtained using the 50,625-member PNA-encoded positional
scanning library (values correspond to the average of five replicates)
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Figure 3.28: Profiles of pepsin obtained using the 50,625-member PNA-encoded positional scanning
library (values correspond to the average of five replicates)
3.9 Conclusion
Two PNA-encoded positional scanning libraries of FRET-based tetrapeptides (625 or
50,625 members) were successfully synthesised by solid phase synthesis. The
“prime” and “non-prime side” substrate specificities of three different proteases
(pepsin, subtilisin A and trypsin) were easily and rapidly profiled using the 625-
member positional scanning library (first sub-library), with assays performed in
solution using minimal amounts of library and protease. Both cleaved and non-
cleaved peptides were hybridised onto a DNA microarray, with just five PNA tags
allowing the rapid deconvolution and identification of the preferred amino acids for
the first position in the tetrapeptide. This strategy was then applied to a larger
50,625-member PNA-encoded positional scanning library. The first enzymatic
assays were performed using trypsin, with cleavage demonstrated. However, the
interpretation of the microarray data revealed a “non-specific” profile, with trypsin
accepting all fifteen amino acids equally! This result disagreed with the known
specificity of trypsin, and the same conclusions were observed using two other
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proteases (chymopapain and pepsin). It was supposed that the immobilisation of a
large number of library members onto a microarray within a few locations could be
responsible for interactions between the two dyes fluorescein and rhodamine,
affecting spot fluorescence and consequently the interpretation of the results.
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Chapter 4: Experimental part
4.1 General section
4.1.1 General information
All solvents and reagents were obtained from commercial suppliers and used without
purification, unless otherwise stated.
NMR spectra were recorded on Bruker ARX-250, DPX-360 and AVA-800
spectrometers operating at 250 MHz, 360 MHz and 800 MHz for 1H and 62.5 MHz,
90 MHz and 200 MHz for 13C spectra respectively, in the solvents indicated at 298
K. 31P NMR spectra were recorded on a Bruker ARX-250 at 101 MHz. All chemical
shifts (δ) are quoted in ppm using the residual hydro solvent as the internal standard
or the 13C natural abundance of the deuterated solvent. Coupling constants (J) are
reported in Hz.
Infrared (IR) spectra were obtained on a Fourier transform IR Bruker Tensor 27
Spectrometer (FTS) fitted with a Specac single reflection diamond attenuated total
reflection (ATR) Golden Gate. All samples were run neat, frequencies are reported in
cm-1 and only frequencies corresponding to significant functional groups are
reported.
Aluminium backed silica plates (Merck silica gel 60 F254) were used for thin layer
chromatography (TLC) to monitor solution-phase reactions. TLC visualisation was
carried out using short wavelength ultraviolet (UV) light at 254 nm. Flash column
chromatography was performed on silica gel using Keiselgel 60, 230-400 mesh, as
supplied by Merck.
Microwave assisted peptide syntheses were performed using a CEM Liberty™
microwave peptide synthesiser. All amino acids used were of L configuration, unless
specified. MALDI-TOF MS analyses were performed on an Applied Biosystems
Voyager DESTR MALDI-TOF mass spectrometer. Sinapic acid was used as a matrix
and positive ion mass spectra are reported.
HPLC spectra were obtained using Agilent Technologies HP1100 Chemstations.
Solvents used were (A) H2O/0.1% TFA and (B) CH3CN/0.04% TFA, (C) H2O/0.1%
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formic acid and (D) MeOH/0.1% formic acid, at a flow rate of 1 mL/min. The
columns used were a Discovery C18 (column 1) from Supelco (50 mm x 4.6 mm, 5
µm), a Luna C18 (column 2) from Phenomenex (150 mm x 4.6 mm, 5 µm) and a
Gemini C18, 110 Å (column 3) from Phenomenex (100 mm x 4.6 mm, 5 µm). The
following methods were used:
- Method 1 [column 1, eluents (A) and (B)]: 95% to 5% (A) over 6 min, 5% (A) for 2
min
- Method 2 [column 1, eluents (A) and (B)]: 90% to 10% (A) over 3 min, 10% (A)
for 1 min
- Method 3 [column 2, eluents (C) and (D)]: 100% (C) for 5 min, 0% to 60% (D)
over 10 min, 100% (D) for 5 min
- Method 4 [column 3, eluents (C) and (D)]: 95% to 5% (C) over 10 min
Analytical HPLC/evaporative light scattering detector (ELSD) spectra were obtained
with the same system (using the same eluents, methods and flow rates) coupled to a
Polymer Lab 100 ES ELSD.
Electrospray ionisation (ESI)/MS analyses were performed on an Agilent
Technologies LC/MSD Series 1100 quadrupole mass spectrometer (QMS), equipped
with an electrospray ion source. Major peaks are reported with percentage intensities
of the base peak.
Preparative reverse phase-HPLC purifications were performed on an Agilent
Technologies HP1100 Chemstation eluting with (A) H2O/0.1% TFA and (B)
CH3CN/0.1% TFA on a Waters X-Terra RP18 preparative column (150 mm x 19
mm, 5 μm), at a flow rate of 5 mL/min. The following gradient was used: 100% (A)
to 40% (B) over 5 min, 40% to 70% (B) over 20 min, 70% to 100% (B) over 4 min,
detection by UV at 214, 254 and 440 nm.
Absorption spectra were recorded on an 8453 Agilent UV-Visible
spectrophotometer. Fluorescence measurements were performed on a Jobin Yvon
Spex Fluoromax spectrofluorometer or a FS900 spectrofluorometer.
Microarray printing was performed using a Genetix QArrayMini (Genetix, UK)
contact printer, and hybridisation was carried out using the GeneMachines Hyb4
automated station (Genomic Solutions, UK). Microarrays were scanned with a white
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light scanner (BioAnalyser 4F, LaVision BioTech, Germany). Aldehyde-derivatised
microscope slides and CodeLinkTM activated glass slides were obtained from Genetix
(UK) and Amersham Biosciences (UK) respectively.
4.1.2 General experimental procedures
Calculation of theoretical loading
Theoretical loading of a resin after a reaction was calculated using the equation:
New loading (mmol/g) = [old loading/(1 + (old loading x mass added x 10-3)]
Where: “old loading” is the loading of the starting resin (mmol/g) and “mass added”
is the mass of compound added onto the resin
Quantitative Fmoc test229
To a known mass of resin (e.g. 5 mg), pre-swelled in DMF for 5 min, was added a
solution of 20% piperidine in DMF (1 mL), and the mixture was shaken for 5 min.
The solution cleavage was added to a 10 mL volumetric flask and the volume was
made up to 10 mL with a solution of 20 % piperidine in DMF. The absorbance at 302
nm of the liberated dibenzofulvene-piperidine adduct was measured twice against a
blank solution of 20 % piperidine in DMF and the average value was used. The
loading was calculating using the equation:
Loading (mmol/g) = [(A302 x V)/(ε302 x m)] x 103
Where A302 is the recorded absorbance at 302 nm, V is the diluted volume (10 mL),
ε302 is the extinction coefficient of the dibenzofulvene-piperidine adduct (7800 M-1
cm-1) and m is the mass of resin (mg).
Qualitative nynhidrin test220
To a few resin beads placed in a small test tube were added 3 drops of reagent A and
1 drop of reagent B. The mixture was heated at 100 °C for 5 min. The presence of
resin bound free amine was indicated by a blue colour.
Reagent A: Solution 1: Potassium cyanide (65 mg, 1 mmol) was dissolved in H2O
(100 mL). An aliquot of this solution (2 mL) was diluted with freshly distilled
pyridine (98 mL).  Solution 2: Phenol (40 g, 420 mmol) was dissolved in absolute
EtOH (10 mL). Solutions 1 and 2 were mixed together to give reagent A.
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Reagent B: Ninhydrin (2.5 g, 14 mmol) was dissolved in absolute EtOH (50 mL).
Quantitative ninhydrin test230
To a known mass of resin (e.g. 5 mg) placed in a small test tube was added 6 drops
of reagent A (see above) and 2 drops of reagent B (see above). The mixture was
heated at 100 °C for 5 min. The test tube was placed in a cold water bath, 60%
aqueous ethanol (2 mL) was added and mixed thoroughly. The resin was removed by
filtration through cotton wool and the deep blue filtrate collected in a 25 mL
volumetric flask. The resin was washed with a solution of Et4NCl (0.5 M in DCM, 2
x 0.5 mL) and the sample made up to 25 mL with 60% aqueous ethanol. The
absorbance at 570 nm was measured twice against a blank solution and the average
value was used. The level of amine present was calculated using the equation:
Amount of primary amine residues (mmol/g) = [(A570 x V)/(ε570 x m)] x 103
Where A570 is the recorded absorbance at 570 nm, V is the final volume (mL), ε570 is
an extinction coefficient suitable for most peptides (1.5 x 104 M-1 cm-1) and m is the
mass of resin (mg).
Qualitative chloranil test231
To a few resin beads placed in a small test tube was added one drop of 2%
acetaldehyde in DMF followed by one drop of 2% p-chloranil in DMF. The resin
was allowed to stand for 5 min. Dark blue stained beads indicated the presence of
secondary amines.
Fmoc deprotection
To a resin (e.g. 1 g), pre-swelled in DMF for 10 min, was added a solution of 20%
piperidine in DMF (20 mL), and the mixture was shaken for 10 min. The resin was
washed with DMF (3 x 25 mL) and the deprotection procedure was repeated. The
resin was washed with DMF (3 x 25 mL) and DCM (3 x 25 mL).
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4.2 Experimental for chapter 2
4.2.1 Fmoc solid-phase peptide synthesis






2-[2-(2-aminoethoxy)ethoxy]ethanamine (2.2 mL, 15 mmol, 10 eq) was dissolved in
dry THF (10 mL) and added to 2-chlorotrityl chloride resin (1% divinylbenzene,
loading 1.5 mmol/g, 1 g, 1.5 mmol, 1 eq) and the reaction was stirred for 16 h.  The
resin was washed with DCM/MeOH/DIPEA (17:2:1, 3 x 3 mL), DCM (3 x 3 mL),
DMF (2 x 3 mL) and DCM (2 x 3 mL). The title yellow resin 2.16 was then dried in
vacuo at 40 °C for 16 h.
Loading: determined by a quantitative ninhydrin test, 0.63 mmol/g
IR ν (cm-1): 3055 (m, ν N-H), 1667 (m, ν N-H), 1105 (s, ν C-O)






























Peptide 2.11 was synthesised using a CEM Liberty™ microwave peptide synthesiser.
Fmoc deprotections were performed with a solution of 20% piperidine in DMF (2
cycles of 7 min at 25 °C) under N2 bubbling. For every amino acid coupling, Fmoc-
AA-OH (0.32 mmol, 5 eq) was dissolved in DMF (0.2 M) and added to the
previously prepared resin 2.16 (loading 0.63 mmol/g, 100 mg, 0.063 mmol, 1 eq)
followed by the addition of a solution of HBTU/HOBt (0.32 mmol, 5 eq) in DMF
(0.25 M) and then a solution of 20 % DIPEA in N-methylpyrrolidinone (NMP) (0.63
mmol, 10 eq). A double coupling of 20 min, at 60 °C under microwave irradiation
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and N2 bubbling, was then carried out. Between amino acid couplings and Fmoc
deprotections, the resin was automatically washed with DMF. At the end of the
peptide synthesis, the resin was transferred to a solid phase extraction tube, washed
with DMF (3 x 3 mL) and DCM (3 x 3 mL), capped with a solution of acetic
anhydride and pyridine (50/50, 2 mL) for 1.5 h followed by washings with DMF (3 x
3 mL), DCM (3 x 3 mL), MeOH (2 x 3 mL) and DCM (2 x 3 mL). The completion
of the capping was verified by the Kaiser test (see section 4.1.2). Finally, the peptide
was cleaved from the resin using a TFA/DCM/TIS (50/45/5) solution (2 mL) for 2 h
and precipitated with cold diethyl ether (10 mL). The residue was collected by
filtration, dissolved in CH3CN/H2O, lyophilised and purified by reverse phase
preparative HPLC to afford 2.11 as a white solid (52 mg, 78%).
HPLC (method 1): tR = 4.9 min (100% purity, ELSD)
MALDI-TOF+/MS: m/z (%) 1052.7 [M+H]+ (100)
1H NMR (800 MHz, D2O): δH 7.34 (2H, t, J = 7.5 Hz, ArH-Phe), 7.32-7.18 (3H, m,
ArH-Phe), 7.10-7.03 (2H, m, ArH-Tyr), 6.79-6.74 (2H, m, ArH-Tyr), 4.58-4.51 (1H,
m, Hα-Tyr), 4.49-4.42 (2H, m, Hα-Phe and Hα-Ala), 4.35 (1H, dd, J = 8.5, 5.6 Hz,
Hα-Pro), 4.31-4.18 (3H, m, Hα-Glu and 2 x Hα-Ala), 4.15-3.96 (1H, m, Hα-Ile), 3.75
(2H, td, J = 10.0, 7.0 Hz, Hδ-Pro), 3.72-3.68 (2H, m, CH2O), 3.65-3.52 (4H, m,
CH2O), 3.48-3.36 (2H, m, CH2O), 3.36-3.18 (2H, m, CH2NH), 3.18-3.13 (2H, m,
CH2NH2), 3.11-2.97 (4H, m, Hβ-Phe and Hβ-Tyr), 2.92-2.86 and 1.75-1.58 (1H, m,
Hβ-Ile), 2.50-2.40 (2H, m, Hγ-Glu), 2.24-2.15 and 1.84-1.75 (2H, m, Hβ-Pro), 2.10-
1.87 (4H, m, Hβ-Glu and Hγ-Pro), 2.00 (3H, s, CH3-Ac), 1.38-1.00 (2H, m, Hγ-Ile),
1.31 (3H, d, J = 7.1 Hz, CH3-Ala), 1.27 (6H, t, J = 7.7 Hz, CH3-Ala), 0.92-0.72 (6H,
m, CH3-Ile)
13C NMR (200 MHz, D2O): δC 179.6 (COO-Glu), 177.2 (CO-Ala), 177.0 (CO-Ac),
176.4 (CO-Pro), 176.2 (CO-Ala), 176.0 (CO-Glu), 175.8 (CO-Ala), 175.7 (CO-Ile),
175.5 (CO-Phe), 174.9 (CO-Tyr), 157.1 (COH-Tyr), 138.8 (C-Phe), 133.2 (2 x ArH-
Tyr), 131.9 (2 x ArH-Phe), 131.4 (2 x ArH-Phe), 130.6 (C-Tyr), 129.9 (ArH-Phe),
118.1 (2 x ArH-Tyr), 72.2 (CH2O), 72.1 (CH2O), 71.3 (CH2O), 69.1 (CH2O), 63.1
(Cα-Pro), 61.0 (Cα-Ile), 57.9 (Cα-Phe), 57.5 (Cα-Tyr), 55.6 (Cα-Glu), 52.3 (Cα-Ala),
51.6 (Cα-Ala), 50.4 (Cα-Ala), 50.4 (Cδ-Pro), 41.8 (CH2NH2),  41.4 (CH2NH), 39.7
(Cβ-Phe), 38.9 (Cβ-Tyr), 38.8 (Cβ-Ile), 32.6 (Cγ-Glu), 31.9 (Cβ-Pro), 29.0 (Cβ-Glu),
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27.3 (Cγ-Pro), 27.1 (Cγ-Ile), 24.3 (CH3-Ac), 19.5 (CH3-Ala), 18.9 (CH3-Ala), 18.0
(CH3-Ala), 17.3 (CH3-Ile), 12.8 (CH3-Ile)































Peptide 2.13 was prepared as for peptide 2.11 but capped with 5(6)-
carboxyfluorescein (fluorescein) (120 mg, 0.32 mmol, 5 eq) for 3 h (3 couplings)
followed by washing with 20% piperidine in DMF (2 cycles of 10 min, 2 x 3 mL),
DMF (2 x 3 mL) and DCM (2 x 3 mL). After purification by reverse phase
preparative HPLC, the labelled peptide 2.13 was obtained as a yellow solid (52 mg,
60%).
HPLC (method 1): tR = 5.5 min (100% purity, 440 nm)
MALDI-TOF+/MS: m/z (%) 1369.0 [M+H]+ (100)





































Peptide 2.9 was synthesised manually at 25 °C. The appropriate Fmoc amino acid
(0.35 mmol, 5 eq), HBTU (133 mg, 0.35 mmol, 5 eq) and HOBt (47 mg, 0.35 mmol,
5 eq) were dissolved in DMF (1.4 mL) followed by addition of DIPEA (122 µL, 0.7
mmol, 10 eq). The resulting solution was mixed for 10 s before being added to the
resin 2.16 (loading 0.63 mmol/g, 106 mg, 0.07 mmol, 1 eq) pre-swollen in DMF. The
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mixture was shaken for 1 h. The completion of each coupling was verified by the
Kaiser test (see section 4.1.2). If needed, an extended cycle was repeated until
completion of the reaction. Fmoc deprotection was performed as described in section
4.1.2. After the last amino acid coupling, the resin was capped using acetic anhydride
and pyridine (50/50, 2 mL) for 1.5 h. Finally, the peptide was cleaved from the resin
using Reagent K (TFA/H2O/Phenol/Thioanisole/EDT: 82.5/5/5/5/2.5, 2 mL) for 6 h
and precipitated with cold diethyl ether (10 mL). The residue was collected by
filtration, dissolved in CH3CN/H2O, lyophilised and purified by reverse phase
preparative HPLC to afford 2.9 as an off-white solid (16 mg, 23%).
HPLC (method 1): tR = 3.0 min (100% purity, ELSD)
MALDI-TOF+/MS: m/z (%) 1015.0 [M+H]+ (100)
1H NMR (800 MHz, D2O): δH 4.44 (1H, t, J = 5.7 Hz, Hα-Ser), 4.38 (1H, dd, J =
10.1, 4.7 Hz, Hα-Leu), 4.34-4.29 (4H, m, 2 x Hα-Arg and Hα-Ala and Hα-Leu), 4.22
(1H, q, J = 7.2 Hz, Hα-Ala), 3.90 (2H, d, J = 1.8 Hz, Hα-Gly), 3.89-3.84 (2H, m, Hβ-
Ser), 3.76 (2H, t, J = 5.1 Hz, CH2O), 3.71 (4H, s, CH2O), 3.64 (2H, t, J = 5.5 Hz,
CH2O), 3.45-3.39 (2H, m, CH2NH), 3.23-3.17 (6H, m, 2 x Hδ-Arg + CH2NH2), 2.01
(3H, s, CH3-Ac), 1.89-1.81 (2H, m, Hβ-Arg), 1.80-1.73 (2H, m, Hβ-Arg), 1.72-1.53
(10H, m, 2 x Hγ-Arg + 2 x Hβ-Leu + 2 x Hγ-Leu), 1.41 (3H, d, J = 7.2 Hz, CH3-Ala),
1.35 (3H, d, J = 7.2 Hz, CH3-Ala), 0.94 (6H, t, J = 5.9 Hz, CH3-Leu), 0.88 (6H, dd, J
= 6.1, 4.5 Hz, CH3-Leu)
13C NMR (200 MHz, D2O): δC 178.3 (CO-Ala), 177.8 (CO-Leu), 177.7 (CO-Leu),
177.4 (CO-Ala), 177.0 (CO-Ac), 176.2 (CO-Arg), 176.1 (CO-Arg), 174.6 (CO-Ser),
173.9 (CO-Gly), 159.4 (2 x C=NH-Arg), 72.3 (CH2O), 72.2 (CH2O), 71.5 (CH2O),
69.1 (CH2O), 63.6 (Cβ-Ser), 58.1 (Cα-Ser), 56.1 (Cα-Arg), 56.0 (Cα-Arg), 55.3 (Cα-
Leu), 55.1 (Cα-Leu), 52.7 (Cα-Ala), 52.6 (Cα-Ala), 45.2 (Cα-Gly), 43.2 (Cδ-Arg), 43.2
(Cδ-Arg), 42.3 (Cβ-Leu), 42.2 (Cβ-Leu), 41.8 (CH2NH2),  41.6 (CH2NH), 30.8 (Cβ-
Arg), 30.5 (Cβ-Arg), 27.1 (Cγ-Arg), 27.1 (Cγ-Arg), 27.0 (Cγ-Leu), 27.0 (Cγ-Leu),
24.9 (CH3-Leu), 24.7 (CH3-Leu), 24.2 (CH3-Ac), 23.5 (CH3-Leu), 23.3 (CH3-Leu),
19.1 (CH3-Ala), 19.0 (CH3-Ala)
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The phosphorylated peptide 2.12 was synthesised manually at 25 °C. The appropriate
Fmoc amino acid (0.08 mmol, 5 eq), HBTU (30 mg, 0.08 mmol, 5 eq) and HOBt (11
mg, 0.08 mmol, 5 eq) were dissolved in DMF (0.3 mL) followed by addition of
DIPEA (26 µL, 0.15 mmol, 10 eq). The resulting solution was mixed for 10 s before
being added to the resin 2.16 (loading 0.63 mmol/g, 24 mg, 0.015 mmol, 1 eq) pre-
swollen in DMF. The mixture was shaken for 1 h. The completion of each coupling
was verified by the Kaiser test or the chloranil test for Fmoc-Pro-OH (see section
4.1.2). If needed, an extended cycle was repeated until completion of the reaction.
Fmoc deprotection was performed as described in section 4.1.2. A preformed
protected phosphoamino acid Fmoc-Tyr(HPO3Bzl)-OH (46 mg, 0.08 mmol, 5 eq)
was coupled to the resin for 4 h in order to incorporate the phosphorylated tyrosine
residue. After the last amino acid coupling, the resin was capped using acetic
anhydride and pyridine (50/50, 0.4 mL) for 1.5 h. Finally, the phosphorylated peptide
was cleaved from the resin using Reagent K (0.4 mL) for 4 h and precipitated with
cold diethyl ether (5 mL). The residue was collected by filtration, dissolved in
CH3CN/H2O, lyophilised and purified by reverse phase preparative HPLC to afford
2.12 as an off-white solid (10 mg, 59%).
HPLC (method 1): tR = 5.2 min (100% purity, ELSD)
MALDI-TOF+/MS: m/z (%) 1132.9 [M+H]+ (100)
1H NMR (800 MHz, D2O): δH 7.35 (2H, t, J = 7.5 Hz, ArH-Phe), 7.32-7.20 (3H, m,
ArH-Phe), 7.19-7.12 (2H, m, ArH-Tyr), 7.10-7.05 (2H, m, ArH-Tyr), 4.56 (1H, t, J =
7.7 Hz, Hα-Tyr), 4.51-4.43 (2H, m, Hα-Phe and Hα-Ala), 4.35 (1H, dd, J = 8.3, 5.7
Hz, Hα-Pro), 4.31-4.18 (3H, m, Hα-Glu and 2 x Hα-Ala), 4.13-3.96 (1H, m, Hα-Ile),
3.78 (2H, td, J = 10.2, 7.0 Hz, Hδ-Pro), 3.73-3.68 (2H, m, CH2O), 3.66-3.53 (4H, m,
CH2O), 3.49-3.38 (2H, m, CH2O), 3.38-3.19 (2H, m, CH2NH), 3.19-3.13 (2H, m,
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CH2NH2), 3.13-2.95 (4H, m, Hβ-Phe and Hβ-Tyr), 2.51-2.42 (2H, m, Hγ-Glu), 2.25-
2.17 and 1.81-1.72 (2H, m, Hβ-Pro), 2.10-1.89 (4H, m, Hβ-Glu and Hγ-Pro), 2.00
(3H, s, CH3-Ac), 1.81-1.72 (1H, m, Hβ-Ile), 1.41-1.03 (2H, m, Hγ-Ile), 1.32 (3H, d, J
= 7.1 Hz, CH3-Ala), 1.31 (3H, d, J = 7.2 Hz, CH3-Ala), 1.26 (3H, d, J = 7.1 Hz, CH3-
Ala), 0.91-0.71 (6H, m, CH3-Ile)
13C NMR (200 MHz, D2O): δC 179.7 (COO-Glu), 177.3 (CO-Ala), 177.0 (CO-Ac),
176.5 (CO-Pro), 176.1 (CO-Ala), 176.0 (CO-Glu), 175.9 (CO-Ala), 175.8 (CO-Ile),
175.6 (CO-Phe), 174.8 (CO-Tyr), 153.7 and 153.7 (C-Tyr), 138.8 (C-Phe), 134.3 (C-
Tyr), 133.0 (2 x ArH-Tyr), 131.9 (2 x ArH-Phe), 131.5 (2 x ArH-Phe), 129.9 (ArH-
Phe), 123.2 (2 x ArH-Tyr), 72.2 (CH2O), 72.1 (CH2O), 71.3 (CH2O), 69.1 (CH2O),
63.1 (Cα-Pro), 60.9 (Cα-Ile), 57.9 (Cα-Phe), 57.5 (Cα-Tyr), 55.6 (Cα-Glu), 52.3 (Cα-
Ala), 51.6 (Cα-Ala), 50.5 (Cα-Ala), 50.4 (Cδ-Pro), 41.8 (CH2NH2),  41.5 (CH2NH),
39.7 (Cβ-Phe), 39.0 (Cβ-Tyr), 38.7 (Cβ-Ile), 32.6 (Cγ-Glu), 31.9 (Cβ-Pro), 29.0 (Cβ-
Glu), 27.3 (Cγ-Pro), 27.2 (Cγ-Ile), 24.3 (CH3-Ac), 19.5 (CH3-Ala), 19.0 (CH3-Ala),
18.0 (CH3-Ala), 17.3 (CH3-Ile), 12.7 (CH3-Ile)
31P NMR (146 MHz, D2O): δP - 4.02










































The phosphorylated peptide 2.10 was prepared as for peptide 2.12 except that 50 mg
of resin 2.16 (experimental loading 0.63 mmol/g, 50 mg, 0.03 mmol, 1 eq) was used
and a preformed protected phosphoamino acid Fmoc-Ser(HPO3Bzl)-OH) (75 mg,
0.15 mmol, 5 eq) was coupled to the resin for 6 h. After purification by reverse phase
preparative HPLC, the phosphorylated peptide 2.10 was obtained as a slight
yellowish solid (12 mg, 38%).
HPLC (method 1): tR = 3.4 min (100% purity, ELSD)
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MALDI-TOF+/MS: m/z (%) 1094.9 [M+H]+ (100)
1H NMR (800 MHz, D2O): δH 4.56 (1H, t, J = 5.0 Hz, Hα-Ser), 4.38-4.26 (5H, m, 2
x Hα-Leu and Hα-Ala and 2 x Hα-Arg), 4.23 (1H, q, J = 7.2 Hz, Hα-Ala), 4.21-4.09
(2H, m, Hβ-Ser), 3.91 (2H, s, Hα-Gly), 3.76 (2H, t, J = 5.1 Hz, CH2O), 3.71 (4H, s,
CH2O), 3.64 (2H, t, J = 5.5 Hz, CH2O), 3.45-3.39 (2H, m, CH2NH), 3.25-3.17 (6H,
m, 2 x Hδ-Arg and CH2NH2), 2.01 (3H, s, CH3-Ac), 1.92-1.86 (2H, m, Hβ-Arg),
1.86-1.80 (2H, m, Hβ-Arg), 1.80-1.50 (10H, m, 2 x Hγ-Arg and 2 x Hβ-Leu and 2 x
Hγ-Leu), 1.41 (3H, d, J = 7.2 Hz, CH3-Ala), 1.35 (3H, d, J = 7.2 Hz, CH3-Ala), 0.94
(6H, dd, J = 10.1, 6.2 Hz, CH3-Leu), 0.88 (6H, t, J = 5.8 Hz, CH3-Leu)
13C NMR (200 MHz, D2O): δC 178.1 (CO-Ala), 177.9 (CO-Leu), 177.8 (CO-Leu),
177.3 (CO-Ala), 176.9 (CO-Ac), 176.2 (CO-Arg), 176.0 (CO-Arg), 174.1 (CO-Ser),
174.0 (CO-Gly), 159.4 (2 x C=NH-Arg), 72.3 (CH2O), 72.2 (CH2O), 71.5 (CH2O),
69.1 (CH2O), 66.6 and 66.6 (Cβ-Ser), 57.0 and 56.9 (Cα-Ser), 55.9 (Cα-Arg), 55.8
(Cα-Arg), 55.5 (Cα-Leu), 55.0 (Cα-Leu), 52.8 (Cα-Ala), 52.5 (Cα-Ala), 45.3 (Cα-Gly),
43.2 (2 x Cδ-Arg), 42.2 (Cβ-Leu), 42.2 (Cβ-Leu), 41.8 (CH2NH2), 41.6 (CH2NH),
30.8 (Cβ-Arg), 30.7 (Cβ-Arg), 27.1 (Cγ-Arg), 27.1 (Cγ-Arg), 27.0 (Cγ-Leu), 27.0 (Cγ-
Leu), 24.9 (CH3-Leu), 24.7 (CH3-Leu), 24.2 (CH3-Ac), 23.5 (CH3-Leu), 23.3 (CH3-
Leu), 19.0 (CH3-Ala), 19.0 (CH3-Ala)




(2.12), Ac-Ala-Leu-Arg-Arg-Ala-pSer-Leu-Gly-PEG-NH2 (2.10) and Fluorescein-
Glu-Ala-Ile-Tyr-Ala-Ala-Pro-Phe-PEG-NH2 (2.13) were prepared as 5 mM, 1 mM,
0.5 mM, 0.1 mM, 50 µM, 10 µM, 1 µM and 100 nM solutions in printing buffer (50
mM sodium phosphate, pH 8.5). The peptides and phosphopeptides were printed,
keeping humidity below 50%, onto CodeLinkTM activated glass slides using a
Genetix QArrayMini contact printer, equipped with a 32-pin microarraying head.
Each peptide and phosphopeptide was printed as 16 replicates (4 x 4 sub-arrays),
with a typical spot size of 320 µm, a row pitch of 560 µm and a column pitch of
1120 µm.  20 aQu solid pins with a 150 µm diameter (K2783, Genetix) were used
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and the following printing conditions were applied: 2 stamps per spot, 10 ms
stamping time and 10 ms inking time. After printing, the slides were incubated, in the
dark, at 25 °C for 16 h in a chamber containing a 3 M NaCl solution. Then, the slides
were incubated in a pre-warmed blocking solution (0.1 M Tris, 50 mM ethanolamine,
pH 9.0, 20 mL) at 50 °C for 30 min, rinsed with distilled water (2 x 20 mL), washed
with 4x SSC/0.1% SDS (20 mL) pre-warmed to 50 °C for 30 min and rinsed with
distilled water (20 mL) before being spin-dried by centrifugation (650 rpm for 10
min).
4.2.3 Antibody assays on peptide microarray
The slides were blocked with a pre-warmed buffer containing TPBS (0.05% Tween-
20/PBS, pH 7.4)/1% BSA (20 mL) for 1 h at 30 °C. After washing in PBS (20 mL)
for 5 min at 30 °C, slides, that were covered with a glass cover-slide and kept in a
hybridisation chamber (Genomic Solutions), were probed with the primary antibody,
monoclonal anti-phosphotyrosine clone PY-20 (mouse IgG2b isotype), diluted 1/500
(0.4 μg) in an antibody buffer containing TPBS/ 1% BSA (final volume of 200 μL)
for 1 h at 30 °C. After washing with the antibody buffer (2 x 20 mL) for 10 min at 30
°C, a labeled secondary antibody, Cy3-goat anti-mouse IgG (H+L), diluted 1/1000
(0.1 μg) in the antibody buffer (final volume of 200 μL) was added and slides were
incubated in the dark for 1 h at 30 °C. Slides were then washed in the antibody buffer
(2 x 20 mL for 10 min at 30 °C) and rinsed with Tris buffer (20 mL) at 25 °C before
being spin-dried by centrifugation (1000 rpm for 10 min).
4.2.4 Library synthesis




4.2.5 Solution-phase kinase assays81
Kinase reaction buffers:
Abl buffer (1x): 50 mM Tris-HCl (pH 7.5 at 25 °C), 10 mM MgCl2, 1 mM EGTA, 2
mM DTT, 0.01% Brij 35.
Her2 and VEGFR2 buffer: 50 mM HEPES, pH 7.4, 3 mM MgCl2, 3 mM MnCl2, 1
mM DTT, 3 μM Na-orthovanadate.
The 10,000-member PNA-encoded library was incubated, in solution, at a final
concentration of 50 µM and final volume of 100 µL, in a buffer containing 60 units
of the selected kinase (Abl, Her2 or VEGFR2), 5 mM ATP, kinase reaction buffer
and 0.1% BSA for 24 h at 30 °C.
Hybridisation protocol: before hybridisation, one volume of this buffer was diluted
with one volume of GenHyb buffer (Genetix). Solutions were denatured by heating
at 65 °C for 3 min; 100 µL of the solution was then added onto a 22,500 customised
DNA chip from Oxford Gene Technology (Oxford, UK), which was covered with a
glass cover-slide and kept in a hybridisation chamber (Genomic Solutions) at 60 °C.
Temperature was then slowly lowered to 37 °C over a period of 20 h. Finally, the
chips were washed twice (20 mL) for 10 min at 30 °C in the following buffer (100
mM Nacl, 10 mM citric acid, 0.7% (w/v) N-lauroylsarcosine sodium salt, 0.1 mM
EGTA, pH 7.5), rinsed with distilled water (20 mL) and spin-dried by centrifugation
(1000 rpm for 10 min). Slides were stored in the dark at 25 °C.
4.2.6 Antibody assays on the 22,500 customised DNA microarray
The assay was carried out in analogy to section 4.2.3 except that the labelled
secondary antibody, Cy3-goat anti-mouse IgG (H+L) was diluted 1/500 (0.2 μg) in
the antibody buffer (TPBS/ 1% BSA).
4.2.7 Stripping procedure161
DNA chips could be stripped and re-hybridised up to three times. DNA chips were
incubated in a stripping buffer [2.5 mM Na2HPO4, 0.1% (v/v) SDS, 20 mL] at 95 °C
for 10 min. The procedure was repeated until complete probe removal. The DNA
chips were then washed with distilled water (20 mL), rinsed with Tris buffer (20 mL)
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and spin-dried by centrifugation (1000 rpm for 10 min). Before being re-hybridised
and carrying out further experiments, the chip was scanned using both fluorescein
and Cy3 filters.
4.3 Experimental for chapter 3







Chloroacetic acid (35.35 g, 374 mmol, 1 eq) was added portionwise at 0 °C to 1,2-
ethanediamine (250 mL, 3.74 mol, 10 eq). The reaction was stirred at 25 °C for 16 h.
Excess ethanediamine was evaporated in vacuo at 50 °C (higher temperatures led to
decomposition) to give a yellow oil that was triturated with DMSO (400 mL). The
resulting white solid was collected by filtration, washed with DMSO (3 x 50 mL),
THF (3 x 50 mL) and diethyl ether (3 x 50 mL) before drying in a vacuum oven at 40
°C for 24 h to afford the named compound 3.13 as a white solid (29.1 g, 66%).
ESI+/MS: m/z (%) 192.1 [M+H]+ (28), 214.0 [M+Na]+ (100)
1H NMR (250 MHz, D2O): δH 3.25 (2H, s, CH2CO), 3.02 (2H, m, CH2), 2.88 (2H,
m, CH2)





To a solution of dimedone (50 g, 357 mmol, 1 eq) in DMF (800 mL) were added
acetic acid glacial (21 mL, 357 mmol, 1 eq), DCC (73.7 g, 357 mmol, 1 eq) and
DMAP (4.4 g, 35.7 mmol, 0.1 eq). The reaction was stirred at 25 °C for 36 h.
Precipitated dicyclohexylurea (DCU) was removed by filtration. After evaporation of
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the solvent in vacuo, the residue was dissolved in EtOAc (300 mL), washed with 1 M
aqueous KHSO4 (3 x 100 mL), 10 % aqueous NaHCO3 (3 x 100 mL) and brine (1 x
100 mL). The organic phase was dried over MgSO4 and concentrated in vacuo to
afford Dde-OH 3.15 as an orange oil (49.5 g, 76%).
HPLC (method 2): tR = 3.3 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 183.2 [M+H]+ (100)
1H NMR (250 MHz, CDCl3): δH 2.60 (3H, s, CH3), 2.52 (2H, s, CH2), 2.35 (2H, s,
CH2), 1.07 (6H, s, C(CH3)2)
13C NMR (62.5 MHz, CDCl3): δC 202.4 (C), 197.9 (CO), 195.2 (CO), 112.3 (C),
52.4 (CH2), 46.9 (CH2), 30.6 (C), 28.5 (CH3), 28.2 (CH3)







To a stirred suspension of the acid 3.13 (28.2 g, 239 mmol, 1 eq) in MeOH (870 mL)
at O °C was added dropwise thionyl chloride (87 mL, 1.20 mol, 5 eq). The reaction
was then refluxed for 16 h before cooling to O °C. The resulting solid was filtered,
washed with MeOH/DCM (1/1, 200 mL), diethyl ether (200 mL) and dried in a
vacuum oven at 40 °C for 24 h. The named compound 3.14 was obtained as a white
solid (43 g, 88%) and used without further purification.
HPLC (method 2): tR = 0.9 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 133.1 [M+H]+ (100)
1H NMR (250 MHz, D2O): δH 4.13 (2H, s, CH2CO), 3.85 (3H, s, CH3), 3.58-3.49
(2H, m, CH2), 3.48-3.40 (2H, m, CH2)













To a stirred solution of 3.14 (5 g, 24.4 mmol, 1 eq) and DIPEA (8.5 mL, 48.8 mmol,
2 eq) in DCM (80 mL) was added portionwise Dde-OH 3.15 (4.45 g, 24.4 mmol, 1
eq). The mixture was stirred at 25 °C for 16 h. After evaporation of the solvent in
vacuo, the residue was dissolved in EtOAc (100 mL) and extracted with 1 M aqueous
KHSO4 (4 x 30 mL). The aqueous extracts were combined, brought to pH 9 with
NaHCO3 and extracted with DCM (4 x 30 mL). The organic phases were combined,
washed with brine (1 x 30 mL), dried over MgSO4 and concentrated in vacuo to
afford the named compound 3.10 as an orange oil (4.6 g, 64%).
HPLC (method 2): tR = 2.2 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 297.2 [M+H]+ (100)
1H NMR (250 MHz, CDCl3): δH 13.47 (1H, br s, NH-Dde), 3.70 (3H, s, OCH3),
3.50-3.40 (4H, m, NH(CH2)2), 2.91 (2H, t, J = 6.1 Hz, NHCH2CO), 2.53 (3H, s,
CCH3), 2.33 (4H, s, CH2-Dde), 1.79 (1H, br s, NH), 0.99 (6H, s, (CH3)2-Dde)
13C NMR (62.5 MHz, CDCl3): δC 197.1 (CO), 173.3 (C), 172.7 (CO), 107.9 (C),









To a stirred suspension of adenine (50 g, 370 mmol, 1 eq) in DMF (800 mL) was
added NaH (60 % dispersion in mineral oil, 13.7 g, 407 mmol, 1.1 eq). After stirring
for 1 h at 25 °C, the mixture was cooled to 0 °C and methyl 2-bromoacetate (69 mL,
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740 mmol, 2 eq) was added dropwise. The mixture was stirred at 25 °C for 16 h.
After evaporation of the solvent in vacuo, the yellow oil was precipitated with H2O,
collected by filtration and washed with H2O. The resulting solid was then dried in an
oven at 40 °C for 16 h to afford the named compound 3.17 as a white solid (38 g,
50%).
HPLC (method 2): tR = 0.9 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 208.2 [M+H]+ (100)
1H NMR (250 MHz, d6-DMSO): δH 8.14 (1H, s, CH), 8.12 (1H, s, CH), 7.32 (2H,
br s, NH2), 5.09 (2H, s, CH2), 3.70 (3H, s, CH3)
13C NMR (62.5 MHz, d6-DMSO): δC 168.4 (CO), 155.9 (CNH2), 152.6 (CH), 149.6










To a stirred suspension of 3.17 (6 g, 29 mmol, 1 eq) in pyridine/DCM (1/1, 180 mL)
was added NEM (3.7 mL, 29 mmol, 1 eq) and 4-monomethoxytrityl chloride (13.4 g,
43.5 mmol, 1.5 eq). The mixture was heated at 40 °C for 16 h. After evaporation of
the solvents in vacuo, the residue was dissolved in EtOAc (360 mL), washed with 1
M aqueous KHSO4 (90 mL), 10 % aqueous NaHCO3 (90 mL), brine (90 mL) and
dried over MgSO4. After evaporation of the solvent in vacuo, the resulting orange oil
was purified by silica gel chromatography using EtOAc as an eluent to afford the
named compound 3.18 as a yellowish solid (11.4 g, 82%).
Rf (EtOAc) = 0.52
HPLC (method 2): tR = 3.3 min (100% purity, 254 nm)
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ESI+/MS: m/z (%) 273.3 [Mmt]+ (100), 480.5 [M+H]+ (29)
1H NMR (250 MHz, d6-DMSO): δH 8.21 (1H, s, CH-pur), 7.91 (1H, s, CH-pur),
7.40-7.16 (12H, m, CH-Mmt), 6.85 (2H, d, J = 4.3 Hz, CHCOCH3-Mmt), 5.10 (2H,
s, CH2), 3.71 (3H, s, OCH3-Mmt), 3.69 (3H, s, OCH3)
13C NMR (62.5 MHz, d6-DMSO): δC 168.0 (CO), 157.3 (C), 153.1 (C), 151.0 (CH),
148.4 (C), 144.7 (C), 141.4 (CH), 136.7 (C), 129.5 (CH), 128.1 (CH), 127.3 (CH),










The ester 3.18 (4 g, 8.3 mmol, 1 eq) was suspended in 1 M aqueous NaOH (90 mL),
refluxed for 2 h and stirred at 25 °C for 2 h. The solution was then cooled to 0 °C.
Following the addition of 1 M aqueous KHSO4 (110 mL), the mixture was stirred at
0 °C for 30 min. After extraction with EtOAc (2 x 100 mL), the organic phases were
washed with brine (20 mL), dried over MgSO4 and concentrated in vacuo to afford
the named compound 3.19 as an off-white solid (3.3 g, 86%).
HPLC (method 2): tR = 3.5 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 464.1 [M-H]- (100)
1H NMR (250 MHz, d6-DMSO): δH 8.20 (1H, s, CH-pur), 7.91 (1H, s, CH-pur),
7.38-7.16 (12H, m, CH-Mmt), 6.85 (2H, d, J = 8.9 Hz, CHCOCH3-Mmt), 4.97 (2H,
s, CH2) 3.71 (3H, s, OCH3-Mmt)
13C NMR (62.5 MHz, d6-DMSO): δC 169.2 (CO), 157.6 (C), 153.4 (C), 151.2 (CH),
148.8 (C), 145.1 (C), 141.9 (CH), 137.0 (C), 129.8 (CH), 128.4 (CH), 127.6 (CH),



















To a solution of 3.19 (3.48 g, 7.48 mmol, 1 eq) in CH3CN (60 mL) was added HBTU
(3.41 g, 8.98 mmol, 1.2 eq) and DIPEA (1.3 mL, 7.48 mmol, 1 eq). The mixture was
stirred for 3 min and added to a solution of 3.10 (2.2 g, 7.48 mmol, 1 eq) in CH3CN
(60 mL). The resulting solution was stirred at 25 °C for 1 h and the solvent was
removed in vacuo. The residue was dissolved in EtOAc (150 mL), washed with 1 M
aqueous KHSO4 (3 x 50 mL), 10% aqueous NaHCO3 (50 mL), brine (50 mL), dried
over MgSO4 and concentrated in vacuo. The residue was dissolved in a minimum
amount of EtOAc, precipitated with hexanes, collected by filtration and dried in
vacuo. The residue was then dissolved in a minimum amount of EtOAc, precipitated
with an excess of petroleum ether, collected by filtration and dried in vacuo to afford
the named compound 3.20 as a pale yellowish solid (4.75 g, 85%).
HPLC (method 2): tR = 3.7 min (96% purity, 254 nm)
ESI+/MS: m/z (%) 273.0 [Mmt]+ (100), 744.3 [M+H]+ (29)
1H NMR (250 MHz, d6-DMSO) two rotamers: δH 13.26 and 13.16 (1H, br s, NH-
Dde), 8.09 and 8.08 (1H, s, CH-pur), 7.88 (1H, s, CH-pur), 7.42-7.12 (12H, m, CH-
Mmt), 6.85 (2H, d, J = 8.8 Hz, CHCOCH3-Mmt), 5.25 and 5.08 (2H, s, CH2COO),
4.52 and 4.12 (2H, s, CH2CO), 3.86-3.76 (2H, m, CH2N), 3.74 and 3.60 (3H, s,
OCH3), 3.72 (3H, s, OCH3-Mmt), 3.57-3.46 (2H, m, CH2N), 2.56 and 2.46 (3H, s,
CH3C), 2.29 and 2.26 (4H, s, CH2-Dde), 0.94 and 0.93 (6H, s, (CH3)2-Dde)
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13C NMR (62.5 MHz, d6-DMSO) two rotamers: δC 196.5 and 196.4 (CO), 173.1
(CO), 169.8 (CO), 169.3 (CO), 167.7 and 167.0 (C), 157.6 (C), 153.3 (C), 151.1
(CH), 149.0 and 148.9 (C), 145.1 (C), 142.3 and 142.1 (CH), 137.0 (C), 129.8 (CH),
128.4 (CH), 127.6 (CH), 126.4 (CH), 119.7 and 119.7 (C), 112.9 (CH), 107.3 and
107.2 (C), 69.8 (C), 54.9 (CH3), 52.3 (CH2), 51.8 (CH3), 48.0 (CH2), 46.5 (CH2),

















The ester 3.20 (3.56 g, 4.79 mmol, 1 eq) was suspended in a 2:1 (v/v) mixture of
MeOH and 2 M Cs2CO3 (30 mL) and stirred for 1 h. After evaporation of MeOH in
vacuo, the remaining solution was diluted with H2O (150 mL), washed with EtOAc
(50 mL), acidified with 1 M aqueous KHSO4, extracted with DCM (3 x 100 mL).
The organic extracts were washed with brine (100 mL), dried over MgSO4 and the
solvent was evaporated in vacuo. The residue was dissolved in a minimum amount of
EtOAc, precipitated with hexanes, collected by filtration and dried in vacuo to afford
the named compound 3.21 as a pale yellowish solid (2.53 g, 72%).
HPLC (method 2): tR = 3.6 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 728.2 [M-H]- (100)
1H NMR (250 MHz, d6-DMSO) two rotamers: δH 13.26 and 13.16 (1H, br s, NH-
Dde), 8.10 and 8.08 (1H, s, CH-pur), 7.87 (1H, s, CH-pur), 7.38-7.12 (12H, m, CH-
Mmt), 6.85 (2H, d, J = 8.8 Hz, CHCOCH3-Mmt), 5.24 and 5.07 (2H, s, CH2COO),
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4.40 and 4.03 (2H, s, CH2CO), 3.81-3.74 (2H, m, CH2N), 3.71 (3H, s, OCH3-Mmt),
3.60-3.47 (2H, m, CH2N), 2.56 and 2.46 (3H, s, CH3C), 2.29 and 2.26 (4H, s, CH2-
Dde), 0.99 and 0.93 (6H, s, (CH3)2-Dde)
13C NMR (62.5 MHz, d6-DMSO) two rotamers: δC 196.5 (CO), 173.1 (CO), 170.7
(CO), 170.2 (CO), 167.6 and 166.8 (C), 157.6 (C), 153.3 (C), 151.1 (CH), 149.0 (C),
145.1 (C), 142.1 (CH), 137.0 (C), 129.8 (CH), 128.4 (CH), 127.6 (CH), 126.5 (CH),
119.7 (C), 112.9 and 112.7 (CH), 107.3 and 107.2 (C), 69.8 (C), 54.9 (CH3), 52.3
(CH2), 49.1 (CH2), 47.9 and 46.6 (CH2), 43.7 (CH2), 40.9 (CH2), 29.7 (C), 27.8 and








To a stirred suspension of thymine (20 g, 158.6 mmol, 1 eq) and K2CO3 (21.9 g,
158.6 mmol, 1 eq) in DMF (500 mL) was added dropwise methyl 2-bromoacetate
(19 mL, 206.2 mmol, 1.3 eq). The mixture was then stirred vigorously at 25 °C for
16 h, collected by filtration and evaporated to dryness in vacuo. The solid residue
was cooled to 0 °C, treated with water (300 mL), 1 M aqueous KHSO4 (20 mL) and
stirred for 30 min. The precipitated was collected by filtration, washed with water (3
x 100 mL) to afford the named compound 3.23 as a white solid (18.16 g, 58%).
HPLC (method 2): tR = 1.2 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 199.0 [M+H]+ (100)
1H NMR (250 MHz, d6-DMSO): δH 11.41 (1H, br s, NH), 7.49 (1H, s, CH), 4.48
(2H, s, CH2), 3.68 (3H, s, OCH3), 1.75 (3H, s, CH3)
13C NMR (62.5 MHz, d6-DMSO): δC 168.7 (CO), 164.3 (CO), 150.9 (CO), 141.5










The ester 3.23 (44 g, 0.22 mol, 1 eq) was suspended in 2 M aqueous NaOH (750 mL)
and refluxed for 3 h. The solution was then cooled to 0 °C, treated with 1 M aqueous
KHSO4 (200 mL) and stirred for 30 min. The compound was collected by filtration,
washed with water (3 x 150 mL) and freeze dried for 16 h to afford the named
compound 3.24 as a white solid (20.35 g, 50%).
HPLC (method 2): tR = 0.9 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 183.0 [M-H]- (100)
1H NMR (250 MHz, d6-DMSO): δH 13.12 (1H, br s, CO2H), 11.36 (1H, br s, NH),
7.50 (1H, s, CH), 4.37 (2H, s, CH2), 1.76 (3H, s, CH3)
13C NMR (62.5 MHz, d6-DMSO): δC 169.6 (CO), 164.3 (CO), 150.9 (CO), 141.7















Compound 3.25 was synthesised from 3.24 (10.1 g, 54.9 mmol, 1 eq) in analogy to
3.20 and obtained as a buff coloured solid (19.6 g, 77%).
HPLC (method 2): tR = 2.6 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 463.1 [M+H]+ (100)
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1H NMR (250 MHz, d6-DMSO) two rotamers: δH 13.20 and 13.14 (1H, br s, NH-
Dde), 11.31 and 11.30 (1H, br s, NH), 7.33 and 7.31 (1H, s, CH), 4.67 and 4.51 (2H,
s, CH2COO), 4.40 and 4.11 (2H, s, CH2CO), 3.72 and 3.62 (3H, s, OCH3), 3.71-3.65
(2H, m, CH2N), 3.58-3.47 (2H, m, CH2N), 2.53 and 2.47 (3H, s, CH3C-Dde), 2.30
and 2.27 (4H, s, CH2-Dde), 1.75 (3H, s, CH3), 0.95 and 0.94 (6H, s, (CH3)2-Dde)
13C NMR (62.5 MHz, CD3COOD) two rotamers: δC 200.7 and 200.5 (CO), 176.7
and 176.5 (CO), 171.1 and 171.0 (CO), 170.2 and 169.5 (CO), 167.2 (C), 152.9
(CO), 143.9 (CH), 111.5 (C), 109.0 and 108.9 (C), 53.5 and 53.1 (CH3), 52.7 (CH2),
52.5 (CH2), 50.9 (CH2), 49.5 and 48.7 (CH2), 42.6 and 42.0 (CH2), 30.8 (C), 28.2















The ester 3.25 (5 g, 10.81 mmol, 1 eq) was suspended in 1:1 (v/v) mixture of MeOH
and 2 M Cs2CO3 (100 mL) and stirred for 1 h. After evaporation of MeOH in vacuo,
the aqueous phase was acidified with 4 M HCl (pH = 1) and the solvents were
removed in vacuo. The residue was treated with hot 2-propanol and the hot
suspension was passed through a filter. The filtrate was collected and 2-propanol was
removed in vacuo. The residue was sonicated with water (25 mL), the resulting
precipitated was collected by filtration and freeze dried to afford the named
compound 3.26 as an off-white solid (1.94 g, 40%).
HPLC (method 2): tR = 2.4 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 447.1 [M-H]- (100)
1H NMR (250 MHz, d6-DMSO) two rotamers: δH 13.28-13.06 (1H, m, NH-Dde),
11.32 and 11.30 (1H, br s, NH), 7.34 and 7.32 (d, 1H, J = 0.9 Hz, CH), 4.66 and 4.50
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(2H, s, CH2COO), 4.28 and 4.02 (2H, s, CH2CO), 3.75-3.61 (2H, m, CH2N), 3.43-
3.23 (2H, m, CH2N), 2.53 and 2.47 (3H, s, CH3C-Dde), 2.29 and 2.26 (4H, s, CH2-
Dde), 1.75 (3H, s, CH3), 0.94 and 0.93 (6H, s, (CH3)2-Dde)
13C NMR (62.5 MHz, d6-DMSO) two rotamers: δC 196.9 and 196.7 (CO), 173.5
(CO), 171.1 and 170.7 (CO), 168.4 and 167.7 (CO), 164.7 (C), 151.4 and 151.3
(CO), 142.4 and 142.3 (CH), 108.5 (C), 107.8 and 107.6 (C), 52.8 (2 x CH2), 49.2
(CH2), 48.1 and 46.8 (CH2), 41.3 (CH2), 30.1 (C), 28.2 (CH3), 17.7 and 17.6 (CH3),








To a stirred suspension of cytosine (10 g, 90 mmol, 1 eq) in pyridine/DCM (1/1, 550
mL) was added NEM (11.5 mL, 90 mmol, 1 eq) and 4-monomethoxytrityl chloride
(41.7 g, 135 mmol, 1.5 eq). The mixture was heated at 50 °C for 16 h. After
evaporation of the solvents in vacuo, the resulting oil was precipitated with diethyl
ether (200 mL). The resulting precipitated was collected by filtration, washed with
water (3 x 100 mL), THF (3 x 100 mL) and dried in vacuo to afford the named
compound 3.28 as a white solid (29 g, 84%).
HPLC (method 2): tR = 3.1 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 273.0 [Mmt]+ (100), 789.2 [2M+Na]+ (22)
No NMR spectrum was recorded since the named compound 3.28 was insoluble in












Compound 3.29 was synthesised from 3.28 (10 g, 26.1 mmol, 1 eq) in analogy to
3.18 and obtained as an off-white solid (10.4 g, 87%).
HPLC (method 2): tR = 3.3 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 454.0 [M-H]- (100)
1H NMR (250 MHz, d6-DMSO): δH 8.40 (1H, br s, NH), 7.46 (1H, d, J = 6.8 Hz,
CH-Cyt), 7.40-7.03 (12H, m, CH-Mmt), 6.84 (2H, d, J = 8.5 Hz, CH-Mmt), 6.20
(1H, d, J = 6.8 Hz, CH-Cyt), 4.33 (2H, s, CH2), 3.72 (3H, s, OCH3-Mmt), 3.61 (3H,
s, OCH3)
13C NMR (62.5 MHz, d6-DMSO): δC 169.1 (CO), 164.0 (C), 157.4 (C), 154.5 (CO),
148.8 (C and CH), 136.7 (C), 129.9 (CH), 128.5 (CH), 127.4 (CH), 126.1 (CH),












The ester 3.29 (10.4 g, 22.8 mmol, 1 eq) was suspended in 2 M aqueous NaOH (100
mL) and the mixture was refluxed for 2 h. The solution was then cooled to 25 °C,
washed with DCM (3 x 25 mL) and acidified with 2 M aqueous HCl until pH 2. The
resulting precipitated was collected by filtration, washed with small portions of water
until the filtrate was neutral (pH 7) and freeze dried for 16 h to afford the named
compound 3.30 as a white solid (7.5 g, 74%).
HPLC (method 2): tR = 3.0 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 440.1 [M-H]- (100)
1H NMR (250 MHz, d6-DMSO): δH 8.37 (1H, br s, NH), 7.46 (1H, d, J = 7.1 Hz,
CH-Cyt), 7.36-7.05 (12H, m, CH-Mmt), 6.87 (2H, d, J = 8.1 Hz, CH-Mmt), 6.19
(1H, d, J = 7.0 Hz, CH-Cyt), 4.24 (2H, s, CH2) 3.73 (3H, s, OCH3-Mmt)
13C NMR (62.5 MHz, d6-DMSO): δC 170.4 (CO), 164.4 (C), 157.8 (C), 155.1 (CO),
148.4 (C), 145.3 (CH), 137.2 (C), 130.4 (CH), 129.0 (CH), 127.8 (CH), 126.6 (CH),



















To a solution of the acid 3.30 (2.3 g, 5.21 mmol, 1 eq) and PyBOP (2.98 g, 5.73
mmol, 1.1 eq) in DMF (15 mL) at 0 °C was added DIPEA (1.8 mL, 10.42 mmol, 2
eq) and then the Dde-protected backbone 3.10 (1.5 g, 5.21 mmol, 1 eq), the reaction
was stirred under N2 at 25 °C for 16 h. The solvent was removed in vacuo, the
residue was re-dissolved in DCM (150 mL), washed with 1 M aqueous KHSO4 (50
mL), 10 % aqueous NaHCO3 (50 mL) and brine (50 mL). The organic phase was
dried over MgSO4 and the solvent was evaporated in vacuo. The residue was
dissolved in a minimum amount of MeOH, precipitated with an excess of water,
collected by filtration and freeze dried to give the named compound 3.31 (2.14 g,
57%) as a pale yellowish solid.
HPLC (method 2): tR = 3.5 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 273.1 [Mmt]+ (100), 720.3 [M+H]+ (53)
1H NMR (250 MHz, CDCl3): δH 13.48 and 13.33 (1H, br s, NH-Dde), 7.39 and 6.97
(13H, m, 12 x CH-Mmt and CH-Cyt), 6.78 and 6.77 (2H, d, J = 8.8 Hz, CHCOCH3-
Mmt), 5.08 (1H, d, J = 7.1 Hz, CH-Cyt), 4.58 and 4.41 (2H, s, CH2COO), 4.27 and
4.02 (2H, s, CH2CO), 3.78-3.60 (7H, m, OCH3-Mmt and 2 x CH2N), 3.55 (3H, s,
OCH3), 2.54 and 2.50 (3H, s, CH3C), 2.28 and 2.27 (4H, s, CH2-Dde), 0.95 and 0.94
(6H, s, (CH3)2-Dde)
13C NMR (62.5 MHz, CDCl3): δC 197.8 (CO), 174.1 and 173.9 (CNH), 169.9 and
169.8 (CO), 168.3 and 167.7 (CO), 165.5 (C), 158.7 (C), 155.9 (CO), 146.6 and
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146.3 (CH), 143.8 (C), 135.5 (C), 129.9 (CH), 128.6 (CH), 128.3 (CH), 127.5 (CH),
113.6 (CH), 95.2 (CH), 70.8 (C), 55.2 (CH3), 52.9 and 52.5 (CH3), 52.7 (CH2), 50.4
(CH2), 49.0 and 48.6 (CH2), 48.1 (CH2), 41.3 and 40.7 (CH2), 29.9 (C), 28.1 (CH3),

















Compound 3.32 was synthesised from 3.31 (3.2 g, 4.4 mmol, 1 eq) in analogy to 3.21
and obtained as a pale yellowish solid (2.4 g, 77%).
HPLC (method 2): tR = 3.3 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 704.2 [M-H]- (41)
1H NMR (250 MHz, MeOH-d4) two rotamers: δH 7.50-7.24 (11H, m, 10 x CH-
Mmt and CH-Cyt), 7.21 (2H, d, J = 8.9 Hz, CH-Mmt), 6.97 (2H, d, J = 8.9 Hz, CH-
Mmt), 5.35 and 5.31 (1H, d, J = 7.8 Hz, CH-Cyt), 4.88 and 4.75 (2H, s, CH2COO),
4.34 and 4.14 (2H, s, CH2CO), 3.85-3.64 (7H, m, OCH3-Mmt and 2 x CH2N), 2.57
and 2.55 (3H, s, CH3C), 2.33 and 2.29 (4H, s, CH2-Dde), 0.99 and 0.96 (6H, s,
(CH3)2-Dde)
13C NMR (62.5 MHz, MeOH-d4) two rotamers: δC 200.1 and 199.8 (CO), 176.0
(CNH), 172.1 (CO), 169.4 (CO), 164.9 (C), 161.3 and 161.1 (C), 152.7 (CO), 148.8
(CH), 143.7 (C), 135.0 (C), 131.3 (CH), 129.9 (CH), 129.8 (CH), 129.5 (CH), 115.2
(CH), 94.8 and 94.7 (CH), 74.4 (C), 55.9 (CH3), 53.5 (CH2), 50.7 (CH2), 50.4 (CH2),













To a stirred suspension of Fmoc-Lys-OH (5 g, 13.6 mmol, 1 eq) in ethanol (100 mL)
was added Dde-OH 3.15 (5 g, 27.2 mmol, 2 eq) and TFA (104 µL, 1.36 mmol, 0.1
eq). The mixture was refluxed for 60 h and concentrated in vacuo. The orange
residue was dissolved in EtOAc (200 mL), washed with 1 M aqueous KHSO4 (2 x
100 mL), brine (1 x 100 mL), dried over MgSO4 and the solvent was evaporated in
vacuo. The resulting yellow oil was triturated with hexane to give a yellowish solid
that was recrystallised from ethyl acetate/hexane to afford Fmoc-Lys(Dde)-OH 3.38
as an off-white solid (5 g, 69%).
HPLC (method 1): tR = 9.3 min (100% purity, 254 nm)
ESI+/MS: m/z (%) 533.2 [M+H]+ (100)
1H NMR (250 MHz, d6-DMSO): δH 13.34 (1H, br s, COOH), 12.72 (1H, br s, NH-
Dde), 7.97 (2H, d, J = 7.4 Hz, CH-Fmoc), 7.81 (2H, d, J = 7.2 Hz, CH-Fmoc), 7.50
(2H, t, J = 7.4 Hz, CH-Fmoc), 7.42 (2H, d, J = 7.2 Hz, CH-Fmoc), 5.84 (1H, br s,
NH), 4.41-4.38 (1H, m, CH), 4.33 (2H, d, J = 8.2 Hz, CH2-Fmoc), 4.09-3.95 (1H, m,
CH-Fmoc), 3.57-3.49 (2H, m, CH2-NH), 2.55 (3H, s, CH3-Dde), 2.32 (4H, s, CH2-
Dde), 1.91-1.72 (2H, m, CH2-Lys), 1.71-1.56 (2H, m, CH2-Lys), 1.55-1.37 (2H, m,
CH2-Lys), 1.00 (6H, s, (CH3)2-Dde)
13C NMR (62.5 MHz, d6-DMSO): δC 196.3 (CO-Dde), 173.8 (COOH), 172.7
(C=CNH), 156.1 (COO), 143.7 (C-Fmoc), 140.6 (C-Fmoc), 127.5 (CH-Fmoc), 127.0
(CH-Fmoc), 125.2 (CH-Fmoc), 120.0 (CH-Fmoc), 106.8 (C=CNH), 65.5 (CH2-
Fmoc), 53.6 (CH-Lys), 52.2 (2 x CH2-Dde), 46.6 (CH-Fmoc), 42.4 (CH2NH), 30.3
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3-{2-[2-(3-aminopropoxy)ethoxy]ethoxy}-1-propanamine (2.2 g, 10 mmol, 1 eq)
was dissolved in CH3CN (50 mL) and succinic anhydride (1 g, 10 mmol, 1 eq) in
CH3CN (25 mL) was added dropwise over an hour. The reaction was allowed to
proceed for an additional 3 h at 25 °C. After the waxy product settled, the organic
solvent was decanted. The product was re-diluted in a mixture of H2O and CH3CN
(1/1, 100 mL) and cooled to 0 °C for 30 min before Fmoc-OSu (4.4 g, 13 mmol, 1.3
eq) in CH3CN (25 mL) was added. Enough DIPEA was then added to maintain the
pH around 8-9 throughout the reaction. After stirring for 16 h at 25 °C, the solvents
were removed in vacuo. The resultant product was dissolved in 10% aqueous
NaHCO3 (100 mL) and washed with EtOAc (25 mL). The aqueous phase was then
acidified with 1 M HCl to pH 2 and extracted with EtOAc (3 x 50 mL). The
combined organic phases were washed with H2O (50 mL), dried over MgSO4 and
evaporated in vacuo to afford Fmoc-PEG spacer-OH 3.43 as a waxy product (4 g,
74%).
HPLC (method 2): tR = 3.4 min (100% purity, 254 nm)
ESI-/MS: m/z (%) 319.0 [Fmoc]- (100), 541.2 [M-H]- (87)
1H NMR (250 MHz, MeOH-d4): δH 7.79 (2H, d, J = 7.1 Hz, CH-Fmoc), 7.64 (2H,
d, J = 7.1 Hz, CH-Fmoc), 7.39 (2H, t, J = 7.4 Hz, CH-Fmoc), 7.32 (2H, dd, J = 7.4,
1.2 Hz, CH-Fmoc), 4.36 (2H, d, J = 6.7 Hz, CH2-Fmoc), 4.19 (1H, t, J = 6.6 Hz, CH-
Fmoc), 3.66-3.39 (12H, m, CH2O), 3.33-3.11 (4H, m, CH2NH), 2.62-2.49 (2H, m,
CH2CO), 2.48-2.35 (2H, m, CH2CO), 1.72 (4H, quint., J = 6.5 Hz, CH2)
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13C NMR (62.5 MHz, MeOH-d4): δC 176.2 (CO), 174.5 (CO), 158.9 (CO), 145.4
(C-Fmoc), 142.7 (C-Fmoc), 128.8 (CH-Fmoc), 128.2 (CH-Fmoc), 126.2 (CH-Fmoc),
121.0 (CH-Fmoc), 71.5 (CH2O), 71.2 (CH2O), 69.9 (CH2O), 69.7 (CH2O), 67.5
(CH2-Fmoc), 54.9 (CH-Fmoc), 39.1 (CH2NHCOO), 37.9 (CH2NHCO), 31.7
(CH2COOH), 30.8 (CH2), 30.4 (2 x CH2)
4.3.2 Synthesis of PNA-encoded positional scanning libraries
4.3.2.1 General experimental procedures
Dde deprotection20
NH2OH.HCl (6.25 g, 9 mmol, 1.3 eq) and imidazole (4.59 g, 6.75 mmol, 1 eq) were
dissolved in 25 mL of NMP and the mixture was sonicated until complete
dissolution. Just before reaction, 5 volumes of this solution were diluted with 1
volume of DMF. The solution was added to the resin and the resulting mixture was
shaken for 1 h at 25 °C. The resin was finally washed with DMF (3 x) and DCM (3
x).
Dde/Mmt-protected PNA monomer couplings4
Dde/Mmt-protected PNA monomer (5 eq) and PyBOP (4.8 eq) were dissolved in
DMF (0.1 M) followed by the addition of NEM (10 eq). The resulting solution was
mixed for 10 sec. before adding to the PEGA resin (1 eq) pre-swelled in DMF and
the mixture was shaken for 6 h. Resins were washed with DMF (3 x), DCM (3 x),
MeOH (3 x) and DCM (3 x).
This procedure was also used for the couplings of Fmoc-Rink amide linker, Fmoc-
PEG spacer-OH, rhodamine and 5(6)-carboxyfluorescein.
Fmoc-amino acid couplings
Fmoc-amino acids (5 eq), PyBOP (4.8 eq) and HOBt (5 eq) were dissolved in DMF
(0.1 M) followed by the addition of DIPEA (10 eq). The resulting solution was
mixed for 10 sec. before adding to the PEGA resin (1 eq) pre-swelled in DMF and
the mixture was shaken for 6 h. Resins were washed with DMF (3 x), DCM (3 x),




 625-member PNA-encoded positional scanning library (first sub-library)
The resin (8.25 µmol, 1 eq) was pre-swelled in dry DCM under N2 for 20 min and
washed with dry DCM (3 x 2 mL) under N2. A solution of PhSiH3 (25 µL, 0.198
mmol, 24 eq) in dry DCM (350 µL) was then added and the resin was stirred
manually under N2. A solution of Pd(PPh3)4 (0.95 mg, 0.825 µmol, 0.1 eq) in dry
DCM (1 mL) was added and the resin was shaken for 15 min with a balloon of N2.
The resin was washed with dry DCM under N2 (3 x 2 mL) and the process was
repeated once.
 50,625-member PNA-encoded positional scanning library
The same protocol was applied for each sub-library but using 0.116 mmol of resin (1
eq).
Cleavage of a sub-library from the resin
Each sub-library was cleaved from the resin using a TFA/TIS/DCM (90/5/5) solution
(1 mL or 6 mL for the 625 or 50,625-member library respectively) for 2 h and
precipitated with cold diethyl ether. The residue was collected by filtration and dried
in vacuo for 2 h to afford the expected compound as a solid.
4.3.2.2 Library synthesis
 625-member PNA-encoded positional scanning library (first sub-library)
















Deprotection and coupling protocols are described in section 4.3.2.1. Fmoc-Rink-
amide linker (96 mg, 0.178 mmol, 5 eq) was first attached to PEGA resin (89 mg,
0.0356 mmol, 1 eq) following stepwise couplings with Fmoc-Lys(Dde)-OH 3.38 (95
mg, 0.178 mmol, 5 eq), Fmoc-PEG spacer-OH 3.43 (97 mg, 0.178 mmol, 5 eq) and
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Fmoc-Lys(Aloc)-OH (81 mg, 0.178 mmol, 5 eq). Then, the Dde group was removed
and seven common PNA monomers GATCATC (from N → C) (0.178 mmol, 5 eq)
were coupled to the resin to afford the named compound 3.45.
Loading: determined by a quantitative Fmoc test, 0.12 mmol/g (theoretical loading:
0.18 mmol/g).
Characterisation: a small sample of resin 3.45 was cleaved using a TFA/TIS/DCM
(90/5/5) solution (500 µL) for 1 h.
HPLC (method 4): tR = 6.7 min (91% purity, ELSD)
MALDI-TOF+/MS: m/z (%) 2923.1 [M+H]+ (100)
Synthesis of the first sub-library (3.51)
Deprotection, coupling and cleavage protocols are described in section 4.3.2.1. The
synthesis was then carried out as follows: [1] split the common part of the library
3.45 into five different pools (6.6 µmol of resin 3.45 per pool); [2] Fmoc
deprotection (see section 4.1.2); [3] Fmoc-amino acid couplings (33 µmol per pool, 5
eq); [4] Take one fourth of the amount of resin in each pool; [5] Dde deprotection;
[6] Dde/Mmt-protected PNA monomer couplings (8.25 µmol per pool, 5 eq); repeat
steps [5] and [6] four times; [7] the five resin pools were then mixed; repeat steps
from [1] to [3] followed by step [7] three times. Then, Fmoc-γ-Abu-OH (13.5 mg,
41.25 µmol, 5 eq) and rhodamine (20 mg, 41.25 µmol, 5 eq) were respectively
coupled followed by Aloc-deprotection and coupling with 5(6)-carboxyfluorescein
(16 mg, 41.25 µmol, 5 eq). Before cleavage, the sub-library was treated with 20%
piperidine in DMF (500 µL, 2 cycles of 10 min),151 washed with DMF (2 x 500 µL)
and DCM (2 x 500 µL). Final cleavage from the resin was carried out using a
TFA/TIS/DCM (90/5/5) solution (1 mL) for 2 h to afford the first sub-library 3.51 as
purple solid (28.3 mg, 67%).
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 50,625-member PNA-encoded positional scanning library
















Deprotection and coupling protocols are described in section 4.3.2.1. Fmoc-Rink-
amide linker (2.7 g, 5 mmol, 5 eq) was first attached to PEGA resin (2.52 g, 1 mmol,
1 eq) following stepwise couplings with Fmoc-Lys(Dde)-OH 3.38 (2.66 g, 5 mmol, 5
eq), Fmoc-PEG spacer-OH 3.43 (2.7 g, 5 mmol, 5 eq) and Fmoc-Lys(Aloc)-OH
(2.26 g, 5 mmol, 5 eq) to afford the named compound 3.44.
Loading: determined by a quantitative Fmoc test, 0.22 mmol/g (theoretical loading:
0.28 mmol/g).
Characterisation: a small sample of resin 3.44 was cleaved using a TFA/TIS/DCM
(90/5/5) solution (500 µL) for 1 h.
HPLC (method 2): tR = 3.3 min (86% purity, 254 nm)
MALDI-TOF+/MS: m/z (%) 1046.2 [M+H]+ (100)
















Common part of the library 3.44 (0.529 g, 0.116 mmol, 1 eq) was washed with DMF
(2 x 5 mL), DCM (6 x 5 mL) and pre-swelled in DCM for 30 min. The Dde group
was removed and four common PNA monomers (TCTA, from N → C) (0.58 mmol,




Characterisation: a small sample of resin 3.52 was cleaved using a TFA/TIS/DCM
(90/5/5) solution (500 µL) for 1 h.
HPLC (method 2): tR = 2.9 min (78% purity, 254 nm)
MALDI-TOF+/MS: m/z (%) 2104.6 [M+H]+ (100)
Synthesis of the first sub-library (3.56)
Deprotection, coupling and cleavage protocols are described in section 4.3.2.1.
Synthesis of the first sub-library was carried out as follows: [1] split the common
part of the first sub-library 3.52 into fifteen different pools (7.7 µmol of resin 3.52
per pool); [2] Fmoc deprotection (see section 4.1.2); [3] Fmoc-amino acid couplings
(38.5 µmol per pool, 5 eq); Amino acids in the first position were then encoded by
eight PNA monomers (Table 3.2). [4] Dde deprotection; [5] Dde/Mmt-protected
PNA monomer couplings (38.5 µmol, 5 eq); repeat steps [4] and [5] seven times; [6]
the fifteen resin pools were then mixed; repeat steps from [1] to [3] followed by step
[6] three times. Then, Fmoc-γ-Abu-OH (189 mg, 0.58 mmol, 5 eq) and rhodamine
(283 mg, 0.58 mmol, 5 eq) were respectively coupled followed by Aloc-deprotection
and coupling with 5(6)-carboxyfluorescein (218 mg, 0.58 mmol, 5 eq). Before
cleavage, the sub-library was treated with 20% piperidine in DMF (6 mL, 2 cycles of
10 min),151 washed with DMF (2 x 6 mL) and DCM (2 x 6 mL). Final cleavage from
the resin was carried out using a TFA/TIS/DCM (90/5/5) solution (6 mL) for 2 h to
afford the first sub-library 3.56 as a magenta solid (176 mg, 30%).
















The named compound 3.53 was synthesised in analogy to 3.52 but using the four
common PNA monomers (ACAT, from N → C).
HPLC (method 2): tR = 2.9 min (84% purity, 254 nm)
MALDI-TOF+/MS: m/z (%) 2113.9 [M+H]+ (100)
Chapter 4
-162-
Synthesis of the second sub-library (3.57)
The procedure applied to 3.56 was followed except that amino acids in the second
position of the tetrapeptide were encoded by eight PNA monomers (Table 3.2) to
afford the second sub-library 3.57 as a magenta solid (175 mg, 29%).
















The named compound 3.54 was synthesised in analogy to 3.52 but using the four
common PNA monomers (ATCA, from N → C).
HPLC (method 2): tR = 2.9 min (83% purity, 254 nm)
MALDI-TOF+/MS: m/z (%) 2114.5 [M+H]+ (100), 2136.5 [M+Na]+ (18)
Synthesis of the third sub-library (3.58)
The procedure applied to 3.56 was followed except that amino acids in the third
position of the tetrapeptide were encoded by eight PNA monomers (Table 3.2) to
afford the third sub-library 3.58 as a magenta solid (256 mg, 43%).
















The named compound 3.55 was synthesised in analogy to 3.52 but using the four
common PNA monomers (TACT, from N → C).
HPLC (method 2): tR = 3.0 min (85% purity, 254 nm)
MALDI-TOF+/MS: m/z (%) 2103.9 [M+H]+ (100), 2125.9 [M+Na]+ (75)
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Synthesis of the fourth sub-library (3.59)
The procedure applied to 3.56 was followed except that amino acids in the fourth
position of the tetrapeptide were encoded by eight PNA monomers (Table 3.2) to
afford the fourth sub-library 3.59 as a magenta solid (206 mg, 35%).
4.3.3 Enzymatic assays
DNA microarray production
3’-amino modified 12-mer DNAs oligomers were purchased from Sigma-Genosys
(UK) (Table 3.3) or Bioneer (Korea) (Table 3.4). The dried oligonucleotides were
centrifuged and re-suspended in 1 x TE (10 mM Tris, pH 7.5-8.0, 1mM EDTA) to
give a 200 µM final concentration. Before printing, 10 µL of the solution of
oligomers and 10 µL of spotting solution (2 M NaCl, 3 M NaHCO3, pH 8) were
mixed onto a 384-well plate. DNA printing was performed using a Genetix
QArrayMini (Genetix) contact printer. One solid pin (20 aQu solid pins with a 150
µm diameter, Genetix) was used in order to print 3’-amino modified DNA oligomers
(18 mers) on aldehyde-coated glass slides keeping humidity at 70 %. For the 625
member library, each DNA oligomer was printed in five replicates (1 x 5 sub-arrays),
and this pattern was duplicated across the microarray. A different pattern was used
for the 50,625 member PNA-encoded positional scanning library (see below). Then,
the microarrays were kept at 25°C for 16 h in a chamber containing a filter paper
saturated with a 3 M NaCl solution and stored in the dark. Finally, the chips were
washed with 0.2 % Sodium Dodecyl Sulphate (SDS) (2 x 2 min) and distilled water
(2 x 2 min). Imine reduction was performed by washing the slides for 5 min with a
solution containing 50 mg of NaBH4 in 15 mL of PBS and 5 mL of EtOH. The chips
were then washed with distilled water (1 min), 0.2 % SDS (3 x 1 min) and distilled
water (1 min). After spin-drying by centrifugation (4000 rpm for 6 min), the chips
were stored in the dark at 25°C before hybridisation was carried out.
Arraying pattern used for the 50,625 member PNA-encoded positional scanning
library
Each DNA oligomer was printed in five replicates (1 x 5 sub-arrays). A typical spot
size of 200 µm, a row pitch of 670 µm and a column pitch of 670 µm were used as
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well as the following printing conditions: 1 stamp per spot, 10 ms stamping time and
10 ms inking time.
Hybridisation onto DNA microarrays
The procedure described in section 4.2.5 was adapted. The hybridisation temperature
was slowly lowered to 30 °C over a period of 5 h or 9 h for the 625 and 50,625-
member PNA-encoded positional scanning libraries respectively.
Enzyme buffers
- trypsin: 67 mM sodium phosphate buffer, pH 7.6 at 25°C (625-member PNA-
encoded library 3.51) or 0.9% sodium chloride aqueous solution (50,625-member
PNA-encoded library, sub-libraries 3.56, 3.57, 3.58 and 3.59).
- subtilisin A: 10 mM sodium acetate buffer, 5 mM calcium acetate, pH 7.5.
- chymopapain: 50 mM sodium acetate, pH 6.2, 2 mM cysteine, 0.1 mM EDTA.
- pepsin: 0.2 M sodium citrate buffer (pH 4.5).
General procedure for fluorometric assays
The proteases subtilisin A, trypsin (TPCK treated, from bovine pancreas),
chymopapain (from papaya latex) and pepsin (from porcine gastric mucosa) were
purchased from Sigma.
The 625-member PNA encoded first sub-library 3.51 or one pool of the 50,625-
member PNA-encoded positional scanning library (sub-libraries 3.56, 3.57, 3.58 or
3.59) was diluted in the corresponding protease buffer (see section 4.3.3) (final
volume of 125 µL) to give a final concentration of 100 or 50 µM for the 625 and
50,625-member libraries respectively. The enzymatic reaction was started by
addition of the protease (60 µL) at a final concentration of 10 µM or 20 nM for the
625 and 50,625-member libraries respectively. The solution was agitated for 30 sec.
and the fluorescence of the solution was measured by spectrofluorometry using an
excitation wavelength of 480 nm and an emission wavelength of 520 nm. The change




General procedure for proteolytic assays
The 625-member PNA encoded first sub-library 3.51 (solubilised in distilled water)
was diluted in the corresponding protease buffer (see section 4.3.3) to give a final
concentration of 100 µM and a final volume of 200 µL. The enzymatic reaction was
started by addition of the protease (20 µL) at a final concentration of 10 µM. The
solution was then incubated at 37 °C for 2 h and diluted with distilled water to give a
final concentration of 10 µM. One volume of this solution was diluted with one
volume of the GenHyb hybridisation buffer (see section 4.2.5) and used for
hybridisation on DNA microarrays (see section 4.3.3).
The above protocol was adapted for the 50,625-member PNA encoded positional
scanning library. Mother solutions of the sub-libraries 3.56, 3.57, 3.58 and 3.59 were
first diluted 10 times in DMSO (up to 10%) and distilled water, and then in the
corresponding protease buffer (see section 4.3.3) to give a final concentration of 50
µM and a final volume of 100 µL. A 20 nM protease final concentration was added
and the solution was incubated at 37 °C for 2 h. Protease concentrations were
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Appendix I: Sequences of the 155 “hits” identified from the Abl screening. The one-letter amino-acid
code is used.
1) FQSEYEVIK 33) FQSEYIPIK 65) FQKEYSEIK 97) FQPKYEEIK 129) FQvEYRVIK
2) FQSEYESIK 34) FQEEYESIK 66) FQVAYSSIK 98) FQEEYSVIK 130) FQPSYSEIK
3) FQSEYSFIK 35) FQSEYKPIK 67) FQSEYKIIK 99) FQvEYKSIK 131) FQRVYSKIK
4) FQSEYVFIK 36) FQpEYSSIK 68) FQvEYEVIK 100) FQKVYERIK 132) FQvSYSVIK
5) FQVIYESIK 37) FQpEYVEIK 69) FQPEYKFIK 101) FQESYEVIK 133) FQESYSPIK
6) FQSIYEPIK 38) FQPRYSSIK 70) FQPSYESIK 102) FQREYKIIK 134) FQSSYEVIK
7) FQSIYSPIK 39) FQSEYVIIK 71) FQSEYVRIK 103) FQSEYVvIK 135) FQEKYSVIK
8) FQPEYSEIK 40) FQKVYSEIK 72) FQKVYEEIK 104) FQFSYFIIK 136) FQSKYSVIK
9) FQSEYEEIK 41) FQSVYEEIK 73) FQEEYSRIK 105) FQvEYFKIK 137) FQEPYEEIK
10) FQVEYESIK 42) FQVEYSVIK 74) FQSVYEPIK 106) FQvEYpKIK 138) FQEKYSEIK
11) FQSEYSSIK 43) FQvEYFFIK 75) FQpVYSSIK 107) FQEEYKKIK 139) FQvEYKpIK
12) FQKIYSVIK 44) FQVEYSSIK 76) FQKVYEFIK 108) FQSVYKVIK 140) FQESYSKIK
13) FQPEYESIK 45) FQPAYESIK 77) FQKEYFVIK 109) FQvEYRSIK 141) FQvEYRKIK
14) FQEVYSSIK 46) FQEVYKVIK 78) FQvEYKVIK 110) FQvVYSKIK 142) FQEEYKVIK
15) FQRIYSEIK 47) FQSEYERIK 79) FQSEYVKIK 111) FQPKYEVIK 143) FQKEYSKIK
16) FQPEYVVIK 48) FQpEYVVIK 80) FQvVYSPIK 112) FQpVYEKIK 144) FQEEYKpIK
17) FQSEYVSIK 49) FQEEYEVIK 81) FQvEYVSIK 113) FQvEYRpIK 145) FQSKYEEIK
18) FQEEYVFIK 50) FQpEYKVIK 82) FQKEYEEIK 114) FQSEYRVIK 146) FQEaYSSIK
19) FQEVYSFIK 51) FQEVYEEIK 83) FQESYSVIK 115) FQvEYSRIK 147) FQEKYEPIK
20) FQSEYEFIK 52) FQSVYSPIK 84) FQVEYKPIK 116) FQSEYEpIK 148) FQKEYEKIK
21) FQPIYRSIK 53) FQpEYISIK 85) FQSRYESIK 117) FQREYSKIK 149) FQpEYKKIK
22) FQEEYSPIK 54) FQRVYSVIK 86) FQRVYSSIK 118) FQvEYEvIK 150) FQEEYSvIK
23) FQKIYSEIK 55) FQEVYFVIK 87) FQEEYSpIK 119) FQVSYSSIK 151) FQVSYEKIK
24) FQRVYSEIK 56) FQREYFSIK 88) FQKVYESIK 120) FQSSYEEIK 152) FQvEYvRIK
25) FQPVYEKIK 57) FQvEYEFIK 89) FQSSYSEIK 121) FQpEYEpIK 153) FQEaYESIK
26) FQEEYSFIK 58) FQKEYFPIK 90) FQvVYERIK 122) FQKEYESIK 154) FQvSYEvIK
27) FQSEYFFIK 59) FQREYSFIK 91) FQPAYSSIK 123) FQvEYVvIK 155) FQKPYEVIK
28) FQpEYESIK 60) FQvEYIEIK 92) FQPEYKRIK 124) FQESYESIK
29) FQvEYSPIK 61) FQpVYSVIK 93) FQpEYKSIK 125) FQPEYKKIK
30) FQKIYEKIK 62) FQSAYSSIK 94) FQvEYSvIK 126) FQvEYKRIK
31) FQSEYEIIK 63) FQFEYSSIK 95) FQEVYKIIK 127) FQpSYSVIK
32) FQSEYEKIK 64) FQSVYSFIK 96) FQSVYSKIK 128) FQSSYVPIK
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Appendix II (first part): Sequences of the 299 “hits” identified from the Her2 screening. The one-
letter amino-acid code is used.
1) FQpRYPpIK 39) FQKIYSRIK 77) FQSEYpSIK 115) FQVPYEFIK 153) FQKaYSSIK
2) FQVRYFpIK 40) FQVKYSPIK 78) FQpAYpSIK 116) FQKSYpSIK 154) FQKaYFpIK
3) FQFaYppIK 41) FQPRYvSIK 79) FQSaYFpIK 117) FQRaYpSIK 155) FQPSYEpIK
4) FQpIYppIK 42) FQRSYSEIK 80) FQSRYpFIK 118) FQEKYSpIK 156) FQvRYvSIK
5) FQpAYpRIK 43) FQEAYppIK 81) FQSEYFpIK 119) FQvEYvKIK 157) FQKSYRpIK
6) FQKIYppIK 44) FQKaYPpIK 82) FQKVYIPIK 120) FQVaYRPIK 158) FQREYKPIK
7) FQFAYpSIK 45) FQFRYKSIK 83) FQvSYRpIK 121) FQKRYEFIK 159) FQESYEpIK
8) FQPAYFpIK 46) FQRaYSpIK 84) FQSRYSEIK 122) FQRKYvpIK 160) FQEVYFSIK
9) FQEAYRSIK 47) FQREYpvIK 85) FQvSYRIK 123) FQpVYVKIK 161) FQVIYvKIK
10) FQIaYppIK 48) FQRSYRRIK 86) FQRSYvSIK 124) FQEVYEKIK 162) FQpaYVKIK
11) FQPRYSpIK 49) FQKEYIpIK 87) FQVSYSRIK 125) FQKSYFSIK 163) FQIaYSSIK
12) FQISYppIK 50) FQpKYSSIK 88) FQSEYIEIK 126) FQpSYppIK 164) FQVEYvpIK
13) FQRSYFpIK 51) FQKRYppIK 89) FQvRYPpIK 127) FQFKYSpIK 165) FQvSYPpIK
14) FQVRYRSIK 52) FQKAYSpIK 90) FQRKYppIK 128) FQSPYSpIK 166) FQRaYPpIK
15) FQSIYRSIK 53) FQISYSpIK 91) FQVaYppIK 129) FQEKYKpIK 167) FQpKYPVIK
16) FQEIYKRIK 54) FQERYvpIK 92) FQSaYpSIK 130) FQKRYESIK 168) FQpaYSpIK
17) FQpRYREIK 55) FQKRYFSIK 93) FQRKYpvIK 131) FQSVYFpIK 169) FQESYSRIK
18) FQpRYPSIK 56) FQSAYSPIK 94) FQERYvSIK 132) FQSaYSpIK 170) FQpSYvSIK
19) FQSRYppIK 57) FQvSYppIK 95) FQKSYpKIK 133) FQKSYEKIK 171) FQKSYFpIK
20) FQFSYERIK 58) FQRRYvRIK 96) FQSSYSSIK 134) FQFEYEKIK 172) FQvaYEpIK
21) FQvaYFpIK 59) FQSSYvpIK 97) FQVKYSpIK 135) FQpAYSSIK 173) FQSKYpSIK
22) FQFaYSpIK 60) FQpSYPpIK 98) FQERYFSIK 136) FQSEYvpIK 174) FQvSYSpIK
23) FQRRYpSIK 61) FQISYpSIK 99) FQVSYKpIK 137) FQKSYSpIK 175) FQPSYEPIK
24) FQIaYPpIK 62) FQREYEpIK 100) FQREYppIK 138) FQpSYSpIK 176) FQvEYpSIK
25) FQSRYPSIK 63) FQVSYREIK 101) FQpAYEKIK 139) FQEEYppIK 177) FQFSYvSIK
26) FQEaYppIK 64) FQSRYpSIK 102) FQPKYvpIK 140) FQVEYSFIK 178) FQSSYRSIK
27) FQIVYSSIK 65) FQpEYPpIK 103) FQFKYpSIK 141) FQSAYvSIK 179) FQKSYSEIK
28) FQRAYpPIK 66) FQKVYFpIK 104) FQERYpSIK 142) FQVaYpSIK 180) FQpEYpSIK
29) FQPSYFSIK 67) FQpPYppIK 105) FQvSYFpIK 143) FQSaYvpIK 181) FQEEYPpIK
30) FQvaYFSIK 68) FQPIYIVIK 106) FQvRYpSIK 144) FQPSYpSIK 182) FQKVYppIK
31) FQIEYSRIK 69) FQERYFFIK 107) FQVPYRpIK 145) FQKPYpFIK 183) FQVVYSSIK
32) FQISYKRIK 70) FQFEYpSIK 108) FQISYvSIK 146) FQKRYSpIK 184) FQESYvEIK
33) FQISYRpIK 71) FQvRYVFIK 109) FQKSYSFIK 147) FQEKYvpIK 185) FQpAYvSIK
34) FQvAYvpIK 72) FQVSYppIK 110) FQvRYppIK 148) FQRKYPSIK 186) FQpRYvKIK
35) FQIPYvpIK 73) FQKRYpSIK 111) FQEVYVVIK 149) FQpSYFSIK 187) FQFSYSpIK
36) FQRaYVRIK 74) FQSRYSpIK 112) FQSRYvSIK 150) FQEaYpFIK 188) FQSaYpvIK
37) FQSIYPpIK 75) FQESYIRIK 113) FQPSYvpIK 151) FQKaYKSIK 189) FQSEYPpIK
38) FQIaYpSIK 76) FQVEYKVIK 114) FQVSYRpIK 152) FQPaYSEIK 190) FQESYPpIK
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Appendix II (second part): Sequences of the 299 “hits” identified from the Her2 screening. The one-
letter amino-acid code is used.
191) FQVKYRSIK 213) FQVSYEEIK 235) FQvSYvSIK 257) FQKKYppIK 279) FQSKYSvIK
192) FQpaYRKIK 214) FQEKYvSIK 236) FQSSYPSIK 258) FQRKYEKIK 280) FQpKYpSIK
193) FQEPYSSIK 215) FQvaYvSIK 237) FQSSYKSIK 259) FQKRYpKIK 281) FQKEYEPIK
194) FQvEYvSIK 216) FQEEYRpIK 238) FQVVYPKIK 260) FQPSYvSIK 282) FQEEYvSIK
195) FQSaYSPIK 217) FQESYRFIK 239) FQREYvSIK 261) FQEKYppIK 283) FQFKYIvIK
196) FQSKYvpIK 218) FQKKYvFIK 240) FQVaYKSIK 262) FQERYRvIK 284) FQpEYSSIK
197) FQFaYvSIK 219) FQKSYvSIK 241) FQpSYSSIK 263) FQSVYvSIK 285) FQEKYSEIK
198) FQEKYFEIK 220) FQESYSpIK 242) FQVKYpvIK 264) FQKEYpSIK 286) FQKSYpvIK
199) FQVVYpKIK 221) FQpEYvpIK 243) FQvRYKVIK 265) FQKEYKpIK 287) FQEKYVRIK
200) FQvaYSSIK 222) FQRKYvKIK 244) FQKKYSKIK 266) FQKEYSFIK 288) FQvKYvRIK
201) FQKRYpEIK 223) FQEKYRpIK 245) FQRKYSpIK 267) FQKSYESIK 289) FQKKYvSIK
202) FQSSYSFIK 224) FQpaYSPIK 246) FQEaYKPIK 268) FQRKYpKIK 290) FQKSYpEIK
203) FQvAYKSIK 225) FQKaYKpIK 247) FQSaYKFIK 269) FQpPYKPIK 291) FQREYKSIK
204) FQpKYvSIK 226) FQKEYRSIK 248) FQKVYvpIK 270) FQvPYKpIK 292) FQKSYSvIK
205) FQRKYSSIK 227) FQKKYSvIK 249) FQvKYppIK 271) FQRaYpKIK 293) FQKKYpSIK
206) FQpEYKvIK 228) FQKSYPpIK 250) FQKEYSpIK 272) FQKVYEPIK 294) FQKaYvVIK
207) FQSEYppIK 229) FQSaYRPIK 251) FQKaYvRIK 273) FQEaYSEIK 295) FQvKYVPIK
208) FQPaYSSIK 230) FQSKYRFIK 252) FQvKYvpIK 274) FQKKYSFIK 296) FQvKYKpIK
209) FQPSYSSIK 231) FQSSYpRIK 253) FQIRYvVIK 275) FQEPYvEIK 297) FQEEYEvIK
210) FQpKYvKIK 232) FQSaYERIK 254) FQvEYpvIK 276) FQSaYKSIK 298) FQvKYpKIK
211) FQvEYSpIK 233) FQRaYSvIK 255) FQvKYRPIK 277) FQSKYvFIK 299) FQVKYKKIK
212) FQEVYEpIK 234) FQVKYSVIK 256) FQERYvKIK 278) FQvVYSEIK
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Appendix III: Sequences of the top 50 “hits” identified from the VEGFR2 screening. The one-letter
amino-acid code is used.
1) FQIAYPFIK 14) FQPRYRSIK 27) FQpAYISIK 40) FQPRYpKIK
2) FQFRYEIIK 15) FQIVYVRIK 28) FQEAYEFIK 41) FQPRYpEIK
3) FQIAYPPIK 16) FQVAYIpIK 29) FQFEYPRIK 42) FQPEYESIK
4) FQFEYISIK 17) FQPEYIvIK 30) FQFRYPSIK 43) FQFIYRPIK
5) FQPAYIvIK 18) FQISYFSIK 31) FQIAYRSIK 44) FQVAYSSIK
6) FQIRYPPIK 19) FQIAYFEIK 32) FQIRYpEIK 45) FQIRYKIIK
7) FQEAYPEIK 20) FQFAYIpIK 33) FQpIYVFIK 46) FQRRYpSIK
8) FQIAYvpIK 21) FQFVYFRIK 34) FQRIYpRIK 47) FQIaYpFIK
9) FQFRYKFIK 22) FQPSYIpIK 35) FQpAYEEIK 48) FQPIYRpIK
10) FQIVYppIK 23) FQIIYSFIK 36) FQvIYPSIK 49) FQFRYEKIK
11) FQEIYIPIK 24) FQFIYEEIK 37) FQFKYFRIK 50) FQSIYFRIK
12) FQIVYREIK 25) FQFRYSvIK 38) FQFaYFPIK
13) FQFSYFSIK 26) FQPIYpFIK 39) FQSAYSRIK
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Appendix IV: Median values and standard errors of the ratio of fluorescein/rhodamine (five
replicates) calculated after enzymatic assay with pepsin (625-member PNA-encoded positional
scanning library)
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine







Ala (duplicate) 0,105484549 0,002943523
Ser (duplicate) 0,077187209 0,001509803
Lys (duplicate) 0,088175009 0,001266744
Glu (duplicate) 0,054808912 0,000703658
Pro (duplicate) 0,079824635 0,001442406
Appendix V: Median values and standard errors of the ratio of fluorescein/rhodamine (five replicates)
calculated after enzymatic assay with subtilisin A (625-member PNA-encoded positional scanning
library)
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine







Ala (duplicate) 0,654410652 0,056794691
Ser (duplicate) 0,284242084 0,005633034
Lys (duplicate) 0,238276756 0,006686731
Glu (duplicate) 0,142058441 0,003398875
Pro (duplicate) 0,189564069 0,014303455
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Appendix VI: Median values and standard errors of the ratio of fluorescein/rhodamine (five
replicates) calculated after enzymatic assay with trypsin (625-member PNA-encoded positional
scanning library)
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine







Ala (duplicate) 3,219626168 0,284608895
Ser (duplicate) 0,378708148 0,021960912
Lys (duplicate) 2,300243605 0,111898463
Glu (duplicate) 0,469775281 0,030903061
Pro (duplicate) 1,348504551 0,049651044
Appendix VII (first part): Median values and standard errors of the ratio of fluorescein/rhodamine
(five replicates) calculated after enzymatic assay with trypsin (50,625-member PNA-encoded
positional scanning library). The numbers (1), (2), (3) and (4) represent the amino acids encoded in
the first, second, third and fourth sub-libraries respectively.
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine
Standard errors of the
ratio of fluorescein/rhodamine
Pro (1) 0,512684156 0,0053
Thr (1) 0,48671885 0,0086
Tyr (1) 0,414548052 0,0150
Arg (1) 0,504991979 0,0111
Glu (1) 0,499160291 0,0091
His (1) 0,440835229 0,0138
Lys (1) 0,424113348 0,0174
Phe (1) 0,4553458 0,0150
Ser (1) 0,432391637 0,0163
Trp (1) 0,455771576 0,0125
Val (1) 0,380207691 0,0143
Ala (1) 0,460480365 0,0104
Gln (1) 0,451866238 0,0353
Gly (1) 0,412047254 0,0100
Ile (1) 0,390723943 0,0117
Pro (2) 0,374823313 0,0098
Thr (2) 0,338079981 0,0075
Tyr (2) 0,314632632 0,0072
Arg (2) 0,456797099 0,0072
Glu (2) 0,352706506 0,0092
His (2) 0,326281815 0,0051
Lys (2) 0,311408269 0,0025
Phe (2) 0,427825754 0,0098
Ser (2) 0,33989809 0,0047
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Appendix VII (second part): Median values and standard errors of the ratio of
fluorescein/rhodamine (five replicates) calculated after enzymatic assay with trypsin (50,625-member
PNA-encoded positional scanning library). The numbers (1), (2), (3) and (4) represent the amino acids
encoded in the first, second, third and fourth sub-libraries respectively.
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine
Standard errors of the
ratio of fluorescein/rhodamine
Trp (2) 0,339506545 0,0058
Val (2) 0,305565278 0,0087
Ala (2) 0,448581288 0,0172
Gln (2) 0,401343468 0,0089
Gly (2) 0,337501961 0,0069
Ile (2) 0,315027097 0,0075
Pro (3) 0,589709763 0,0180
Thr (3) 0,515820943 0,0122
Tyr (3) 0,44923525 0,0135
Arg (3) 0,523689551 0,0095
Glu (3) 0,456875468 0,0108
His (3) 0,427128008 0,0151
Lys (3) 0,412917485 0,0105
Phe (3) 0,48071841 0,0134
Ser (3) 0,466614214 0,0185
Trp (3) 0,437041651 0,0162
Val (3) 0,404002931 0,0246
Ala (3) 0,522692721 0,0100
Gln (3) 0,484006314 0,0161
Gly (3) 0,463140179 0,0265
Ile (3) 0,408800612 0,0122
Pro (4) 0,542402361 0,0353
Thr (4) 0,455311364 0,0119
Tyr (4) 0,441425021 0,0143
Arg (4) 0,602178381 0,0193
Glu (4) 0,449454927 0,0175
His (4) 0,474646857 0,0190
Lys (4) 0,452389554 0,0204
Phe (4) 0,56370095 0,0219
Ser (4) 0,561056106 0,1051
Trp (4) 0,445637428 0,0166
Val (4) 0,452837893 0,0576
Ala (4) 0,515199884 0,0120
Gln (4) 0,46578856 0,0184
Gly (4) 0,478595924 0,0192
Ile (4) 0,45967812 0,0200
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Appendix VIII (first part): Median values and standard errors of the ratio of fluorescein/rhodamine
(five replicates) calculated after enzymatic assay with chymopapain (50,625-member PNA-encoded
positional scanning library). The numbers (1), (2), (3) and (4) represent the amino acids encoded in
the first, second, third and fourth sub-libraries respectively.
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine
Standard errors of the
ratio of fluorescein/rhodamine
Pro (1) 0,626989724 0,019162873
Thr (1) 0,667693523 0,052493697
Tyr (1) 0,560068216 0,024841138
Arg (1) 0,648314797 0,031734147
Glu (1) 0,750158529 0,121093727
His (1) 0,60725846 0,02075028
Lys (1) 0,601751556 0,01724031
Phe (1) 0,634275114 0,019159656
Ser (1) 0,609491236 0,011890696
Trp (1) 0,628397667 0,016061516
Val (1) 0,540541968 0,015891027
Ala (1) 0,651470225 0,01754194
Gln (1) 0,666253038 0,011225183
Gly (1) 0,623170116 0,006646447
Ile (1) 0,535624274 0,00610106
Pro (2) 0,459059944 0,036950833
Thr (2) 0,546473913 0,03675631
Tyr (2) 0,482407968 0,010073198
Arg (2) 0,502550277 0,026676672
Glu (2) 0,500126935 0,022452691
His (2) 0,488197882 0,008722781
Lys (2) 0,476258993 0,004674795
Phe (2) 0,500128524 0,011453786
Ser (2) 0,529582515 0,016959364
Trp (2) 0,499358999 0,011097825
Val (2) 0,465889481 0,008106327
Ala (2) 0,567223237 0,01180252
Gln (2) 0,540125535 0,035253149
Gly (2) 0,497513114 0,012878881
Ile (2) 0,458549343 0,012599655
Pro (3) 0,809107833 0,058996634
Thr (3) 0,699202668 0,034638241
Tyr (3) 0,607446552 0,003981597
Arg (3) 0,577773352 0,024795897
Glu (3) 0,65826002 0,020413562
His (3) 0,621856734 0,007350107
Lys (3) 0,613649188 0,019381016
Phe (3) 0,57931598 0,035526272
Ser (3) 0,684141693 0,019819054
Trp (3) 0,633067024 0,004793043
Val (3) 0,58375879 0,027415066
Ala (3) 0,627755616 0,037525647
Gln (3) 0,668483803 0,024038264
Gly (3) 0,67466708 0,010754464
Ile (3) 0,654049557 0,015451285
Pro (4) 0,714795244 0,089997482
Thr (4) 0,609141565 0,016836553
Tyr (4) 0,626196426 0,008233358
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Appendix VIII (second part): Median values and standard errors of the ratio of
fluorescein/rhodamine (five replicates) calculated after enzymatic assay with chymopapain (50,625-
member PNA-encoded positional scanning library). The numbers (1), (2), (3) and (4) represent the
amino acids encoded in the first, second, third and fourth sub-libraries respectively.
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine
Standard errors of the
ratio of fluorescein/rhodamine
Arg (4) 0,669935828 0,082450907
Glu (4) 0,57325757 0,038908812
His (4) 0,625279767 0,006726961
Lys (4) 0,595313259 0,009009654
Phe (4) 0,607302756 0,080934185
Ser (4) 0,737096605 0,025302226
Trp (4) 0,623929167 0,010277412
Val (4) 0,661757486 0,01771507
Ala (4) 0,579542966 0,045455096
Gln (4) 0,695667125 0,033391515
Gly (4) 0,640712756 0,008425195
Ile (4) 0,644800745 0,016665683
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Appendix IX (first part): Median values and standard errors of the ratio of fluorescein/rhodamine
(five replicates) calculated after enzymatic assay with pepsin (50,625-member PNA-encoded
positional scanning library). The numbers (1), (2), (3) and (4) represent the amino acids encoded in
the first, second, third and fourth sub-libraries respectively.
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine
Standard errors of the
ratio of fluorescein/rhodamine
Pro (1) 0,875384635 0,140316307
Thr (1) 0,749043794 0,099672962
Tyr (1) 0,758231477 0,016624087
Arg (1) 0,843318801 0,128500488
Glu (1) 0,723391778 0,013449623
His (1) 0,780989772 0,014878933
Lys (1) 0,282036156 0,017790919
Phe (1) 0,351831438 0,106808879
Ser (1) 0,818363011 0,092472501
Trp (1) 0,625432364 0,056348153
Val (1) 0,790373709 0,010197512
Ala (1) 0,449861383 0,175153351
Gln (1) 0,793969871 0,080810739
Gly (1) 0,676950355 0,087833595
Ile (1) 0,771190157 0,150367213
Pro (2) 0,784434181 0,009604871
Thr (2) 0,541201743 0,027261376
Tyr (2) 0,601176666 0,004811907
Arg (2) 0,79972906 0,092495805
Glu (2) 0,651361004 0,073782778
His (2) 0,587776824 0,067760268
Lys (2) 0,656171318 0,015841065
Phe (2) 0,804694222 0,103355683
Ser (2) 0,670587234 0,080257524
Trp (2) 0,610710133 0,067187315
Val (2) 0,710730557 0,018020322
Ala (2) 0,360275043 0,096147796
Gln (2) 0,697230959 0,090367739
Gly (2) 0,58609429 0,009829616
Ile (2) 0,689649769 0,114962705
Pro (3) 0,738729981 0,024829391
Thr (3) 0,585766235 0,059377152
Tyr (3) 0,635662114 0,061347245
Arg (3) 0,794161598 0,029426282
Glu (3) 0,62941306 0,075439116
His (3) 0,647382092 0,076930329
Lys (3) 0,618884981 0,007367057
Phe (3) 0,829874278 0,0206433
Ser (3) 0,677162882 0,087930347
Trp (3) 0,652179284 0,095379397
Val (3) 0,63315908 0,088405947
Ala (3) 0,750372628 0,004381807
Gln (3) 0,669839894 0,024253742
Gly (3) 0,621587967 0,078496183
Ile (3) 0,630348007 0,084364432
Pro (4) 0,682657144 0,068907805
Appendices
-185-
Appendix IX (second part): Median values and standard errors of the ratio of fluorescein/rhodamine
(five replicates) calculated after enzymatic assay with pepsin (50,625-member PNA-encoded
positional scanning library). The numbers (1), (2), (3) and (4) represent the amino acids encoded in
the first, second, third and fourth sub-libraries respectively.
Encoded amino acid
Median values of the ratio of
fluorescein/rhodamine
Standard errors of the
ratio of fluorescein/rhodamine
Thr (4) 0,584332091 0,049916419
Tyr (4) 0,699179817 0,012124259
Arg (4) 0,674457766 0,004316153
Glu (4) 0,635039888 0,082174768
His (4) 0,625258425 0,08720222
Lys (4) 0,611701579 0,085816257
Phe (4) 0,68988552 0,082587051
Ser (4) 0,684434445 0,081638005
Trp (4) 0,659044193 0,00390701
Val (4) 0,650042481 0,009429924
Ala (4) 0,632967498 0,053227016
Gln (4) 0,667135397 0,006259801
Gly (4) 0,667000262 0,004809481
Ile (4) 0,646735378 0,009360053
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A 10,000 Member PNA-Encoded Peptide Library for
Profiling Tyrosine Kinases
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ABSTRACT A 10,000 member peptide nucleic acid (PNA) encoded peptide li-
brary was prepared, treated with the Abelson tyrosine kinase (Abl), and decoded
using a DNA microarray and a fluorescently labeled secondary antiphosphoty-
rosine antibody. A dual-color approach ensured internal referencing for each and
every member of the library and the generation of robust data sets. Analysis iden-
tified 155 peptides (out of 10,000) that were strongly phosphorylated by Abl in
full agreement with known Abl specificities. BLAST analysis identified known cel-
lular Abl substrates such as c-Jun amino-terminal kinase as well as new potential
target proteins such as the G-protein coupled receptor kinase 6 and diacylglycerol
kinase gamma. To illustrate the generalization of this approach, two other ty-
rosine kinases, human epidermal growth factor 2 (Her2) and vascular endothelial
growth factor receptor 2/kinase insert domain protein receptor (VEGFR2/KDR),
were profiled allowing characterization of specific peptide sequences known to in-
teract with these kinases; under these conditions Her2 was demonstrated to
have a marked preference for D-proline perhaps offering a unique means of target-
ing and inhibiting this kinase.
M ore than 500 kinases have been identifiedwithin the human genome, with some 90 be-lieved to be protein tyrosine kinases, al-
though to date only a small proportion of them have
been fully characterized (1, 2). The uniqueness of any ki-
nase arises from its ability to phosphorylate hydroxy
residues in a highly selective and specific manner, a pro-
cess by which kinases can exert exquisite and selec-
tive control over many cellular processes. Their dysfunc-
tion can be catastrophic and lead to a variety of disease
states such as cancer, cardiovascular disease, inflam-
mation, and diabetes (3). For instance, the breakpoint
cluster region (Bcr)-Abl fusion protein has been associ-
ated with chronic myelogenous leukemia (4, 5). Many
small-molecule kinase inhibitors such as Fasudil for
Rho-dependent kinase (6), Sirolimus for mammalian tar-
get of rapamycin (7), Imatinib for Bcr-Abl (8), and Ge-
fitinib for epidermal growth factor receptor (9) have thus
emerged, but there is still a huge demand for the devel-
opment of approaches that would help in the design of
new kinase inhibitors (10).
A necessity in the area of kinase analysis is the abil-
ity to determine and understand the exact substrate
specificity of any kinase, and over the past decade sev-
eral kinases profiling methods have been developed.
For example in 1995 a solution peptide library (prepared
by split and mix methods) was used to determine the
substrate specificity of nine tyrosine kinases by trapping
phosphorylated peptide mixtures onto a ferric chelat-
ing column and subsequent Edman sequencing, giving
a consensus peptide sequence for each kinase (11). A
positional scanning peptide library tagged with biotin at
the C-terminus, containing nine positions surrounding
a central serine/threonine residue, was used to profile
eight serine/threonine protein kinases, with the peptide
mixtures treated in parallel with -[32P]-ATP and a spe-
cific kinase before being immobilized onto avidin-
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coated membranes allowing quantifica-
tion by phosphorimaging (12). Another
example was the use of mRNA-protein
and peptide fusion libraries that were de-
signed to have a tyrosine residue sur-
rounded by five random amino acids to
interrogate the v-abl tyrosine kinase.
These libraries were designed to have
one tyrosine residue surrounded by five
random amino acids. Following modifica-
tion of the libraries by v-abl, phosphory-
lated residues were isolated via rounds of
immunoprecipitation with the phospho-
tyrosine-specific 4G10 antibody. Finally,
amplification by PCR of the mRNA al-
lowed DNA microarray identification (13).
Direct bead-based assays have also al-
lowed the identification of the substrate specificity of
two protein tyrosine kinases, p60c-src and zeta-chain-
associated protein kinase 70 (ZAP-70) (14). In this case,
phosphorylated peptides (on beads) were identified us-
ing an antiphosphotyrosine antibody with subsequent
ladder-based analysis (15) by matrix-assisted laser de-
sorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS). Another bead-based platform has re-
cently been used to study kinase phosphorylation, via
parallel peptide synthesis and subsequent encoding,
with detection through chemical phosphate activation
and dye coupling. Surprisingly, dyes were then detected
using antibodies, presumably due to the low level of la-
beling (16). Several microarray-based methods have
also been developed. Thus, self-assembled monolay-
ers of alkanethiolates displaying peptides on gold sur-
faces combined with MALDI-TOF MS have been used to
study kinases, although only seven peptides were stud-
ied (17). Microarrays of 710 peptides, generated by
SPOT synthesis (18), with subsequent oxime attach-
ment to a glass slide and phosphorylation in the pres-
ence of radioactive ATP allowed “phosphorimaging”
and analysis of kinase specificity (19).
RESULTS AND DISCUSSION
Library Design and Synthesis. Herein is described
an approach that allows the screening and analysis of
10,000 kinase substrates in a single experiment, with
analysis of ALL 10,000 members of the library on a one-
by-one basis via the combined application of DNA mi-
croarrays, fluorescently labeled secondary antibodies
and PNA-split and mix encoding (20–23) (the basic con-
cept of nucleic acid encoding goes back to the early
days of combinatorial chemistry (24)). This was
achieved by the split and mix synthesis of a 10,000
member PNA-encoded library containing the peptide se-
quence -Phe-Gln-AA4-AA3-Tyr-AA2-AA1-Ile-Lys- (Figure 1),
with the expected phosphorylation site surrounded by
four variable positions (AA1, AA2, AA3, and AA4), each
containing 10 different amino acids. The library con-
tained both natural and unnatural amino acids with dif-
fering properties (hydrophobic, hydrophilic, neutral, ba-
sic, and acidic); Tyr was not included in the randomized
positions to avoid multiple phosphorylation sites. Each
amino acid was encoded by a specific PNA triplet to give
an encoding PNA tag composed of 12 PNA monomers
(Supplementary Table 1). The orthogonality and robust-
ness of the PNA and peptide split and mix chemistry
have been reported previously (25–27). In this case,
four bases were used, but isothermal sequences can
be generated by the use of three bases (20, 28). The
PNA tag was also supplemented with two common PNA
sequences at the C-terminus (CC) and three at the
N-terminus (AAG) to help control the selectivity of hybrid-
ization and reduce mismatches (29). Two PEG spacers
were also added between the peptide arm and the PNA
oligomer to distance the peptide away from the PNA
strand, and finally, every peptide was labeled with 5(6)-
carboxyfluorescein in order to allow internal control of
























Figure 1. General structure of the 10,000 member PNA-encoded library, where AA1, AA2, and AA4 are
[Ile, Val, Phe, Pro, Arg, Glu, Lys, D-Pro, Ser, D-Val] and AA3 is [Ile, Val, Ala, Pro, Arg, Glu, Lys, D-Ala,
Ser, Pro].
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Abl Kinase Assay. Following solid-phase synthesis,
the library was incubated with the kinase Abl (the
Abelson nonreceptor tyrosine kinase that is involved
in the regulation of cell proliferation, transcription, and
apoptosis (30)) and ATP allowing phosphorylation of
any peptides recognized by Abl, with subsequent pull
down (hybridization) of the 10,000 member PNA-
encoded library onto the DNA microarray. The arrays
used contained 22,575 features with 10,000 oligonucle-
otide sequences complementary to the PNA sequences
(each in duplicate) and 2575 control DNA sequences
that were designed to be noncomplementary to any of
the PNA tags in the library. In this approach, all 10,000
peptides are in essence “delivered” to a specific ad-
dress on the array by virtue of their specific and unique
tag (zip or postcode) via antiparallel PNA/DNA duplex
formation (Scheme 1) (20, 21).
General Detection Method for Phosphorylated
Peptides on Microarrays. At this stage the DNA array
was converted into a peptide array containing some
phosphorylated peptides that were subsequently de-
tected using a primary/secondary antibody approach.
Therefore, an antiphosphotyrosine antibody (mouse
IgG) was added on the array followed by addition of a
Cy3-labeled secondary antibody (antimouse IgG) (31).
Any phosphorylated peptides (“hits”), localized onto its
defined DNA, were readily identified by scanning the
DNA microarray using a Cy3 filter (control experiments
were carried out to prove the selectivity of the detection
method using peptide microarrays, see Supporting In-
formation). Since every peptide was also
labeled with fluorescein, the resulting ra-
tio of Cy3/Fluorescein provided an inter-
nal control for each and every member of
the library, which is crucial due to natu-
ral variations in melting temperatures,
concentrations, and differences in hy-
bridization efficiency between the
10,000 different library members. The
use of just Cy3 fluorescence for example
would mean it would be impossible to
distinguish between high-efficiency
phosphorylation of a PNApeptide con-
jugate that hybridizes poorly and low ef-
ficiency kinase modification with a
higher concentration. Comparing the
Cy3/Fluorescein ratio of every feature
allows relative quantification of the fluorescence inde-
pendently of any other factors and Abl can be accurately
profiled, with the highest ratio of Cy3/Fluorescein
corresponding to the peptide best recognized by Abl
(Scheme 1).
Data Analysis. An Excel macro allowed every DNA se-
quence to be correlated to its PNA tag and hence its pep-
tide, which in combination with BlueFuse (BlueGnome)
allowed extensive mining and manipulation. Analysis of
the images obtained after scanning the chip using a
fluorescein filter showed a total absence of fluorescence
on the 2575 control sequences, confirming highly selec-
tive hybridization (Figure 2). Since fluorescein was used
as a label for each library member, analysis of the array
using the fluorescein channel confirmed that all library
members had been synthesized and hybridized onto
the DNA microarray. In order to quantify the level of
phosphorylation, a second channel (Cy3) was used
(Scheme 1). Although similarities with gene expression
profiling exist, the analysis used here differed in many
respects due to the fact that the majority of the features
in the Cy3 channel had little if any signal (most pep-
tides were nonphosphorylated). In order to gain valu-
able data, only features (specific peptides) with a Cy3 in-
tensity twice that of the background were considered
(giving some 703 initial hits). These data were then veri-
fied by identification of all duplicates from within these
703 single signals (duplicates of each DNA oligomer ex-
isted scattered across the array) removing those with a
standard deviation higher than 0.25 (comparing normal-
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1. = Anti-phosphotyrosine 
  antibody (mouse IgG)
2. = Cy3-labeled anti-mouse







Scheme 1. Schematic representation of the hybridization of a PNA-encoded library incubated with
the protein tyrosine kinase Abl and ATP onto a DNA microarray followed by identification of the
“hits” using an antiphosphotyrosine antibody and a secondary Cy3-labeled antibodya
aUsing ratios of Cy3/Fluorescein, the kinase Abl can be accurately profiled.
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ture with values ranging from 0 to 1). In doing so, 155
peptides (“310 duplicative hits”) gave data for Abl, with
very high confidence (see Supporting Information for de-
tails). The same analysis approach was used for the
two other kinases (see Supplementary Figure 2 for Abl
profiles and Supplementary Figure 3 for the image of the
chip obtained using a Cy3 filter).
Specificity of Abl. Broad specificity for the amino ac-
ids in positions AA4 and AA1 was found whereas a high
selectivity was clearly observed for the amino acids
around the phosphorylation site (Tyr) in the AA3 and
AA2 positions. Glu seems to play a crucial role in Abl
phosphorylation since it was the most frequent amino
acid found in each randomized position, confirming that
this protein tyrosine kinase accepts acidic residues
around the phosphorylation site (Asp was not chosen
as a building block in the library synthesis due to its
similarity to Glu) (11, 14). Glu (85 “hits” out of 155,
55%) was clearly the most accepted amino acid in the
AA3 position. Thus, an acidic, negatively charged amino
acid on the amino side of tyrosine seems to be impor-
tant for efficient phosphorylation by Abl.Smaller propor-
tions of Val (18%) and Ser (11%) were also observed.
In the AA2 position, Abl displayed a preference for po-
lar amino acids such as Ser (35%) and acidic residues
such as Glu (32%). In the AA4 and AA1 positions, Abl
was observed to be less specific and accepted a broad
range of amino acids such as Ser (24%), Glu (19%),
D-Val (17%) in the AA4 position and Ser (22%), Val
(18%), Glu (13%) in the AA1 position (Figure 3). When
these results were compared with the sequences of
known Abl kinase substrates, marked similarities were
displayed (Table 1).
Figure 2. Image of a 10,000 member PNA-encoded kinase library hybridized onto a
22,575 member custom DNA microarray, following incubation with Abl, obtained us-
ing a fluorescein filter. Every fluorescent spot represents a unique peptide, whose
sequence is known via its PNA tag and location on the array. Empty white circles (in-
sert) correspond to DNAs that were designed to be noncomplementary to any of the
PNA tags in the library and were printed as controls of the hybridization process.
Note the variation in fluorescence intensity which highlights differences in hybrid-
ization and synthesis efficiency that have to be controlled using relative ratios of




























































(D)-P (D)-V E F I K P R S V
Amino acid (AA1)
Figure 3. Bar graphs for Abl showing the proportion of amino acids at the four randomized positions (AA4, AA3,
AA2, and AA1) in the 155 “hits”.
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Specificity of the Top Peptide Sequences for Abl.
The data from the 155 “hits” could also be analyzed to
determine the best substrates accepted by Abl, and the
sequences of the top 10 peptides are listed in Table 2.
The motif SEY appeared 5 times (out of 10), revealing
this to be an important factor in Abl specificity. More-
over, among the 155 “hits”, 21 peptides contained the
SEY motif and 14 were found in the top 40 peptide se-
quences (Supplementary Table 2). The Abl optimal sub-
strate predicted by Songyang (11) contains the motif
I/VYXXP, where X represents any amino acid. Although
Pro is replaced by Ile in our library (Figure 1), 8 peptides
contained Ile (5%, Figure 3) in the AA3 position and
they were among those giving the highest ratios of Cy3/
Fluorescein (Supplementary Figure 2). Thus in the top
10 peptide sequences, Ile appeared three times in the
AA3 position (Table 2).
Interacting Partners for Abl. A BLAST search using
the Swiss-Prot database was performed with the top
25 peptide sequences identified (32, 33). The results
were observed to be in agreement with known Abl sig-
naling pathways and proteins implicated in leukemia
(30, 3436). Thus, the second best peptide sequence
(SEYES) was the well-known Abl substrate, c-Jun amino-
terminal kinase (Table 3) (34). Although the role of Abl
with G protein coupled receptor kinases and diacylglyc-
erol kinase is not fully understood, our data reveal that
Abl may interact with these proteins (37, 38).
Screening Additional Kinases. To further demon-
strate the validity of the method, two additional ki-
nases (Her2 and VEGFR2/KDR) were screened using
the same 10,000 member PNA-encoded peptide library,
giving two new profiles (Supplementary Figures 4 and
5). Her2 has been found to be amplified in more than
25% of human primary breast cancers (39) and VEGFR2/
KDR plays crucial roles in angiogenesis and vasculogen-
esis (40). Surprisingly, Her2 showed a remarkable pref-
erence for the unnatural amino acid D-Pro at the
C-terminus site of the phosphorylation site. Thus, look-
ing at the 299 “hits”, in the AA1 position, D-Pro was the
most accepted amino acid (34%) along with Ser (28%).
This was also observed in the AA2 position, where D-Pro
(22%), Ser (20%), and D-Val (17%) were the most com-
mon amino acids. Moreover, in the top 15 peptides
(Supplementary Table 3), 10 peptides in the AA1 posi-
tion and 7 in the AA2 position contained D-Pro, with the
sequence D-Pro/D-Pro (AA2/AA1) represented five times.
These results were particularly interesting since even
though L-Pro was present in positions AA1 and AA2, Her2
had a clear preference for D-Pro. The marked preference
for this unnatural amino acid was unexpected and
would not be observed in other library screens. How-
ever, it is already known that protein kinase C can phos-
phorylate both D- and L-amino acids (41). Her2 was
less specific for the amino acids in positions AA4 and
AA3, but a small preference for Lys (18%), Glu (14%),
and Ser (14%) in the AA4 position and Ser (23%), Lys
TABLE 1. Comparison between the sequences of known Abl substrates and the most frequent amino
acids obtained from the library screening (32)a
Substrate Swiss-Prot Position Sequence
SHP1 PTN6_HUMAN (MOUSE) Y536 SEYGN
SHP1 PTN6_HUMAN (MOUSE) Y564 DVYEN (EVYEN)
Mdm2 MDM2_HUMAN (MOUSE) Y394 (Y393) EDYSQ (DDYSQ)
p62dok DOK1_MOUSE Y314 SVYSD
p62dok DOK1_MOUSE Y397 EGYEL
Myogenic factor 3 MYOD1_MOUSE Y30 DFYDD
Myogenic factor 3 MYOD1_MOUSE Y212 MDYSG
aThe known tyrosine phosphorylation site is indicated and bold letters represent amino acids that were common to our study (one-letter
amino acid codes are used).
TABLE 2. Sequences of the top 10 peptides, recognized by Abl, with the highest ratios of Cy3/Fluo-
resceina
Peptide sequence Ratio Cy3/Fluorescein Peptide sequence Ratio Cy3/Fluorescein
1) SEYEV 4.50 6) SIYEP 3.44
2) SEYES 4.45 7) SIYSP 3.32
3) SEYSF 4.16 8) PEYSE 3.29
4) SEYVF 4.03 9) SEYEE 3.27
5) VIYES 3.62 10) VEYES 3.26
aThe one letter amino acid code is used.
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(17%), and D-Ala (16%) in the AA3 position could be no-
ticed (Supplementary Figure 4). Unlike the two other ki-
nases, VEGFR2/KDR was less specific and accepted a
broad range of amino acids, giving a much greater num-
ber of “hits” (829 “hits”) (Supplementary Figure 5). A
slight preference for polar amino acids (both acidic and
basic) immediately adjacent to the phosphorylation site
(positions AA3 and AA2) could be observed: Glu (AA3/
AA2, 20%/16%), Lys (AA3/AA2, 17%/16%), and Ser
(AA3/AA2, 17%/14%) were the most commonly ob-
served amino acids. In the AA4 and AA1 positions, Lys
(15%) and D-Pro (18%), respectively, were the most
common amino acids.
Interacting Partners for Her2 and VEGFR2/KDR. A
BLAST search using the Swiss-Prot database was per-
formed with the top 25 peptide sequences of Her2 and
VEGFR2/KDR (Table 4, Supplementary Tables 3 and 4).
Although only six peptide sequences (within the top
25) contained natural amino acids for Her2, proteins
that are known to interact with Her2 or present in breast
cancer could be identified (42–44). For VEGFR2/KDR,
the results were also in agreement with known signal-
ing proteins (45–47).
CONCLUSION
The high-throughput screening of 10,000 tyrosine
kinase Abl substrates in a single experiment has
been demonstrated via the detection of tyrosine-phos-
phorylated peptides (“hits”) using a nonradioactive,
selective and sensitive method based on a primary
antiphosphotyrosine antibody and a fluorescently la-
beled secondary antibody. The use of PNA-encoded li-
braries simplified the deconvolution process while us-
ing minimal amounts of kinase (60 pmol), library (5
nmol), and antibodies (0.4 g per antibody). ALL
10,000 members of the library were analyzed, allow-
ing a unique insight into the substrate requirements of
Abl; however it is a general method as there is no
need to have any previous knowledge about an opti-
TABLE 3. Predicted proteins for Abl identified by running a BLAST search using peptide sequences
from the 25 top peptides and the Swiss-Prot database (only proteins with the highest scores were
selected)
Protein name Swiss-Prot Identified sequence
G-protein coupled receptor kinase GRK6_MOUSE SEYEV
c-Jun N terminal kinase JIP2_MOUSE SEYES
Diacylglycerol kinase gamma DGKG_MOUSE SEYSS
G-protein coupled receptor kinase GRK5_MOUSE EVYSS
CC chemokine receptor CCR6_MOUSE RVYSE
Epidermal growth factor receptor substrate EP15_MOUSE PVYEK
TABLE 4. Predicted protein targets for Her2 and VEGFR2/KDR identified by running a BLAST search
using peptide sequences from the 25 top peptides identified from the microarray and the Swiss-
Prot database (only proteins with the highest scores were selected)a
Tyrosine kinase Protein name (sequence) Swiss-Prot Identified sequence
Her2 Breast tumor-amplified kinase (YQETYKRI) STK6_HUMAN FQEIYKRI
Her2 G protein coupled receptor 158 (EIYKRKK) GP158_ HUMAN EIYKRIK
Her2 Ephrin receptor EPHA7 (FQTRYPS) EPHA7_ HUMAN FQSRYPS
VEGFR2/KDR Leptin receptor isoform 1 (FQIRY) LEPR_HUMAN FQIRY
VEGFR2/KDR Protein kinase C, theta (IVYRD) KPCT_ HUMAN IVYRE
VEGFR2/KDR Endothelial differentiation G protein coupled receptor 6 (IIYSF) EDG6_ HUMAN IIYSF
aBold letters for the identified peptide sequence represent amino acids that are common to the predicted protein.
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mal kinase substrate. The dual color approach (ratio
of Cy3/Fluorescein) was essential to allow accurate
profiling and gave a set of peptides that were phos-
phorylated in agreement with known Abl interacting
partners, while new target proteins were quickly and
simply identified by analysis of the top peptide se-
quences and BLAST searching. Moreover, it is known
that Abl accepts a wide range of substrates and one of
the advantages of our method is that optimal pep-
tides for Abl, rather than consensus sequences, can
be identified. Finally, unlike other methods (14) that
give large number of “hits” without relative quantifica-
tion, the approach described here offers the advantage
of not only detecting phosphorylated peptides but also
quantifying the extent of phosphorylation. The approach
was used to profile and identify specific proteins for two
other tyrosine kinases, Her2 and VEGFR2/KDR, showing
its generality, while adaptations (16) will allow serine and
threonine kinases to be analyzed allowing rapid and ef-
ficient substrate deorphaning.
METHODS
Materials. Fmoc amino acids were purchased from GL Bio-
chem except Fmoc-Tyr(HPO3Bzl)-OH and Fmoc-Ser(HPO3Bzl)-OH
which were from LC Sciences. CodeLink activated slides were
obtained from Amersham Biosciences. ATP and monoclonal an-
tiphosphotyrosine clone PY-20 were from Sigma, Cy3-goat anti-
mouse IgG (HL) conjugate (ZyMax grade) was from Invitrogen.
Abl, mouse recombinant (Escherichia coli) was from New En-
gland Biolabs, Her2 (human, recombinant, N-terminal GST tag)
and VEGFR2/KDR (human, recombinant, N-terminal GST tag)
were purchased from BPS Bioscience.
Library Synthesis. The PNA-encoded peptide library (see
Figure 1 for general structure of the library and Supplementary
Table 1 for PNA code) was synthesized according to published
procedures (25, 26). It was carried out on PEGA resin with a Rink
linker where Fmoc-PEG spacer-Lys(Dde)-OH [PEG spacer  NH-
(CH2)3-O-(CH2)2-O-(CH2)2-O-(CH2)3-NH-CO-(CH2)2-CO] was at-
tached as the core unit presenting two different orthogonal pro-
tecting groups (Fmoc  20% piperidine in DMF and Dde 
hydroxylamine, pH 5.0). This orthogonality allowed elongation
of either the peptide or PNA arm at will through selective Fmoc
and Dde chemistries.
Thus, Fmoc-Rink-amide linker was attached to PEGA resin fol-
lowing stepwise couplings with Fmoc-Lys(Dde)-OH (48), Fmoc-
PEG spacer-OH (49), Fmoc-Lys(Boc)-OH, and Fmoc-Ile-OH. Then,
the Dde group was removed (NH2OH.HCl/imidazole in NMP/
DCM, 1 h) and two cytosine PNA monomers were coupled to
the resin. The synthesis was then carried out as follows: (1) Split
into 10 different pools. (2) Dde deprotection. (3) Dde/Mmt PNA
monomer coupling: Dde-PNA(Mmt)-OH (5.5 equiv) and PyBOP
(5 equiv) were dissolved in DMF (0.1 M) followed by addition of
NEM (11 equiv). The resulting solution was mixed for 10 s be-
fore being added to the resin preswollen in DMF, and the mix-
ture was shaken for 3 h. Repeat (2) and (3) twice. (4) Fmoc
deprotection (20% piperidine in DMF, two cycles of 10 min).
(5) Fmoc amino acids couplings: Fmoc-AA-OH (5.5 equiv), Py-
BOP (5 equiv), and HOBt (5.5 equiv) were dissolved in DMF (0.08
M) followed by addition of DIPEA (16 equiv). The resulting solu-
tion was mixed for 10 s before being added to the resin, and the
mixture was shaken for 3 h. (6) The 10 resin pools were mixed.
(7) The resin was split again into 10 pools; repeat steps (2) to
(6). After encoding two positions and before splitting, Fmoc-
Tyr(tBu)-OH was coupled to the resin. Then the synthesis contin-
ued (steps (1)(7)). At the end of the encoding process, Fmoc-
Gln(Trt)-OH, Fmoc-Phe-OH, and Fmoc-PEG spacer-OH were
respectively coupled followed by coupling of guanine, adenine,
and adenine PNA-protected monomers at the PNA arm as previ-
ously described. Finally, the library was labeled using 5(6)-
carboxyfluorescein (Fluorescein) (5.5 equiv), PyBOP (5 equiv),
and NEM (5 equiv) in DMF (0.1 M). Before cleavage, the library
was treated with 20% piperidine in DMF (5  10 min) (50). Fi-
nal cleavage from the resin was carried out using TFA/TIS/DCM
(90/5/5) for 1 h. The crude compound was precipitated from
cold diethyl ether, sonicated for 5 min, and centrifuged for 5 min
at 4000 rpm. The supernatant was then discarded, and the pro-
cess was repeated four times to give rise to a yellow solid.
Solution-Phase Kinase Assay. The 10,000 member PNA-
encoded library was incubated, in solution, at a final concentra-
tion of 50 M and final volume of 100 L, in a buffer contain-
ing 60 units of the selected kinase (Abl, Her2, or VEGFR2/KDR),
5 mM ATP, kinase reaction buffer (for Abl 1x, 50 mM Tris-HCl (pH
7.5 at 25 °C), 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01%
Brij 35; or for Her2 and VEGFR2/KDR, 50 mM HEPES, pH 7.4,
3 mM MgCl2, 3 mM MnCl2, 1 mM DTT, 3 M Na-orthovanadate)
and 0.1% BSA for 24 h at 30 °C. Before hybridization, 1 volume
of this buffer was diluted with 1 volume of GenHyb buffer (Ge-
netix). Solutions were denatured by heating at 65 °C for 3 min;
100 L of the solution was then poured onto a 22,500 custom-
ized DNA chip from Oxford Gene Technology (Oxford), which was
covered with a glass cover slide and kept in a hybridization
chamber (Genomic Solutions) at 60 °C. Temperature was then
slowly lowered to 37 °C over a period of 21 h. Finally, the chips
were washed twice (20 mL) for 10 min at 30 °C in the following
buffer (100 mM Nacl, 10 mM citric acid, 0.7% (w/v) N-lauroyl-
sarcosine sodium salt, 0.1 mM EGTA, pH 7.5), rinsed with dis-
tilled water (20 mL), and spin-dried by centrifugation (1000 rpm
for 10 min) (20).
Antibody Assay on the 22,500 Customized DNA Chip. To avoid
any unspecific binding, the slides were blocked with a pre-
warmed buffer containing TPBS (0.05% Tween-20/PBS, pH
7.4)/1% BSA (20 mL) for 1 h at 30 °C. After being washed in
PBS (20 mL) for 5 min at 30 °C, slides, that were covered with
a glass cover-slide and kept in a hybridization chamber
(Genomic Solutions), were probed with the primary antibody,
monoclonal antiphosphotyrosine clone PY-20 (mouse IgG2b iso-
type), diluted 1/500 (0.4 g) in an antibody buffer containing
TPBS/1% BSA (final volume of 200 L) for 1 h at 30 °C. After the
slides were washed with the antibody buffer (2  20 mL) for
10 min at 30 °C, a labeled secondary antibody, Cy3-goat anti-
mouse IgG (HL), diluted 1/500 (0.2 g) in the antibody buffer
(final volume of 200 L) was added and slides were incubated
in the dark for 1 h at 30 °C. Slides were then washed in the an-
tibody buffer (2  20 mL for 10 min at 30 °C) and rinsed with Tris
buffer (20 mL) at 25 °C before being spin-dried by centrifuga-
tion (1000 rpm for 10 min) (31).
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